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This thesis is concerned with the design, synthesis and characterisation of a 
series of trans-dichloride bis-quinaldamide ruthenium (III) complexes. The  
anti-cancer, anti-bacterial and anti-fungal properties were investigated, with the 
lead compounds undergoing further chemical and biological mechanistic studies. 
Chapter 1 presents an overview of metal complexes as therapeutic agents, their 
interaction with DNA and project aims. 
Chapter 2 discusses the synthesis and characterisation of the novel 
quinaldamide ligands. 
Chapter 3 is focused on the synthesis and characterisation of the trans-dichloride 
ruthenium (III) complexes that displayed promising anti-cancer results. 
Chapter 4 discusses the biological evaluation of the ruthenium complexes under 
normoxia conditions. Lead compounds are analysed to a wider panel of cell lines 
and hypoxia conditions. Two outperforming compounds were taken for further 
mechanistic studies. Anti-bacterial and anti-fungal properties are also discussed. 
Chapter 5 contains the chemical investigations (hydrolysis and hydrophobicity) 
of selected compounds. 
Chapter 6 contains experimental details and characterisation data for all the 
compounds described in Chapters 2 and 3. All the protocols for the studies 
discussed in Chapter 4, and all experimental details of Chapter 5. 
Chapter 7 summaries this thesis and the future work. 
Appendix includes a summary of the x-ray crystallographic data for the crystalline 
compounds found in this work.
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of DNA from one original DNA molecule 
Telomerase a protein which adds a repeat sequence to the end of 
telomeres 
Telomere a region of repetitive nucleotide sequences at each end 
of a chromosome 
Transcription the first step of gene expression, in which a particular 
segment of DNA is copied into RNA 
Transcription factors proteins that control the rate of transcription 
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1.1 Introduction 
1.1.1 Structure and role of DNA 
The nature of living organisms is determined by their genes, which are specific 
sequences of nucleic acids required for protein synthesis.1 Genes are embedded 
in DNA, which is a biopolymer whose discovery involved several scientists and 
stages. The first X-ray crystallography images of DNA obtained by Rosalind 
Franklin2 together with the seminal idea of DNA coined by Maurice Wilkins 
allowed James Watson and Francis Crick to understand and to solve the 
‘mysterious’ molecule of life.3 In 1958, Crick postulated that the transference of 
genetic information between two consecutive generations is essential for life.4 
This later became known as the “Central Dogma of Biology” (Figure 1-1).5 
After considering all the plausible biological mechanisms, Crick concluded that 
genetic information is transcribed in a unidirectional manner from the DNA to 
proteins through RNA, which cannot be modified nor affect genes. This process 
encompasses three transitions: biologically permitted, possible for specific 
situations and prohibited. However, the unidirectionality of this process remains 
one of the most controversial topics within biology.5 
 
Figure 1-1: Scheme of the Central Dogma of Biology: bold lines represent 
permitted transitions; dashed lines possible ones and the absence of lines 
means prohibited process.6 
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1.1.2 Structure of DNA and its participation in cellular recognition 
DNA is a biopolymer derived from nucleotides which are characterised by having 
a highly negatively charged phosphate backbone. Structurally, it is found as a 
regular double helix whose strands are linked together through hydrogen bonds 
and hydrophobic interactions between the nitrogenous bases as shown in Figure 
1-2 (Adenine (A), Guanine (G), Cytosine (C), and Thymine (T)). 
Depending on the conditions of the medium, this helix adopts different 
conformations: the A-Form, the B-Form and the Z-Form. However, the B-DNA 
form is the most common and recognisable by most transcription factors.7 It has 
a diameter of around 20 Å with 10 bases per loop; the distance within two bases 
is 3.4 Å and the rotation per residue is 36°. Despite its regularity, it can show 
deviations depending on the torsion angles of the nucleotide sequence.8,9 Thus, 
two different grooves are found: the major is wide and relatively shallow, whereas 
the minor is narrow and deep, as shown in Figure 1-2. The width is given by the 
nitrogenous bases sequence and, generally, the areas rich in A/T are narrower 
than G/C. Groove hydration studies show association to the major groove is a 
process principally driven by enthalpy and unfavourable to the minor which is 
compensated by entropic contribution.10 These factors justify that proteins 
recognise DNA preferably through the major groove. 
 
Figure 1-2: Left: structure of DNA showing the minor and the major grooves.  
Top Right: colour code of the elements that form DNA. Bottom Right: structure of the 
nitrogenous bases that constitute DNA. 
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The cellular genome is organised in chromosomes, formed by one single 
molecule of linear DNA. Unlike prokaryotic cells, which lack a nuclear membrane, 
eukaryotic chromosomes are not found free inside the cytoplasm but contained 
inside the cellular nucleus, which, at the same time, is separated from the 
cytoplasm by the nuclear membrane. Chromosomes are formed by tangled fibres 
of a protein-DNA complex called chromatin whose minimal structural unit is the 
nucleosome constituted by a DNA sequence linked to an eight-protein complex 
named histone. The role of chromatin is primordial in the regulation of the gene 
expression, facilitating or impeding access to the transcriptional machinery of the 
DNA strands, and, consequently triggering or inhibiting the transcription 
process.11,12 
1.1.3 Gene Expression 
Gene expression is the process that the cell uses to generate a protein by 
decoding the information kept in the nucleotide sequence of a gene. This includes 
the transcription process, whereby a specific nucleotide sequence is copied to 
give the RNA molecule, and the translation process which uses the RNA as 
template to synthesise proteins (Figure 1-3). 
In some cases, the final product of the gene expression is the RNA itself, although 
the vast majority is used to determine the synthesis of a specific protein. The RNA 
copied is known as messenger RNA (mRNA), which, in eukaryotic cells, is held 
to a transformation process in the nucleus to give the mature mRNA that will be 
transported to the cytosol for translation. This process is constituted by three 
steps: initiation, elongation and termination. 
Gene expression is a perfectly regulated process, following a specific pattern in 
each cell that determines its function and morphology. This control can occur in 
any of the steps, but mostly the regulation of the gene expression is produced in 
the transcription process.13 
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Figure 1-3: Representation of gene expression. Image adapted from the 
National Human Genome Research Institute by Allyson Cunningham.14 
1.2 Interactions of small molecules with DNA 
One of the most active fields in biological chemistry and medicinal chemistry is 
the development of therapeutic molecules, especially when acting at the DNA 
level.15 These compounds, also called linking agents (binders), can be organic 
molecules as well as organometallic/coordination compounds that interact with 
DNA in five ways: 
a) Intercalation 
An intercalator is any molecule that can be placed between the base pairs of a 
nucleic acid in either groove being driven by π-stacking, charge transfer 
interactions, hydrogen bonds or electrostatic interactions. Intercalation leads to 
the deformation of the DNA helix and is generally non-selective. A classic 
example is ethidium bromide (Figure 1-4), widely used as a fluorescent probe for 
DNA determining affinity constants by FID (Fluorescent Intercalator 
Displacement).16,17 
 
Figure 1-4: Chemical structure of ethidium bromide. 
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b) External electrostatic interaction 
DNA is negatively charged, thus metallic cations and polycationic organic 
molecules can stabilise it by neutralising the repulsive forces between 
phosphates. The complex [Zn(DIP)2(DMP)](NO3)2·2H2O (Figure 1-5) was 
reported to have this behaviour. It is favoured due to the release of counterions 
to the medium (entropically favourable), while also being enthalpy favoured 
through interaction between DNA and stabilising molecules.18 
 
Figure 1-5: Chemical structure of [Zn(DIP)2(DMP)]2+  
c) Insertion into DNA grooves 
It has been observed there are some small oligonucleotides (~10-20 base pairs) 
capable of forming a triple helix interacting through the major groove. These 
interactions are established due to the formation of Hoogsteen-like bonds 
between base pairs,19 which differ from Watson-Crick base pairs in the geometry 
of the bonds and are rarely observed. These agents have been used to regulate 
gene expression because they can alter the functionality of transcription factors 
that use this groove to activate or silence genes.20 Unlike what happens with 
transcription factors, molecules of relatively small size have a predisposition to 
joining to a selective minor groove sequence. The first natural products showing 
this behaviour were dicationic compounds.21,22 The interaction in the minor groove 
is determined by hydrogen bond formation, van der Waals bonds, electrostatic 
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and hydrophobic interactions. The core structure of a well-known family is shown 
in Figure 1-6. 
  
Figure 1-6: Chemical structure of the DNA groove intercalator naphthalene derivative 
d) Covalent Interaction 
Molecules that interact in this way are called alkylating agents. The most 
favourable DNA positions to be modified are the N7 and the C2-NH2 of guanine 
and N3 and N7 of adenine. Chlormethine and busulfan (Figure 1-7) are examples 




Figure 1-7: Top, structures of guanine (left) and adenine (right). 
  Bottom, structure chlormethine (left) and busulfan (right). 
e) Non-classical Insertion 
DNA may contain specific areas with non-complementary base pairs. These 
disturbances can be recognized by metal complexes with ligands incapable of 
intercalation but inserting between the non-complementary pair. An example of 
this binding agent is Δ-[Ru(Bpy)2(dppz)]2+.23,24 
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Figure 1-8: Left, two Δ-[Ru(Bpy)2(dppz)]2+ complexes (red) intercalating two 
adenine-adenine mismatches (blue). Right, structure of a ruthenium complex 
which inserts into two mismatch site.24 
1.3 Cancer 
Gene expression is controlled by different biomolecules and, like a machine, does 
not always work perfectly. When a mistake in the translation process is made, 
cells try to fix it. Often, the repair does not occur causing a mutation, which is a 
permanent alteration of the nucleotide sequence in the genome. It can have 
different effects in the phenotype, but the worst scenario is when this alteration 
cannot be controlled, and cells start dividing uncontrollably. 
Cancer is the term for this kind of mutation and is well-known for being the world’s 
leading fatal disease. The cells divide through a process called mitosis which is 
controlled by oncogenes and tumour suppressor genes. The fast and 
uncontrolled growing of cells, the survival of the old and damaged ones and the 
lower bio-specificity of cancerous cells are some molecular symptoms of suffering 
this illness.25 Normal or healthy cells regularly undergo apoptosis or programmed 
cell death whereas cancerous cells do not, causing a lump or tumour which is an 
abnormal mass of tissue caused by the unrestricted over-expression of 
mutations. Additionally, there are two kinds of tumours, benign, which are 
harmless, not cancerous and easily treated if detected early, and malignant, 
which are harmful and life threatening. The main difference relies on its invasion 
to other tissues, benign being small and with a spherical shape, meanwhile the 
malignant tumour does not have a regular shape and spreads very quickly. 
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In general, cancer affects any organ and can be spread throughout the body 
(metastasis). Cancer therapy is used to fight this illness, and involves many 
different techniques including surgery, chemo- and radiotherapy, immunotherapy 
and hormonal therapy.26 
1.4 First Generation of Platinum Based Anti-Cancer 
Compounds: Cisplatin 
Platinum-based anti-cancer complexes are the most successful drugs to date for 
the treatment of various cancers, either as first-line treatments or as supporters 
in combinatorial treatment. Among all the platinum-based drugs, cisplatin or  
cis-diamminedichloroplatinum(II) is the most famous. Its anti-cancer activity was 
serendipitously discovered in 1965 by Rosenberg when it was found to inhibit 
bacterial cell division from the effect of an electromagnetic field using an aqueous 
solution of NH4Cl and platinum electrodes.27 After demonstrating its effect on a 
mouse model, cisplatin was the first metal-based drug entering to clinical trials in 
1971 and was approved in 1978 as an anti-cancer agent by the Food and Drug 
Administration. 
 
Figure 1-9: Structure of cisplatin 
Cisplatin is a neutral complex showing a square planar geometry. The cis-chloro 
conformer is responsible for its anti-cancer activity as the trans-chloro derivative 
is highly unstable. Blood plasma has a high chloride concentration (~100 mM) 
prohibiting the hydrolysis of cisplatin, whereas the very low chloride concentration 
inside the cells (~3 mM) facilitates hydrolysis, making cisplatin an active 
electrophile reacting with nucleophilic sites. The N7 atoms of the imidazole rings 
of guanine and adenine bases from DNA are found to be the most preferred 
cytotoxic targets.28 
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Figure 1-10: Hydrolysis of cisplatin 
X-ray diffraction shows that aquated cisplatin species can crosslink to DNA in 
different trends being the following the main three types.29 DNA monoadducts are 
formed when one molecule of water is lost from the aquated cisplatin. Intrastrand 
crosslinks take place when two chloride ligands of the aquated cisplatin are 
replaced by purine nitrogen atoms on adjacent bases of the same DNA strand.30-
33 Additionally, DNA crosslinks include the interstrand crosslinks (Figure 1-11). 
All cisplatin crosslinks to DNA lead to the disruption of its helical structure that 
cannot be identified by repair enzymes, hence triggering a series of events 
leading to the inhibition of DNA replication34,35 which is responsible for the anti-
cancer activity of cisplatin. 
   
Figure 1-11: DNA-cisplatin crosslinking adducts.36 
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Since only a small fraction of intracellular cisplatin is bound to DNA,37,38 there is 
a high interest in knowing the mechanism of action of cisplatin in killing cancer 
cells. Despite the success of cisplatin towards the death of cancer cells, this 
therapeutic agent is associated with toxicities such as nephrotoxicity and 
ototoxicity. It has also been shown that some cancer cell lines are able to develop 
resistance towards cisplatin through changes in the cell environment.39-42 These 
include drug transport that leads to a decrease of intracellular cisplatin 
accumulation, an increase in drug detoxification systems, an increase in DNA 
repair system, changes in tolerance mechanisms from damage of DNA and 
changes in cell death pathways leading to apoptosis. 
1.5 Second Generation Platinum Anti-Cancer Compounds 
Due to the side effects discussed above, a second generation of platinum-based 
complexes was introduced. Carboplatin, (Figure 1-12, 1) [cis-diammine-1,1-
cyclobutane dicarboxylate platinum(II)] introduced into the clinic in 1989,43,44 has 
a bidentate dicarboxylate ligand replacing the chlorides of cisplatin, being more 
lipophilic than the latter. It hydrolyses forming adducts with DNA,45 but the main 
difference relies on the variation in aquation rates releasing the active Pt(II) 
complex that contributes to cancer cell death.46  
Nedaplatin (Figure 1-12, 2) was found to have the highest anti-cancer activity of 
this second generation possessing lower nephrotoxicity in comparison to 
cisplatin.47 Oxaliplatin (Figure 1-12, 3) was found to be effective in cisplatin-
resistant cells for a range of different cancers.48,49 It is the third successful 
derivative of platinum drugs and entered the clinic in 1994.50,51 Formed by an 
oxalate ligand which undergoes hydrolysis and diaminocyclohexane, it differs to 
cisplatin and carboplatin in the effect rather than the mechanism of action 
showing lower nephrotoxicity and ototoxicity. 
Lobaplatin (Figure 1-12, 4) is currently in phase II clinical trials for cisplatin-
resistant ovarian cancer, head, neck and small-cell lung cancers, showing cell 
cycle arrest in the S phase of DNA (growing phase).52-54 ZN0473  
(Figure 1-12, 5) is sterically hindered and hydrolyses around four times slower 
than cisplatin, which contributes to its high activity against cisplatin-resistant cell 
lines.55 Satraplatin (JM216) (Figure 1-12, 6) is the first orally administrated 
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platinum complex,56 differing from its counterparts by being a platinum(IV) 
complex designed to accommodate two axial acetate groups, increasing 
lipophilicity,57 with comparable efficiency to many well established platinum 
drugs. It is active against cisplatin resistant cell lines in vitro and shows low 
toxicity levels.58 Satraplatin could possibly be a highly successful drug if it passes 
through its current phase III trials in combination therapy by the FDA.59  
 
Figure 1-12: Molecular structure of 1) Carboplatin, 2) Nedaplatin, 3) Oxaliplatin 
4) Lobaplatin, 5) ZN0473 and 6) Satraplatin 
1.6 Introduction of Ruthenium into Medicine 
Currently, further research is ongoing into new metal-based drugs in order to 
eradicate the problem of resistance to platinum-based drugs and to reduce its 
toxic effects. To this aim, ruthenium-based complexes were proposed as good 
candidates.60-62 The rationale behind this choice is because of the intrinsic 
properties of Ru. Firstly, under aqueous conditions, it undergoes ligand exchange 
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relatively slowly compared to platinum complexes.63 It is widely thought that this 
is a key process in the effectiveness of metal-based drugs, hence most 
complexes alter structurally before interaction with biological targets.64,65 
Secondly, under physiological conditions, ruthenium can be found in different 
oxidation states (II, III, IV). The “activation by reduction” hypothesis 66 states that 
ruthenium(III) behaves as a prodrug, which can be reduced to the more active 
and more selective ruthenium(II) drug in the hypoxic environment (Figure 
1-13).65,67 This is because cancer cells have a greater rate of metabolism than 
normal cells using anaerobic respiration producing a considerable amount of 
lactic acid, hence lowering the pH and creating a reducing environment due to 
the oxygen deficiency.68 Finally, ruthenium has iron-mimicking capability in 
binding in vivo to different biomolecules. For example, it can be transported into 
tumour cells via transferrin receptors allowing greater selectivity.65 Metal 
complexes of Ru(II) and (III) have been previously investigated as potential 
anticancer agents, immunosuppressant,69 anti-microbial70 and anti-malarial 
agents.71 
 
Figure 1-13: Adaption of ‘activation by reduction’ hypothesis 
Historically, the interest in ruthenium compounds as anti-cancer agents began in 
the 1970s when ruthenium red was probed and found to exhibit anti-tumor 
properties.72 This compound (ammoniated ruthenium oxychloride, {[(NH3)5Ru-O-
Ru(NH3)4-O-Ru(NH3)5]Cl6·4H2O}) is widely used to stain polysaccharides, but 
also exhibits a variety of biological effects inhibiting Ca2+ signalling and interfering 
with the movement of other cations.72,73 This triggered a systematic investigation 
into ruthenium complexes.74,75  
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1.6.1 NAMI and NAMI-A 
Sodium trans-[Ru(III)Cl4(Im)(DMSO-S)] (NAMI, ‘New Anti-tumor Metastasis 
Inhibitor’) was first synthesised and found to be active against solid metastasising 
tumours in mice.76 At a later stage in pre-clinical experiments, its sodium 
counterion was replaced by imidazolium (NAMI-A), to avoid co-precipitation of 
DMSO with Na+.77 The imidazolium salt was discovered by Sava et al. It is more 
stable towards air oxidation and was the first Ru drug to successfully finish Phase 
1 clinical trials, being the most successful ruthenium anti-cancer drug to date 
(Figure 1-14).78 It was found to be inactive against primary cancer cell lines, 
however it has the same anti-metastatic properties as NAMI. 
NAMI-A is synthetically easier to reproduce. Biologically, both complexes have 
shown activity, reducing lung metastasis in mice, and their anti-metastatic activity 
has been shown to have no relation to their cytotoxicity against cancerous cells.78 
Contrary to cisplatin and other ruthenium complexes, they have a different mode 
of action which involves extracellular activity, being something unique related to 
both agents.78,79,80  
 
Figure 1-14: Chemical Structures of NAMI (left) and NAMI-A (right) 
In NAMI-A, the π-acceptor DMSO ligand stabilises Ru(III) influencing its 
behaviour in aqueous solution, showing two well-separated hydrolysis steps. 
After administration, gives a reactive aqua complex in slightly acidic environment 
by suppressing the hydrolysis of Cl- and slowly dissociating DMSO.81 At 
physiological pH, the thiol groups of glutathione reduce NAMI-A to Ru(II) species 
(NAMI-AR) with further chloride hydrolysis. It was proposed that its anti-
metastatic activity is strictly related to the presence of the DMSO ligand.82 
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Figure 1-15: Different hydrolysis pathways of NAMI-A 
1.6.2 KP418, KP1019 and NKP1019 
Imidazolium [trans-tetrachlorobis(imidazole)-ruthenate(III)] (KP418 or ICR) has 
been shown to be much less toxic than its indazole analogue, however it still 
shows high activity against colorectal carcinoma models in mice.83 Indazolium 
[trans-tetrachlorobis(indazole)-ruthenate(III)] (KP1019) (Figure 1-16) was 
discovered by Keppler et al. and has shown great activity in vitro against a range 
of cell lines. KP1019 is active against colon carcinomas and primary human 
tumours. Inhibiting approximately one third of tumours, the only side-effect of 
KP1019 is production of red blood cells.84 
Although KP1019 has poor water solubility, the substitution of the indazolium for 
sodium (NKP1019) increases its water solubility, improving its potential for clinical 
use.85 The active species are hydrolysis products, where KP418 shows an 
aquation rate similar to cisplatin. However, KP1019 hydrolyses more slowly and 
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via a different pathway, being dependent upon both temperature and pH. It is 
thought that ruthenium complexes target the N7 position of both guanine and 
adenine. KP1019 shows less interstrand cross-linking than cisplatin.84 
After in vivo studies of KP1019 and the analysis of all the data obtained, the 
‘Trojan Horse’ hypotheses was introduced. It describes the selective cellular 
delivery of KP1019 into the tumour using transferrin receptors forming 
endosomes whose pH is lower than the plasma’s triggering the release of the 
complex.86 
 
Figure 1-16: Top, molecular structures of KP418; bottom, KP1019. 
1.6.3 ‘Piano-Stool’ Complexes 
Organometallic complexes contain at least one covalent metal-carbon bond, and 
their potential as anti-cancer agents were once restricted to ruthenocene. 
However, Sheldrick et al. were pioneers in the use of organometallic 6–arene 
ruthenium complexes as anti-cancer agents. The most promising complexes as 
anti-cancer drugs to date take the form [(6-arene)Ru(II)(ethylenediamine)X]+ (X 
= halide) as shown in Figure 1-17.87 Sheldrick also reported that different 
functionalised-arene rings have activity both in vitro and in vivo against a range 
of cancer cell lines, including cisplatin-resistant cell lines. 
 
Figure 1-17: General structure of a ruthenium organometallic 6-arene complex87 
Chapter 1 Introduction and objectives 
- 17 - 
 
Sadler et al. have also studied these types of complexes reporting that the  
2-phenoxy derivatives showed the highest cytotoxicity amongst the polar 
substituents, but further results showed the non-polar substituents had higher 
activity than polar groups.88 They also showed that, on average, polycyclic arenes 
had higher activity than monocyclic arenes. There is a general thought that on 
increasing the number of arenes, the hydrophobicity will increase, allowing better 
passive transport towards the cell.89,90  
McGowan et al. have carried out an extensive work on arene-ruthenium 
complexes in order to increase the activity against cancerous cells, including 
cisplatin-resistant cell lines. These include a range of picolinamide and 
quinaldamide complexes that have been synthesised from the p-cymene 
ruthenium (II) chloride dimer.91 These (N,N) chelating ligands are highly 
interesting due to previous results discussed within the work of Sheldrick87 and 
they have the advantage of also being (N,O) chelating ligands, which gives them 
the potential to target different organelles within cancerous cells. N,N-
coordination to the metal centre stabilises metal ions in their high oxidation states 
because of the strong σ-donor effect,92 whereas N,O-coordination, relatively 
favours lower oxidation states.93 NMR studies have shown that the equilibrium in 
the coordination throughout the (N,O) and (N,N) can be altered by changing 
temperature and pH,94 hence the biological properties may differ between 
species. The IC50 values of the ruthenium complexes with 3-nitro,  
4-nitro and 4-fluoro picolinamide ligands have shown great activity against a 
range of tumour cells in the same order of magnitude as cisplatin and carboplatin, 
with the advantage of being active against cisplatin resistant cell lines. The 
binding mode of these complexes is essential to its cytotoxic behaviour. Studies 
showed that the (N,N) chelating complexes have quick hydrolysis and bind to 
guanine preferentially, whereas switching to (N,O) slows the hydrolysis rate thus 
switching off the activity.94-96 
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Figure 1-18: (N,O) binding mode and (N,N) binding mode. 92,93 
Work has since focused on rhodium and iridium pentamethylcyclopentadienyl 
(Cp*) complexes introducing either a picolinamide (N,N), a ketoiminate (N,O) or a 
naphthoquinone (O,O) ligand. The difference in binding mode showed that 
compounds bound (N,N) displayed better IC50 values against HT-29 and MCF-7.97 
1.7 Trans-dihalide Metal Complexes as Novel Anti-cancer 
Agents 
Iodide has been used as a labile ligand in the design of metal anti-cancer drugs 
for many years.98 After several studies on cisplatin, it was clearly demonstrated 
that complexes containing chlorides as labile ligands are the most reactive but, 
also less selective.99,100 This fact opened a new interest observing the influence 
of monodentate halogenated ligands as leaving groups in biological assays on 
cisplatin. Sadler et al. have reported metal (Ru or Os) p-cymene complexes with 
a chloride or iodide as the labile ligand, and either azopyridine or iminopyridine 
as the chelating ligand. When substituting the chloride for iodide, the biological 
activities vary drastically, with astounding advantages when containing the iodide 
ligand bonded to the metal centre.101,102 
The structure-activity rules for metal anti-cancer drugs were established by 
Rosenberg,103 and Cleare & Hoeschele.104 Their studies were based on variations 
on the structure of cisplatin, changing geometries, ligands and charge, which 
displayed interesting in vivo anti-cancer properties. The trans-platinum complex 
was found to be inactive, meaning that the cis isomer is relevant for anti-cancer 
activity.105,106 This feature could be easily explained due to two main factors: trans 
complexes are highly reactive due to kinetic instability, leading to an increase in 
toxicity, and the cis geometry can help to chelate biological targets within the 
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cells, which is unfeasible for trans. Studies showed that when changing the 
chloride ligand to iodide, their biological activities still show that cis dichloride 
ligands are more potent, as a very high dose was required for the platinum 
diiodide complex to create a maximum effect for its anti-cancer activity. 
Lately, several trans-platinum complexes have been shown to have more anti-
cancer activity when compared to their cis analogues, going against the structure-
activity rules for metal anti-cancer complexes.107,108 The cytotoxicity of trans-
platinum complexes increases significantly both in vitro and in vivo when 
substituting the inert ligands from simple amines to more bulky ligands. 
Mechanistic studies suggest that these bulky ligands can impede the substitution 
of the trans dichloride ligands, which increases the kinetic instability of the trans-
platinum complexes, hence leading to lower toxicity. Trans-platinum anti-cancer 
complexes were proposed by Farrell et al., in which trans dichloride platinum 
complexes that contain at least one aromatic N-donor ligand have shown a 100-
fold higher cytotoxicity than transplatin and comparable with cisplatin,109 against 
different leukemia cells and human ovarian cells. 
 
Figure 1-19: Recently reported active trans-platinum anti-cancer (TPA) 
complexes108 
On the other hand, there are very few known ruthenium based anti-cancer 
complexes containing iodide monodentate ligands or trans labile ligands. 
Additionally, two iodide ligands are also rare, encouraging the exploration of 
structure-activity relationships on trans-dihalide metal-based anti-cancer 
complexes. McGowan et al. have shown that trans-diiodide bis-picolinamide 
metal complexes represent a family of new anti-cancer drugs that exhibit 
interesting and promising results. This new family interacts with different 
biomolecules in a different mode of action which is still unknown.110 
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To strengthen the success of trans ruthenium complex, it is important to introduce 
the family of the dimethyl sulfoxide complexes. Briefly, the results obtained from 
antitumor activity are very striking, showing that the trans-[Ru(II)(DMSO)4(Cl)2] 
has greater activity than its cis analogue.111 
In the cis isomer three DMSO molecules are bound through sulfur in a fac 
configuration and the fourth is oxygen bonded, whereas the trans isomer have all 
the DMSO ligands S-bound. When dissolved in water, the cis isomer loses the  
O-bonded DMSO ligand, however, the trans compound loses two S-bonded 
DMSO ligands giving cis-diaqua species. Then, both hydrolysed isomers undergo 
slow reversible chloride dissociation forming cationic compounds. After this step, 
the trans species contain three reactive groups, wheras the cis one only has two. 
The three remaining DMSO ligands in the cis compound represent a considerable 
steric hindrance making the cis aqua species inert compared to the trans isomer. 
This difference correlates with a higher activity of the trans isomer as an antitumor 
agent. This was proved using circular dichroism (CD) to study the interaction 
between the ruthenium species and DNA. 
 
Figure 1-20: cis-[Ru(II)(DMSO)4(Cl)2] and trans-[Ru(II) (DMSO)4(Cl)2]111 
1.8 Biological Assays 
The first stage of the preclinical phase for anti-cancer drug discovery and 
development is in vitro cytotoxicity screening.112 These assays are widely used to 
measure the effectiveness of drugs towards a range of human cancer cell lines 
and to identify potential drugs for further analysis. After that, drug candidates can 
be classified as inactive, moderately active or highly active based on their IC50 
values. By definition, IC50 is the concentration of the drug that is required to inhibit 
50% of cell proliferation. 
The first cytoxicity screening assay was the MTT assay developed by Mosmann 
(1983).113 It measures the mammalian cell survival and proliferation by means of 
a yellow dye [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] 
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(MTT) which is reduced in situ by living cells to a purple formazan.113 This process 
takes place principally in the mitochondria.114 However, the results of this assay 
might vary depending on the age and the type of the cell medium. This fact was 
linked to the amount of D-glucose present inside the cells, being inversely 
proportional to the reduction of MTT. 
In 1988, Paul et al. developed the XTT assay, which replaces the MTT  
reagent for sodium 3’-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-
methoxy-6-nitro) benzene sulfonic acid hydrate (XTT).115 This undergoes 
bioreduction to give a -2 charge formazan being, therefore, more water soluble. 
Additionally and unlike MTT, it is soluble in the cell medium giving faster and more 
efficient results. Although, this assay also has  problems with either the absence 
or inhibition reduction when missing the electron-coupling reagent.116 It is also 
thought that because of the presence of a disulfonate group, this XTT may have 
difficulties penetrating the cell membrane, which was previously reported.117  
 
Figure 1-21: Tetrazolium salts used for cell survival. Left, MTT assay; Right, 
XTT assay. 
In order to solve the problems associated with both assays, a new non-formazan 
assay based was developed by Skehan et al. in 1990. This was named the SRB 
assay.118 Chemically, it is an aminoxanthene dye known as Sulforhodamine B 
(SRB) which, under mild conditions, binds to an amino acid residue through two 
sulfonic groups.119 Compared to the MTT and XTT assays, it has a shorter 
incubation period and more consistent results over a larger range of cell lines. 
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However, the outcome versus elaboration balance is very similar, thus the MTT 
assay remains widely used.120 
 
Figure 1-22: Structure of Sulforhodamine B 
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1.9 Objectives 
Previously in the McGowan group, attention was paid to how isomers affect the 
anticancer activity. Pure ruthenium (III) trans-dichloride bis-picolinamide 
complexes were impossible to isolate, hence acknowledging what structural 
isomer gave the anticancer activity was difficult. By increasing the size of the 
organic ligands, it is expecting the formation of just one single structural isomer.  
The objectives of this research project are the following: 
I) Design, synthesis and characterisation of quinaldamide ligands obtained 
through a condensation reaction. 
II) Synthesis of functionalised bis-quinaldamide121 trans-dichloride ruthenium 
complexes changing the electronics and the sterics of the quinaldamide 
ligands to establish structure activity relationship (SARs) and assess their 
potential biological activity. 
III) Determine the biological activity of the complexes describe in point II under 
the supervision of the collaborator Professor Roger M. Phillips at the 
University of Huddersfield. 
 
Figure 1-23: General structure for the di-halide complexes explaining the 
different fragments 
The metal complexes describe in objectives, part II and part III contain several 
fragments (Figure 1-23), which have been proven to be important for anti-cancer 
activity. For the neutral complexes, these features are: 
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A) planar aromatic groups which may cause an intercalation process with the 
DNA nucleobases, 
B) the acidic proton which may interact with acceptor sites on the DNA chain as 
a hydrogen binding donor, 
C) the halide labile ligand which will allow to control hydrolysis and, 
D) the functional groups which will either increase or decrease the hydrophilicity 
of the complexes. 
All novel ligands and complexes synthesised will be characterised by means of 
IR spectroscopy, NMR spectroscopy for the ligands, ESI-MS (Electrospray 
Ionization Mass Spectrometry), EA (Elemental Analysis) and X-ray diffraction 
when appropriate. 
The complexes will be assessed for their anti-cancer potential activity by 
determining their cytotoxicities using the MTT assay and gaining structure activity 
relationships by carrying hydrophobicity studies, hydrolysis and further biological 
assays. Complementary biological studies like antibacterial and antifungal 
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2.1 Background 
The development of chemistry in synthesising peptide-based ligands has great 
relevance due to their roles played in biological activity, where the amide bond  
[-C=O-NH-] is the fundamental linker when forming proteins.1 Comparing them to 
the Schiff bases [R2C=NR’], they show better stability towards hydrolysis 
reactions,2 being an important fact for biological systems that allows both protein 
construction and maintenance. The synthetic pathways towards quinaldamide 
derivatives involve the reaction between amines with either 2-quinaldic carboxylic 
acid,3 or the acyl chloride derivative.4 Bhattacharya et al. have developed a 
preparation for high yielding picolinamide ligands adapted from Barnes et al., by 
a condensation reaction of 2-picolinic acid and the respective aniline in presence 
of a base.5,6 The structural similarity between the 2-picolinic acid and the  
2-quinaldic acid (Figure 2-1) allows the reproduction under modified conditions 
of the synthesis of the quinaldamide ligands. 2-quinoline carboxylic acid differs 
from 2-picoline carboxylic acid because the former contains a benzene group 
fused to the N-containing ring. This group was specifically chosen as similar 
structures have been proved to show a great anticancer activity on their own, but 
not when coordinated to a metal. Moreover, these building blocks are present in 
some of the current pharmaceutical drugs, but their bulkiness and rigidity make 
them challenging to work with.7 
 
Figure 2-1: Backbones of 2-picolinamide (left) and 2-quinaldamide (right) 
Both ligands have the ability to chelate to metal centres in three ways: as 
monoanionic N,N-donors, monoanionic N,O-donors and neutral N,O-donors, as 
shown in Figure 2-2. 
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Figure 2-2: Different coordination modes for the quinaldamide ligands, (top left) 
[N,N] anionic, (top right) [N,O] anionic and (bottom) [N,O] neutral 
Coordination chemistry has a wide range of applications, specifically in biology, 
medicine and pharmacology. It was shown that the strong monoanionic −donor 
bonds coordinate to the metal centres stabilising the high oxidation state,8 
whereas the neutral dative/coordinative bonds favour the lower oxidation states.9 
These differences in the potential modes of coordination contained within the 
ligands can tune the cytotoxic activities of the synthesised complexes in this 
thesis. 
2.2 Synthesis of quinaldamide ligands 
The quinaldamide-core ligand is shown in Figure 2-3. All ligands were 
synthesised and used in this project some were previously found in the 
literature;10,11 however, only the functional groups highlighted in blue have crystal 
structures reported in the CCDC data base. Some of the novel ligands 
synthesised in this project with full characterisation are shown in Figure 2-4. 
 
Figure 2-3: Left, chemical structure of the quinaldamide-core ligands;  
Right, ligands reported and highlighted in blue are in the CCDC data base 
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Figure 2-4: Novel functionalised quinaldamide ligands 
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The ligands containing electron withdrawing groups (EWGs) were synthesised 
according to the Scheme 2.1 by a condensation reaction. (See Chapter 6 for 
reaction conditions) 
 
Scheme 2.1: General protocol to synthesise quinaldamide ligands containing 
electron withdrawing groups (EWGs) 
The ligands containing electron donating groups (EDGs) were synthesised 
according to the Scheme 2.2 developed by Qi,12 as following Scheme 2.1 gave 
an insoluble residue proved difficult to characterise. (See Chapter 6 for reaction 
conditions).  
 
Scheme 2.2: General synthetic pathway to obtain quinaldamide ligands 
containing electron donating groups (EDGs) 
 
In Figure 2.5, the general structure, the different R groups with the numbering 
used through this thesis can be found.  
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Figure 2-5: Summary of ligands with their respective numbering. Blue highlighted 
ligands are novel. Green highlighted are found in literature with no 
characterisation data. Black highlighted ligands are already known but used in 
this research project. 
2.3 Characterisation of functionalised quinaldamide ligands 
N-functionalised quinaldamide or 2-quinolinecarboxamide ligands were prepared 
via Scheme 2.1 to obtain ligands electron-withdrawing ligands, and via Scheme 
2.2 to obtain electron-donating ligands as pure products in yields ranging 
between 32 and 86%. They were characterised by means of IR, 1H NMR, 13C{1H} 
NMR, 19F{1H} NMR when appropriate, COSY, NOESY, HMQC, DEPT, elemental 
analysis, high resolution mass spectrometry and single crystal x-ray diffraction 
when crystals were suitable. Due to the similar chemical structure of all the 
quinaldamide ligands, their respective IR and NMR spectra show similar trends. 
Thus, only the spectra recorded for 2.3 are discussed in this section as well as 
its crystal structure. Crystal structures of ligands 2.30 and 2.37 are also discussed 
in this chapter. The full data collected for the remaining ligands can be found in 
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2.3.1 IR spectrum for ligand 2.3 
The IR spectrum for the ligand 2.3 is as shown in Figure 2-6. It can be seen 
several bands of different intensities between 1600-800 cm-1. The ligand is 
constituted by two main functional groups: the moderate NH monosubstituted 
stretching band is observed at 3365 cm-1 and the intense C=O stretching band 
at 1681 cm-1. The peaks coincide with the reported values of amide bonds, where 
the C=O band falls between 1640-1690 cm-1, the NH stretching falls between 
3100-3500 cm-1 and the NH bending falls between 1550-1640 cm-1. The ranges 
for C-H aromatic and C=C are in the right regions for reported aromatic rings 
however with little relevance. 
 
Figure 2-6: IR spectrum of the ligand 2.3 
2.3.2 NMR spectra for ligand 2.3 
A labelled diagram of ligand 2.3 is shown in Figure 2-7. The 1H and 13C{1H} 
spectra are shown in Figure 2-8 and Figure 2-9, respectively. In Table 2.1, the 
chemical shift assignments are collected. In order to assign all of the aromatic 
protons and the carbon atoms contained within the molecular structure, NOESY, 
HMSQ, HMBC and DEPT were carried out. A broad NH singlet is seen at  
10.54 ppm, different peaks with a variety of multiplicities are found between  
8.50-7.50 ppm that correspond to the aromatic protons of the quinaldamide core 
and specified in Table 2.1. Two intense peaks assigned to the protons of the 
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methoxy groups are found at 3.92 and 3.78 ppm. The 13C{1H} NMR spectrum 
shows a C=O peak at 161.8 ppm and the C-OMe peaks can be seen at 55.9 and 
55.5 ppm. 
 
Figure 2-7: Labelled diagram of ligand 2.3 
 
Figure 2-8: 1H NMR spectrum of the ligand 2.3 (CDCl3, 300 MHz, 300 K) 
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Figure 2-9: 13C{1H} NMR spectrum of the ligand 2.3 (CDCl3, 75 MHz, 300 K) 
 
Table 2.1: 1H and 13C{1H} NMR chemical shift assignments for the ligand 2.3 
Chemical Shift 
(d ppm) 
Multiplicity Assignment Chemical Shift 
(d ppm) 
Assignment 
10.54 bs NH 161.80 C10 
8.46 dd H16 156.67 C1 
8.33 d H8 150.37 C6 
8.28 d H7 150.25 C14 
8.14 d H2 146.47 C12 
7.84 dd H5 137.63 C7 
7.72 ddd H3 130.07 C2 
7.57 ddd H4 129.97 C3 
6.51 d H15 129.32 C9 
6.49 d H13 127.93 C4 
3.92 s OMe18 127.75 C5 
3.75 s OMe17 121.32 C11 
   120.57 C16 
   118.79 C8 
   103.84 C15 
   98.88 C13 
   55.99 C18 
   55.59 C17 
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2.3.3 X-Ray structure for ligand 2.3 
Colourless prisms suitable for X-ray diffraction were obtained from a concentrated 
chloroform solution. Ligand 2.3 crystallised in a monoclinic cell and structural 
solution was performed in the space group I2 containing one molecule in the 
asymmetric unit. The molecular structure is shown in Figure 2-10 and selected 
bond lengths and angles are given in Table 2.2. Ligand 2.3 adopts a quasi-planar 
configuration, in which the dihedral angle between the quinaldic ring and the 
aniline ring N(1)-C(9)-C(10)-N(2) is 1.422(3)°. Intramolecular hydrogen bonding 
exists between N(2)...N(1) with a bond distance of 2.676(2) Å, and between 
C(16)-H…O(1) with a bond distance of 2.493 Å. Ligand 2.3 arranges itself in 
parallel planes along the a axis as shown in Figure 2-11 proving that there is − 
stacking with a centroid-centroid distance of 3.911 Å for the quinaldic ring and a 
centroid-centroid distance of 3.638 Å for the aniline rings, when viewed along the 
c axis (Figure 2-12) the ligand adopts a herringbone motif where the planes are 
held together by intermolecular hydrogen bonding between the methoxy 
hydrogens and the oxygens of the next molecules. 
 
Figure 2-10: Molecular structure of ligand 2.3 showing intramolecular hydrogen 
bonds. Displacement ellipsoids are at the 50% probability level 
Table 2.2: Selected angles for ligand 2.3 with esds shown in parenthesis 
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Table 2.3: Selected bond lengths for ligand 2.3 with esds shown in parenthesis 











Figure 2-11: Packing diagram of ligand 2.3 in the a axis showing − stacking 
and intermolecular hydrogen bonds between the 4-methoxy oxygen and the  
4’-methoxy hydrogens of the molecule below. 
 
Figure 2-12: Intermolecular hydrogen bonds (left) in the b axis and (right) in the 
c axis arranged in a herringbone motif. 
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2.3.4 X-Ray structure for ligand 2.30 
Colourless needles suitable for x-ray diffraction were obtained from slow 
evaporation of a solution in methanol. Ligand 2.30 crystallised in an orthorhombic 
cell and solved in the space group P212121 containing one molecule in the 
asymmetric unit. The molecular structure is shown in Figure 2-13 and selected 
bond lengths and angles are given in Table 2.4. Ligand 2.30 adopts a quasi-
planar configuration, in which the torsion angle between the quinaldic ring and 
the aniline ring N(1)-C(9)-C(10)-N(2) is 1.792(8)°. Intramolecular hydrogen 
bonding exists between N(2)...N(1) with a bond distance of 2.612(2) Å, and 
between C(16)-H…O(1) with a bond distance of 2.274 Å. Ligand 2.30 arranges 
itself in parallel planes along the b axis as shown in Figure 2-13 showing − 
stacking interactions with a centroid-centroid distance of 3.783 Å for the quinaldic 
ring and a centroid-centroid distance of 3.753 Å for the aniline ring, when viewed 
along the c axis (Figure 2-12 ) the ligand adopts a herringbone motif where the 
planes are held together by the − stacking described above and hydrogen 
bonds of 2.420 Å between the oxygen of the carbonyl group and the hydrogens 
in the C5 positions. 
 
Figure 2-13: Molecular structure of ligand 2.30 showing intramolecular 
hydrogen bonds. Displacement ellipsoids are at the 50% probability level 
Table 2.4: Selected angles for ligand 2.30 with esds shown in parenthesis 
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Table 2.5: Selected bond lengths for ligand 2.30 with esds shown in parenthesis 










Figure 2-14: Packing diagram of ligand 2.30 (on the left) showing hydrogen 
bonds between the carbonyl group and the perpendicular proton on the opposite 
quinaldamide core (axis a) and the − stacking on the right (axis b). 
 
 
Figure 2-15: Herringbone motif or zig-zag interaction of the ligand 2.30, held by 
−  interactions. 
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2.3.5 X-Ray structure for ligand 2.37 
A colourless block suitable for X-ray diffraction was obtained from a concentrated 
chloroform solution. Ligand 2.37 crystallised in a monoclinic cell solved in the 
space group P21/c containing one molecule in the asymmetric unit. The molecular 
structure is shown in Figure 2-16 and selected angles and bond lengths are given 
in Table 2.6 and Table 2.7. Ligand 2.37 adopts a quasi-planar configuration, in 
which the dihedral angle between the quinaldic ring and the aniline ring  
N(1)-C(9)-C(10)-N(2) is 3.971(2)°. This distortion is attributed to the bulkiness of 
the R group in the aniline ring, it is observed that the bulkier the group the bigger 
the torsion angle. Intramolecular hydrogen bonding exists between N(2)...N(1) 
with a bond distance of 2.660(4) Å, and between C(12)-H…O(1) with a bond 
distance of 2.279 Å. Ligand 2.37 arranges itself in perpendicular and parallel 
planes alternating the position of the ligand as shown in Figure 2-17 held together 
by − stacking interactions with a centroid-centroid distance of 3.981 Å between 
two aniline rings and a centroid shift of 1.890 Å, a centroid-centroid distance of 
3.751 Å with a centroid shift of 1.589 Å between the quinaldic cores and a 
distance of 3.771 Å with a shift of 1.867 Å between the quinaldic core and the 
aniline ring, when viewed along the c axis (Figure 2-17). The ligand adopts a 
square-pattern motif as shown in Figure 2-18. 
 
Figure 2-16: Molecular structure of ligand 2.37 showing intramolecular hydrogen 
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Table 2.6: Selected angles for ligand 2.37 with esds shown in parenthesis 
Bond Angle (°) 





Table 2.7: Selected bond lengths for ligand 2.3 with esds shown in parenthesis 











Figure 2-17: Packing diagram of ligand 2.37 showing − stacking and 
intermolecular hydrogen bonds. 
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Figure 2-18: Packing of the ligand in a square motif  
Crystal data for ligands 2.4, 2.15, 2.16, 2.24, 2.25, 2.29 and 2.37 are given in 
the appendix. 
2.4 Conclusion 
Biological systems are strongly influenced by proteins, thus the peptide chemistry 
of amide ligands is a research field vastly investigated due to their well-known 
stability and cell uptake. Twelve novel functionalised quinaldamide ligands have 
been synthesised and fully characterised by IR, H.R.M.S, NMR (1D and 2D) 
techniques and by elemental analysis and by X-ray crystallography. The crystal 
structures obtained so far have probed the planarity of the ligands with a twist 
between the two fragments, the quinaldic ring and the aniline ring. Only three 
compounds showing different crystals structures were described due to their 
packing similarities independently in the functional groups were electron donating 
groups or electron withdrawing groups. 
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3.1 Background 
Farrell, reported that trans-dichloride platinum anti-cancer complexes containing 
at least one aromatic N-donor ligand have shown greater cytotoxicity than 
transplatin and comparable with cisplatin1 against different leukemia cells and 
human ovarian cells. Metal complexes of the type MX2L2 (X = halide, and L = 
bidentate ligand) were explored by Krause et al. and seen previously to undergo 
isomerisation, giving rise to six different structural geometries (Figure 3-1).2 
Reedijk et al., following the work from Krause with (2-(phenylazo)pyridine (azpy) 
(left structure in Figure 3-2), have reported the anticancer activities of 
Ru(azpy)2Cl2 complexes attributing to the different structural isomers. The low 
cytotoxicity against cancer cells was predominately seen for the trans dichloride 
geometries.3 However, after developing a new ligand, H-pyrimol (4-methyl-2-N-
(2-pyridylmethylene) aminophenol) (right structure in Figure 3-2), which upon 
complexation yielded a series of trans-dichloride Ru(II) compounds, Reedijk et al. 
showed that the their trans complexes were more potent than cisplatin to different 
cell lines.4  
 
Figure 3-1: Possible isomers for ruthenium complexes type RuX2L2 bearing 
homoleptic bidentate ligands. Optical isomers are also shown. 
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Figure 3-2: Left, ligand used by Krause; Right, ligand developed by Reedijk. 
More recently, Glazer et al. has compared the anticancer activities of polypyridyl 
based complexes, cis-Ru(bpy)2Cl2 with trans-Ru(qpy)Cl2, showing the trans 
isomer to be 7-10 times more active than the cis being and similar to the potency 
of cisplatin.5 The wide range of effects caused by the different geometries of the 
complexes in biological fields, triggered research into the formation of different 
isomers focusing on the synthesis and development of transition metal based 
candidates using well known scaffolds like: metal-arenes,6 metal-Cp*,7 and 
ferrocene derivatives.8 
Ruthenium complexes of the type Ru(X)2(L)2 where X is chloride or halide and L 
is a bidentate ligand (picolinamide) have been introduced in the McGowan group 
showing the trans-arrangement of the halides has more potency against a variety 
of cancerous cell lines reaching the nanomolar range. The anticancer activity was 
also increased by replacing the chlorides for iodides.9 
This chapter discusses the selective synthesis, isolation and characterisation of 
a novel family of neutral trans-dichloride ruthenium bisquinaldamide complexes. 
The aim is to add and to expand a new family of compounds based in amide 
linkages and evaluate the biological properties of the complexes. 
3.2 Rationale behind Ru(Cl)2(L)2 type complexes 
The molecular design of Ru(Cl)2(L)2 type complexes involves planar aromatic 
groups and an amide linkage which may interact with the DNA acceptor sites. 
These features will determine the rate of hydrolysis, hydrophobicity and anti-
cancer properties. The general synthesis proceeds via direct addition of two 
equivalents of ligand (L) fully dissolved before addition to the ruthenium precursor 
in hot ethanol. This chapter will compare what the effects are upon addition of a 
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base and if the is base free. The coordination of the quinaldamide is tightly related 
to the substituent groups in the aniline. Theoretically, up to five structural isomers 
are possible in solution state, however, only the trans-dichloride isomer is isolated. 
3.3 Synthesis of the neutral trans-dichloride bisquinaldamide 
ruthenium (III) complexes 
The five possible isomers for dichloride bisquinaldamide ruthenium complexes 
are illustrated in Figure 3-3. The compounds synthesised were characterised by 
high resolution mass spectrometry, elemental analysis, X-ray diffraction and 
infrared spectroscopy confirming a trans-trans-trans arrangement. 
 
Figure 3-3: Possible isomers of dichloride bisquinaldamide ruthenium complexes 
The complexes (general structure found in Figure 3-4 and the numbering of the 
synthesised complexes in Table 3-1) were obtained following both a procedure 
developed in the McGowan group9 and an adaptation of it - the base free reaction. 
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Figure 3-4: Trans-dichloride bisquinaldamide ruthenium (III) backbone where R 
is a functional group either electron donating or withdrawing. 
Table 3-1: Numbering of the synthesised complexes and functionality given by 
the R group 
Complex R Complex R 
3.1 H 3.25 4-F 
3.5 2-Me 3.26 2,4-diF 
3.6 3-Me 3.27 2,5-diF 
3.7 4-Me 3.28 2-Cl 
3.9 2-Et 3.29 3-Cl 
3.10 3-Et 3.30 4-Cl 
3.11 4-Et 3.31 2,4-diCl 
3.12 2-iPro 3.32 2,5-diCl 
3.13 3-iPro 3.33 2-Br 
3.15 2,6-diiPro 3.34 3-Br 
3.16 2-Me-6-iPro 3.35 4-Br 
3.17 2-tBu 3.36 2,4-diBr 
3.18 4-tBu 3.38 2-I 
3.23 2-F 3.39 3-I 
3.24 3-F 3.40 4-I 
 
Chapter 3: Ruthenium (III) dichloride bis-quinaldamide complexes 
- 54 - 
 
 
Scheme 3-1: Optimised base-free synthetic pathway to obtain the ruthenium 
complexes. 
The optimised procedure in Scheme 3-1 differs from the original by not adding a 
base. Two equivalents of a ligand dissolved in hot ethanol was added to a solution 
in hot ethanol of one equivalent of RuCl3·3H2O in 5 mL of ethanol, then the 
mixture was heated to 90ºC with constant stirring for 14h and filtered off. Coloured 
solids were isolated, and the mother liqueurs were left to crystallise. 
3.4 Characterisation of bis-quinaldamide trans-dichloride Ru 
(III) complexes 
This section only discusses the compounds obtained via the base free reaction. The 
MChem student Daniel Kowalski isolated the complexes with substituents in position 
2 and in position 3 by an MSci student Abigail Frith. The unsubstituted quinaldamide 
complex, those substituted in position 4, disubstituted, and the reactions carried out 
by adding triethyl amine as a base were carried out by the author, (Figure 3-5). 
 
Figure 3-5: Chemical structures of the compounds functionalised in different 
position 2 (left), position 3 (middle) and position 4 and disubstituted (right). 
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All complexes in this thesis are novel, however, the discussion in this chapter is 
focused on the those displaying great anticancer activity, calling these 
compounds in Chapter 5: Lead Compounds. Trans-dichloride trans-
bishomoleptic quinaldamide ruthenium neutral complexes were prepared as 
shown in Scheme 3-1 to obtain complexes in Table 3-1 with yields ranging 
between 7% and 65%. The main technique used in this thesis is x-ray diffraction, 
thus the focus of this chapter. The lead compounds are constituted by the 
following R groups: H, 4-tBu, 2-F, 3-Cl, 2,5-diCl and 2-I. The two not discussed 
contain R = 3-iPr and 2,4-diBr (Table 3-1). Additionally, only the characterisation 
of the complex 3.1 formed by the unsubstituted ligand (R = H, ligand 2.1) is 
explained in detail and throughout different sections, due to the structural 
similarities within this novel family allowing to outline general trends: thus the 
main focus is given to the successful candidates as anticancer compounds in 
terms of X-ray characterisation and X-ray powder diffraction. All complexes were 
found to be: soluble in polar aprotic solvents like dimethylformamide and dimethyl 
sulfoxide; scarcely soluble in acetone, chloroform, dichloromethane, acetonitrile 
and octanol; and insoluble in aliphatic, ethers and derivatives of benzene. 
3.5 Ruthenium Complex 3.1 
3.5.1 Infrared Spectroscopy of the complex 3.1 
The IR spectra collected for all the complexes are very similar, with a variety of 
bands and different intensities in the 1700-400 cm-1 region. A comparison  
(Figure 3-6) between the free ligand (2.1) and the complex (3.1) can be made 
focusing on the main functional groups. Theoretically, it is expected a band shift 
towards lower wavenumbers when the complex is synthesised. The C=O stretch 
of the ligand is found at 1674 cm-1 whereas in the complex, an interval between 
1519-1490 cm-1 is observed. The NH group of the free ligands appears at 3339 
cm-1 and a very week band can be seen at 3257 cm-1 for the complex. The peak 
at 3053 cm-1 of C-H aromatic bonds of the ligand appear in the complex around 
3140 cm-1.  
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Figure 3-6: Comparison of the IR spectra of the ligand 2.1 (purple line) and its 
ruthenium complex 3.1 in red. 
3.5.2 High Resolution Mass Spectrometry of the complex 3.1 
Ruthenium has a characteristic isotopic pattern which can be identified by HRMS. 
Figure 3-7 shows the isotopic distribution of the metal complex 3.1 simulated and 
compared to the experimental pattern. The molecular ion [M+H]+ peak is 
668.0308 m/z and the simulated spectrum gives a value of 668.0317 m/z. The 
addition of this proton can be attributed to the nitrogen of the amide linkage of the 
neutral bound ligand. 
 
Figure 3-7: HRMS spectra of the complex 3.1 (left) experimentally determined 
and (right) simulated pattern. 
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The comparison between the results obtained and the predicted pattern proves 
that the complexes can be detected by High Resolution Mass Spectrometry. 
3.5.3 General trends in X-ray Crystallography for the complexes and 
X-ray single crystal diffraction of complex 3.1 
Single crystals suitable for X-ray diffraction were grown for all complexes by slow 
evaporation from saturated solutions in DMF or DMSO. Ligands bound in different 
modes as proved by the crystal structures (the chemical structure for complex R = 
H (3.1) can be found in Figure 3-8), one bound neutrally as an amide and the other 
bound anionically [N,N] or [N,O], being the latter found for complexes with electro-
donating ligands in position 2 of the aniline ring. The complexes present a distorted 
octahedral geometry with bond angles in the range 169.51(10)°- 178.59(4)° for the 
chlorides trans to each other - interestingly, the unsubstituted ligand 2.1 gives the 
more distorted geometry and the 2,5-difluoroquinaldamide ligand (2.27) shows the 
labile ligands closer to 180°. The bond angles for the trans nitrogens of the 
quinaldic cores can be found between 173° - 179°. The ligands bound anionically 
show a chelating angle between 76.65(10)° - 79.8(3)° whereas the neutrally bound 
ligands show angles between 75.27(13)° - 78.75(10)°.  
 
Figure 3-8: Chemical structure of compound 3.1. 
Trans-dichloride bis-(N-phenyl)-quinaldamide ruthenium (III) complex, 3.1, 
(Figure 3-8) was isolated as a red powder and crystallised from DMF yielding red 
plates and red needles. The asymmetric unit of the first compound contains one 
molecule of DMF and water, it crystallised in a monoclinic cell and solved in the 
space group P21/n, whereas the second molecule crystallises with a molecule of 
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DMF in its asymmetric unit making this a triclinic cell and solved in the space 
group P-1. Figure 3-9 shows that for both single crystal structures, only the trans-
trans-trans isomer is isolated. The complexes are arranged in a slightly distorted 
octahedral geometry caused by the ligands as they bend towards one of the 
chlorides, proving that instead of the ideal 180º angle formed between the 
chlorides and the metal is 173.84(3)º for the first structure and slightly more 
distorted for the second one with an angle of 171.99(2) º. However, to prove the 
bulk of the sample is formed only by the trans isomer, X-ray powder diffraction of 
the whole sample must be obtained. See section 3.5.4. 
 
Figure 3-9: Solvent dependent crystal structures for complex 3.1. 
Figure 3-10 shows that the aryl group of the ligands twists out of the plane 
allowing the quinolyl groups to interact with the anionically bound of another 
molecule and the neutrally bound with the neutral one. This rotation prevents the 
formation of hydrogen bond C(12)-H…(O)1 but forming instead the hydrogen 
bond between C(18)-H…O(1) as shown on the left structure in Figure 3-9. 
Further hydrogen bonds can be seen between the ruthenium complex and both 
DMF (between the N(2)-H…O(3)/ODMF with distance of 2.767 Å) and water 
(between OH2O-H… O(2) with a distance of 3.021 Å). 
Table 3-2 summarises the bond lengths to prove that one of the ligands is bound 
deprotonated and the other bound neutrally through the lone pair. The neutral ligand 
shows the carbonyl bond (C(10)…O(1)) distance of 1.264(4) Å, the amide nitrogen 
single bond C(10)…N(2) has a length of 1.324(4) Å, confirming the ligand 
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coordinates neutrally as a L-type. The ligand bound anionically shows similar bond 
lengths being the carbonyl bond length C(26)…O(2) of 1.241(4) Å and the amide 
nitrogen bond length C(26)…N(4) of 1.351(4) Å. Although, in this case, the proton 
attached to the nitrogen of the peptide bond is lost making the ligand an X-type. In 
Table 3-3 all the relevant bond and dihedral angles are summarised. 
Table 3-2: Selected bond lengths for complex 3.1 with labelled atoms 
corresponding to the complex on the left of Figure 3-9 
Bond Length/ Å Bond Length/ Å 
Ru(1)-Cl(1) 2.3561(7) N(1)-C(9) 1.343(4) 
Ru(1)-Cl(2) 2.3461(7) O(2)-C(26) 1.241(4) 
Ru(1)-O(1) 2.096(2) N(2)-C(10) 1.324(4) 
Ru(1)-N(1) 2.110(2) N(3)-C(25) 1.332(4) 
Ru(1)-N(3) 2.076(2) N(4)-C(26) 1.351(4) 
Ru(1)-N(4) 2.023(2) C(9)-C(10) 1.485(4) 
O(1)-C(10) 1.264(4) C(25)-C(26) 1.492(4) 
Table 3-3: Selected bond angles for complex 3.1 with labelled atoms 
corresponding to the complex on the left of Figure 3-9 
Bond Angle/ ° Bond Angle/ ° 
O(1)-Ru(1)-Cl(1) 83.25(6) N(3)-Ru(1)-Cl(2) 89.45(7) 
N(1)-Ru(1)-Cl(1) 88.43(7) O(1)-Ru(1)-Cl(2) 99.46(7) 
Cl(2)-Ru(1)-Cl(1) 173.84(3) O(1)-Ru(1)-N(1) 75.91(8) 
N(3)-Ru(1)-Cl(1) 89.43(7) N(3)-Ru(1)-N(1) 175.59(9) 
N(4)-Ru(1)-Cl(1) 86.27(7) N(4)-Ru(1)-N(1) 104.94(9) 
O(1)-Ru(1)-Cl(2) 90.98(6) N(3)-Ru(1)-O(1) 100.00(8) 
N(1)-Ru(1)-Cl(2) 92.27(7) N(4)-Ru(1)-O(1) 169.46(9) 
N(4)-Ru(1)-N(3) 78.76(9)   
Chapter 3: Ruthenium (III) dichloride bis-quinaldamide complexes 
- 60 - 
 
In terms of  stacking (similar for both structures seen in Figure 3-9), the 
aromatic rings rotate to maximise the interactions and stabilise the molecule’s 
network. The crystal packing in Figure 3-10 shows that molecules interact with 
each other via  stacking of the quinaldic core of the anionically bound ligands 
(highlighted in blue) with a centroid-centroid distance of 3.229 Å and the angle 
between planes of 4.199°. Whereas the quinaldic cores for the neutrally bound 
ligands show a centroid-centroid distances of 3.591 Å and no distortion angle. 
 
Figure 3-10: Crystal packing interactions of the complex 3.1 (similar packing for 
both complexes). 
 
Figure 3-11: Extended crystal structure for complex 3.1. 
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Figure 3-11 shows the expansion of the crystal structure from complex 3.1 
displaying a zig-zag arrangement and the chlorides perpendicularly aligned. 
3.5.4 X-ray powder diffraction of complex 3.1 
The X-ray powder pattern diffraction for complex 3.1 was recorded to prove that 
only one isomer was obtained from both the bulk powder sample and the crystal 
structure, thus determining the purity of the sample biologically tested. Figure 
3-12 shows the comparison of the two PXRD diffractograms corroborating that 
both sets are constituted by only one isomer. Although there are few additional 
peaks, all the main peaks corresponding to the unit cell of the ruthenium complex 
3.1 match very well between the simulated and the experimental data, indicating 
that the complex has a similar structural geometry in both samples. 
 
Figure 3-12: XRPD data overlap of complex 3.1 showing the experimental (black) 
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3.6 Ruthenium complex 3.18 
3.6.1 X-ray single crystal diffraction of complex 3.18 
 
Figure 3-13: Chemical structure for complex 3.18 (left); labelled crystal structure (right). 
Trans-dichloride bis-(N-4tbutylphenyl)-quinaldamide ruthenium (III) complex 
(3.18) (Figure 3-13) was isolated as a red powder and crystallised from DMF as 
red prisms. The asymmetric unit contains one molecule of DMF (crystallisation 
solvent), crystallising in a triclinic cell and solved in the space group P-1.  
Figure 3-13 (right) shows the single crystal being only the trans-trans-trans 
isomer isolated. The ruthenium centre shows a slightly distorted octahedral 
geometry caused by the ligands as they bend towards one of the chlorides 
displaying a Cl-Ru-Cl angle of 174.68(6)º instead of the ideal 180º. The aromatic 
rings twist out to maximise the stability of the compound, fact found across the 
series of complexes. The angle found between N(3)-Ru(1)-N(1) and  
O(2)-Ru(1)-N(2) is 175.55(17)° and 168.93(17)° respectively. 
In terms of  stacking, the aromatic rings rotate to maximise the interaction an 
stabilise the molecule. Specifically, the aryl group of the anionically bound ligand 
twists towards the quinolyl group of the neutrally bound ligand. The same 
happens to the other ligand preventing the formation of hydrogen bond  
C(32)-H…(O)2 but forming instead the hydrogen bond between C(2)-H…O(2) 
with a distance of 2.219 Å. It can be seen another hydrogen bond between amide 
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proton and the oxygen from the DMF. The distance found between N(4)-
H…O(3)/ODMF is 1.943 Å. 
Table 3-4 summarises the bond lengths corresponding to the labelled complex 
in Figure 3-13 which proves one of the ligands is bound after the deprotonation 
of the amide and the other bound neutrally via the lone pair. The neutral ligand 
shows the carbonyl bond (C(30)…O(2)) of 1.268(5) Å, the amide nitrogen single 
bond C(30)…N(4) has a length of 1.325(6) Å acting as an L-type ligand within the 
normal values for free amides. The ligand bound anionically shows similar bond 
lengths being the carbonyl bond length C(10)…O(1) of 1.249(4) Å and the amide 
nitrogen bond length C(11)…N(2) of 1.341(7) Å. Although, in this case, the proton 
attached to the nitrogen of the peptide bond is lost making the ligand an X-type. 
This similarity in bond distances shows the ligands remain almost intact meaning 
the amide bond is weekly disturbed by the coordination of the ruthenium centre. 
Table 3-4 and Table 3-5 summarises all the relevant bond lengths, angles and 
dihedral angles. 
Table 3-4: Selected bond lengths for complex 3.18 with labelled atoms 
corresponding to the complex in Figure 3-13 
Bond Length/ Å Bond Length/ Å 
Ru(1)-Cl(1) 2.3727(15) N(1)-C(9) 1.342(6) 
Ru(1)-Cl(2) 2.3399(15) O(2)-C(30) 1.268(5) 
Ru(1)-O(2) 2.094(3) N(2)-C(10) 1.341(7) 
Ru(1)-N(1) 2.086(4) N(3)-C(29) 1.341(6) 
Ru(1)-N(2) 2.018(4) N(4)-C(30) 1.325(6) 
Ru(1)-N(3) 2.112(4) C(9)-C(10) 1.492(8) 
O(1)-C(10) 1.249(6) C(29)-C(30) 1.500(7) 
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Table 3-5: Selected bond angles for complex 3.18 with labelled atoms 
corresponding to the complex on Figure 3-13 
Bond Angle/ ° Bond Angle/ ° 
O(2)-Ru(1)-Cl(1) 82.37(10) N(2)-Ru(1)-Cl(2) 98.24(14) 
N(1)-Ru(1)-Cl(1) 89.03(12) N(3)-Ru(1)-Cl(2) 90.13(12) 
Cl(2)-Ru(1)-Cl(1) 174.68(6) O(2)-Ru(1)-N(3) 77.23(15) 
N(2)-Ru(1)-Cl(1) 86.79(14) N(3)-Ru(1)-N(1) 175.55(17) 
N(3)-Ru(1)-Cl(1) 90.21(12) N(2)-Ru(1)-N(3) 105.14(17) 
O(2)-Ru(1)-Cl(2) 92.54(10) N(1)-Ru(1)-O(2) 98.32(14) 
N(1)-Ru(1)-Cl(2) 90.22(12) N(2)-Ru(1)-O(2) 168.93(17) 
N(2)-Ru(1)-N(1) 79.20(16)   
 
Figure 3-14 shows the  stacking of the quinaldamide cores. As previously 
discussed, the anionically bound interacts with the same one of another molecule 
and the neutrally bound with the neutral. The green planes show a centroid-
centroid distance of 3.720 Å and the blue planes display a centroid-centroid 
distance of 4.569 Å, which is long for interactions. Figure 3-15 shows the 
stacking of the complex showing a concave-convex packing motif, with the 
chlorides pointing outwards and the organic framework showing the 
encapsulation of the metal centre. 
 
Figure 3-14:  interactions for complex 3.18. 
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3.7 Ruthenium complex 3.23 
3.7.1 X-ray single crystal diffraction for complex 3.23 
 
Figure 3-16: Chemical structure of complex 3.23 (left); labelled crystal structure (right). 
Trans-dichloride bis-(N-2-fluorophenyl)-quinaldamide ruthenium (III) complex 
(3.23) (Figure 3-16) was isolated as a bright red powder and crystallised from 
DMSO as red prisms. The asymmetric unit is a cocrystal formed by one molecule 
of DMSO and one molecule of the complex, crystallised in a triclinic system and 
solved in the space group P-1. Figure 3-16 shows the single crystal for the only 
isomer obtained: the trans-trans-trans. The slightly distortion of the octahedral 
geometry is given by the angle formed between the following trans arranged 
atoms: 178.59(4)° for Cl(1)-Ru(1)-Cl(2), 168.44(12)° for N(2)-Ru(1)-O(2) and 
172.60(11)° for N(1)-Ru(1)-N(3). Figure 3-16 also shows one ligand 
deprotonated (X-type ligand) and one neutral (L-type ligand) showing the 
following bond lengths: the carbonyl group (C(10)-O(1)) of the X-type ligand 
shows a distance of 1.227(5) Å and 1.255(5) Å for the L-type ligand (C(26)-O(2). 
The nitrogen-carbon single bond for the anionic ligand (C(10)-N(2)) shows a 
distance of 1.363(5) Å and 1.336(5) Å for the neutral C(26)-N(4) bond. The 
relevant bond lengths and angles are collected in Table 3-6 and Table 3-7. 
Figure 3-17 shows the of  interactions that display different behaviour than 
the remaining complexes within the series apart from complex 3.32 (see section 
3.9). The ligands bound anionically ([N,N]- coordination) highlighted in blue show 
the quinolyl groups interacting showing a centroid-centroid distance of 3.554 Å. 
Furthermore, the aryl groups (green highlighted) show a centroid-centroid 
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distance of 3.685 Å for the  stacking interaction and with a shift between 
centroids of 1.482 Å. The only hydrogen bond found belongs to  
N(4)-H…O(3)/DMSO showing a distance of 2.768 Å (Figure 3-16). 
 
Figure 3-17: Extended crystal structure of compound 3.23, showing the 
intermolecular  interactions. 
Table 3-6: Selected bond lengths with s.u.s. for complex 3.23 and atom labels 
found in Figure 3-16 
Bond Length/ Å Bond Length/ Å 
Ru(1)-Cl(1) 2.3371(11) N(1)-C(9) 1.325(13) 
Ru(1)-Cl(2) 2.3701(11) N(2)-C(10) 1.363(5) 
Ru(1)-O(2) 2.085(2) N(3)-C(25) 1.348(5) 
Ru(1)-N(1) 2.058(3) N(4)-C(26) 1.336(5) 
Ru(1)-N(2) 2.013(3) C(9)-C(10) 1.495(6) 
Ru(1)-N(3) 2.131(3) C(25)-C(26) 1.490(6) 
O(2)-C(26) 1.255(5)   
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Table 3-7: Selected bond angles with s.u.s. for complex 3.23 and atom labels 
found in Figure 3-16 
Bond Angle/ ° Bond Angle/ ° 
Cl(1)-Ru(1)-Cl(2) 178.59(4) N(2)-Ru(1)-Cl(1) 95.49(10) 
O(2)-Ru(1)-Cl(1) 95.26(9) N(2)-Ru(1)-Cl(2) 85.75(10) 
O(2)-Ru(1)-Cl(2) 83.46(8) N(2)-Ru(1)-O(2) 168.44(12) 
O(2)-Ru(1)-N(3) 76.41(11) N(2)-Ru(1)-N(1) 78.95(13) 
N(1)-Ru(1)-Cl(1) 90.51(10) N(2)-Ru(1)-N(3) 107.26(12) 
N(1)-Ru(1)-Cl(2) 89.06(10) N(3)-Ru(1)-Cl(1) 92.83(9) 
N(1)-Ru(1)-O(2) 96.72(11) N(3)-Ru(1)-Cl(2) 87.44(9) 
N(1)-Ru(1)-N(3) 172.60(11)   
 
 
Figure 3-18: Expansion of the crystal structure for complex 3.23. 
The crystal packing shown in Figure 3-18 displays the oval-shape of the 
complexes where the ligands bend towards one of labile chlorides, encapsulating 
both the ruthenium metal centre and the halide. 
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3.8 Ruthenium complex 3.29 
3.8.1 X-ray single crystal diffraction of complex 3.29 
 
 
Figure 3-19: Chemical structure of complex 3.29 (left); labelled crystal structure (right). 
Trans-dichloride bis-(N-3-chlorophenyl)-quinaldamide ruthenium (III) complex 
(3.29) (Figure 3-19) was isolated as a red powder and crystallised from DMF as 
dark red plates. The asymmetric unit contains one molecule of DMF and the 
complex, it crystallised in a monoclinic cell and solved in the space group P-1. 
Figure 3-19 (right) shows the crystal structure of the trans-trans-trans isomer 
isolated. It also shows the slightly octahedral geometry distortion caused by the 
ligand interactions. Two opposite heteroatoms (O(1) and N(4)) point towards one 
of the chlorides (Cl(2)) and the other two (N(3) and N(1)) towards the other 
chloride (Cl(1)), what creates the chlorides to be far from 180º the angle, being 
the Cl-Ru-Cl angle 169.51(10)º. For trans-purity of the bulk see section 3.8.2. 
The  stacking interactions like the compounds described so far within this 
chapter; the aromatic rings rotate to maximise the interactions an stabilise 
the whole molecule. The ligand bound in a neutral manner shows that the aryl 
group twists facing almost perpendicularly the quinolyl group of the neutrally 
bound ligand, preventing the formation of the intramolecular hydrogen bond 
C(28)-H…O(2) breaking the planarity of the ligand but forming instead the 
hydrogen bond between C(2)-H…O(2) with a distance of 2.965Å. Further 
hydrogen bonds can be seen between the amide proton of the ruthenium complex 
and DMF. The N(2)-H…O(3)/ODMF has a distance of 2.714 Å. 
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The anionically bound ligand ([N,N] coordination) shows the carbonyl bond 
(C(10)-O(1)) has a distance of 1.219(13) Å and the amide nitrogen single bond 
C(10)-N(2) has a length of 1.385(14) Å. It can be confirmed the ligand coordinates 
neutrally as an X-type. The neutrally coordinated shows similar bond lengths 
being the carbonyl bond length C(26)-O(2) of 1.245(12) Å and the amide nitrogen 
bond length C(26)-N(4) of 1.313(13) Å making it an L-type ligand. Overall, one of 
the ligands is negatively charged which coordinates to the ruthenium centre 
without varying the oxidation state of it and one neutral which completes the 
octahedral geometry of the complex. Relevant bond lengths, angles and dihedral 
angles are summarised in Table 3-8 and Table 3-9. 
The extended crystal structure packing shown Figure 3-20 shows that molecules 
interact with each other via  stacking of the quinaldic cores corresponding to 
the deprotonated ligand with a centroid-centroid distance of 3.947 Å highlighted 
in blue and presenting a plane shift of 3.372, whereas the green quinoline cores 
belonging to the neutral ligand show a centroid-centroid distance of 3.523 Å with 
a shift of 3.428° and a slightly torsion of 0.813° between them. 
 
Figure 3-20: Extended crystal structure of compound 3.29, showing the 
intermolecular  interactions. 
Figure 3-21 shows the expansion of the crystal packing displaying a laminar 
shape where the chlorides occupy the void created by the ligands which are 
arrange in a quasi-planar disposition. 
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Figure 3-21: Expansion of the crystal packing of the complex (3.29). 
Table 3-8: Selected bond lengths for complex 3.29 with labelled atoms 
corresponding to the complex in Figure 3-19 
Bond Length/ Å Bond Length/ Å 
Ru(1)-Cl(1) 2.349(3) N(1)-C(9) 1.325(13) 
Ru(1)-Cl(2) 2.388(3) N(2)-C(10) 1.385(14) 
Ru(1)-O(2) 2.104(7) N(3)-C(25) 1.324(13) 
Ru(1)-N(1) 2.096(8)) N(4)-C(26) 1.313(13) 
Ru(1)-N(2) 1.966(9) C(9)-C(10) 1.510(13) 
Ru(1)-N(3) 2.126(8) C(25)-C(26) 1.492(13) 
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Table 3-9: Selected bond angles for complex 3.29 with labelled atoms 
corresponding to the complex in Figure 3-19 
Bond Angle/ ° Bond Angle/ ° 
O(2)-Ru(1)-Cl(1) 87.6(2) N(3)-Ru(1)-Cl(2) 91.4(2) 
N(1)-Ru(1)-Cl(1) 88.4(2) O(2)-Ru(1)-N(1) 101.3(3) 
Cl(2)-Ru(1)-Cl(1) 169.51(10) N(2)-Ru(1)-N(1) 79.8(3) 
N(2)-Ru(1)-Cl(1) 97.0(3) N(3)-Ru(1)-N(1) 176.5(3) 
N(3)-Ru(1)-Cl(1) 89.9(2) N(3)-Ru(1)-O(2) 75.6(3) 
O(2)-Ru(1)-Cl(2) 82.6(2) N(2)-Ru(1)-O(2) 175.3(4) 
N(1)-Ru(1)-Cl(2) 89.8(2) N(2)-Ru(1)-N(3) 103.5(3) 
N(2)-Ru(1)-Cl(2) 92.8(3)   
3.8.2 X-ray powder diffraction 
The x-ray powder pattern diffraction for complex 3.29 was recorded to prove the 
bulk powder sample and the crystal structure are formed by the trans-isomer, thus 
determining the purity of the sample biologically tested. Figure 3-22 shows the 
comparison of the two diffractograms corroborating both sets are constituted by 
only one isomer. The main peaks of the diffractograms of the ruthenium complex 
3.29 proved the complex has a similar structural geometry in both samples.  
 
Figure 3-22: XRPD data overlap of complex 3.29 showing the experimental 
(black) and simulated (red) diffractograms recorded at scan rate of 40 sec/scan. 
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3.9 Ruthenium complex 3.32 
3.9.1 X-ray single crystal diffraction of complex 3.32 
 
Figure 3-23: Chemical structure of compound 3.32 (left); labelled crystal structure (right). 
Trans-dichloride bis-(N-2,5-dichlorophenyl)-quinaldamide ruthenium (III) 
complex (3.32) (Figure 3-23) was isolated as a dark red powder and crystallised 
from DMSO as red needles. The asymmetric unit contains two molecules of 
DMSO, one molecule of water and one molecule of the complex, crystallising in 
a triclinic system and solved in the space group P-1. Figure 3-23 (right) shows 
the crystal structure of compound 3.32 and atom labels. The crystals analysed 
by x-ray crystallography only show the trans-trans-trans isomer. In this particular 
case, the distorted octahedral geometry can be demonstrated by the following 
angles: Cl(1)-Ru(1)-Cl(2) is 174.20(3)°, the N(2)-Ru(1)-O(2) is 167.34(10)° and 
N(1)-Ru(1)-N(3) is 176.27(11)°. It also shows the complex arranged in a slightly 
distorted octahedral geometry caused by the ligands as they bend towards one 
of the chlorides, proving that instead of 180º the angle form between the organic 
moiety and the metal is 173.84(3)º. The aryl fragments twist almost 90° 
encapsulating the ruthenium centre. This fact is easily seen in the extended 
crystal structure shown in Figure 3-25, which also shows one of the chlorides is 
more ‘protected’, due to the aryl twist making the other prone to hydrolyse. Figure 
3-23 also shows one of the ligands is bound deprotonated with a carbonyl 
(C(10)…O(1)) of 1.237(4) Å, the amide nitrogen single bond C(10)…N(2) has a 
length of 1.353(4) Å, confirming the ligand coordinates neutrally acting as an X-
type. The ligand bound neutrally shows similar bond lengths being the carbonyl 
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bond length C(26)…O(2) of 1.265(4) Å and the amide nitrogen bond length 
C(26)…N(4) of 1.317(4) Å. Table 3-10 and Table 3-11 summarise all the relevant 
bond lengths, angles and dihedral angles. 
Figure 3-24 shows the  stacking interactions. Surprisingly, this is the only 
compound, so far, that shows differences in terms of intermolecular interactions. 
The quinaldic cores of the ligands bound anionically (blue highlighted) show a 
 stacking with a centroid-centroid distance of 3.611 Å and for the first time, 
the aryl fragments show a  stacking (green highlighted) with a centroid-
centroid distance of 3.923 Å. Another interesting feature is the lack of inter- and 
intramolecular hydrogen bonds. It was only found one hydrogen between the 
water of crystallisation and the oxygen of the quinaldamide bound anionically 
O(5)H2O-H…O(1) with a distance of 2.001 Å. 
 
Figure 3-24:  interactions of the complex 3.32. 
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Table 3-10: Selected bond lengths and s.u.s. for complex 3.32 labelled as shown 
in Figure 3-23 
Bond Length/ Å Bond Length/ Å 
Ru(1)-Cl(1) 2.3326(8) O(2)-C(26) 1.265(4) 
Ru(1)-Cl(2) 2.3761(9) N(1)-C(9) 1.321(4) 
Ru(1)-O(2) 2.097(2) N(2)-C(10) 1.353(4) 
Ru(1)-N(1) 2.076(3) N(3)-C(25) 1.335(4) 
Ru(1)-N(2) 2.018(3) N(4)-C(26) 1.317(4) 
Ru(1)-N(3) 2.105(3) C(9)-C(10) 1.494(4) 
O(1)-C(10) 1.237(4) C(25)-C(26) 1.495(5) 
Table 3-11: Selected bond angles and s.u.s. for complex 3.32 and atom labels 
found in Figure 3-23 
Bond Angle/ ° Bond Angle/ ° 
Cl(1)-Ru(1)-Cl(2) 174.20(3) N(2)-Ru(1)-Cl(1) 99.04(8) 
O(2)-Ru(1)-Cl(1) 93.50(7) N(2)-Ru(1)-Cl(2) 86.34(8) 
O(2)-Ru(1)-Cl(2) 81.07(7) N(2)-Ru(1)-O(2) 167.34(10) 
O(2)-Ru(1)-N(3) 76.65(10) N(2)-Ru(1)-N(1) 78.75(10) 
N(1)-Ru(1)-Cl(1) 89.90(7) N(2)-Ru(1)-N(3) 104.90(10) 
N(1)-Ru(1)-Cl(2) 89.02(8) N(3)-Ru(1)-Cl(1) 90.28(8) 
N(1)-Ru(1)-O(2) 99.62(9) N(3)-Ru(1)-Cl(2) 90.43(8) 
N(1)-Ru(1)-N(3) 176.27(11)   
 
Chapter 3: Ruthenium (III) dichloride bis-quinaldamide complexes 
- 76 - 
 
 
Figure 3-25: Crystal packing of compound 3.32. 
Figure 3-25 shows the extended packing of complex 3.32 displaying a shell-like 
motif where the ruthenium centres and one of the chlorides of each molecules 
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3.10 Ruthenium complex 3.38 
3.10.1 X-ray single crystal diffraction of complex 3.38 
 
Figure 3-26: Chemical structure of complex 3.38 (left); labelled crystal structure (right). 
Trans-dichloride bis-(N-2-iodophenyl)-quinaldamide ruthenium (III) complex 
(3.38) (Figure 3-26) was isolated as a red powder and crystallised from DMF 
which co-crystallises as red blocks. The asymmetric unit contains one molecule 
of DMF and the complex, solved in a monoclinic cell and solved in the space 
group C2/c. Figure 3-26 (right) shows the labelled crystal structure of the trans-
trans-trans isomer isolated, the twist of the amide links between the aromatic 
rings causes the slightly distorted octahedral geometry giving a concave shape 
to the molecule, more easily seen in the 3D expansion in Figure 3-28. The 
ligands bend towards one chloride, what makes the Cl(1)-Ru(1)-Cl(1) angle to be 
174.22(4)º.  
The neutral ligand shows the carbonyl bond (C(26)…O(2)) has a distance of 
1.2353(5) Å and the amide nitrogen single bond C(26)…N(4) has a length of 
1.331(6) Å confirming the ligand coordinates neutrally as an L-type. The ligand 
bound anionically shows similar bond lengths being the carbonyl bond length 
C(10)…O(1) of 1.225(5) Å and the amide nitrogen bond length C(10)…N(2) of 
1.354(6) Å. Although, the x-ray structure confirms the absence of the amide 
proton making the ligand an X-type. The torsion of the ligand impedes the 
intramolecular hydrogen bond between C(32)…O(2) forming the intermolecular 
hydrogen bond C(2)…O(2) with a length of 2.919 Å holding the integrity of the 
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complex. A further hydrogen bond can be seen between the N(4)-H…ODMF as 
shown in Figure 3-26. Table 3-12 and Table 3-13 show all the relevant bond 
lengths, angles and dihedral angles of complex 3.38 (Figure 3-26). 
The stacking (Figure 3-27) is similar to the compounds describe within this 
chapter. The ligand bound anionically (blue), shows the highlighted quinaldic 
cores interacting showing a centroid-centroid distance of 3.674 Å. The same 
happens to the neutral coordinated ligand which interacts only with another 
neutral bound ligand (green plane) with a centroid-centroid distance of 3.446 Å 
and twist angle between planes of 2.735°. 
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Table 3-12: Selected bond lengths for complex 3.38 with labelled atoms 
corresponding to the complex in Figure 3-26 
Bond Length/ Å Bond Length/ Å 
Ru(1)-Cl(1) 2.3585(12) N(1)-C(9) 1.329(6) 
Ru(1)-Cl(2) 2.3304(12) O(2)-C(26) 1.2353(5) 
Ru(1)-O(2) 2.091(3) N(2)-C(10) 1.354(6) 
Ru(1)-N(1) 2.086(4) N(3)-C(25) 1.337(6) 
Ru(1)-N(2) 2.011(3) N(4)-C(26) 1.331(6) 
Ru(1)-N(3) 2.123(4) C(9)-C(10) 1.504(6) 
O(1)-C(10) 1.225(5) C(25)-C(26) 1.482(6) 
Table 3-13: Selected bond angles for complex 3.38 with labelled atoms 
corresponding to the complex in Figure 3-26 
Bond Angle/ ° Bond Angle/ ° 
Cl(2)-Ru(1)-Cl(1) 174.22(4) N(3)-Ru(1)-Cl(2) 86.68(10) 
N(1)-Ru(1)-Cl(1) 87.98(10) O(2)-Ru(1)-N(1) 99.59(13) 
O(2)-Ru(1)-Cl(1) 90.93(10) N(2)-Ru(1)-N(1) 79.35(14) 
N(2)-Ru(1)-Cl(1) 95.84(11) N(3)-Ru(1)-N(1) 173.54(14) 
N(3)-Ru(1)-Cl(1) 95.94(10) N(3)-Ru(1)-N(2) 105.27(14) 
O(2)-Ru(1)-Cl(2) 84.75(9) N(2)-Ru(1)-O(2) 173.10(14) 
N(1)-Ru(1)-Cl(2) 88.96(10) N(3)-Ru(1)-O(2) 75.27(13) 
N(2)-Ru(1)-Cl(2) 88.40(11)   
 
The crystal packing in Figure 3-28 shows a helix-like motif where the molecules 
are held together through three different alternating  stacking interactions 
involving: the [N,O] quinaldic core… [N,N] aryl ring with a centroid-centroid 
distance of 3.654 Å; [N,O] quinaldic core…[N,O] quinaldic core of 3.976 Å and 
[N,N] quinaldic core…[N,N] quinaldic core of 3.679 Å.  
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Figure 3-28: Z-axis view of the crystal packing expansion of complex 3.38. 
3.11 Side product when using basic conditions: Complex 3.25a 
Previously, McGowan et al. reported the synthesis of picolinamide ligands and 
different metal salts where a base was required to deprotonate one of the amide 
protons to coordinate to the metal. It was assumed that, due to chemical 
similarity, the reactivity of the quinaldamide ligands would be similar. However, 
upon addition of triethylamine as a base, the reaction yielded dark coloured 
compounds proving impossible to crystallise and analyse. Unless for one 
reaction, two different sets of crystals were isolated: needles belonging to the 
neutral trans-dichloride complex and red plates belonging to a cis-dichloride 
ruthenium (III) charged complex. In Figure 3-29, the two quinaldamide ligands 
are deprotonated in a cis position, and the triethylammonium salt as counterion. 
Although, tuning the charge of the metal complexes could have great potential, 
the focus of this chapter is to describe the trans-dichloride complexes that were 
tested for their anticancer, antibacterial and antifungal activity (Chapter 4). 
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Figure 3-29: Chemical structure of the charged side product (left) and the 
labelled crystal structure of the cis-dichloride bis-(2,5-difluoroquinaldamide) 
ruthenate (III) triethylammonium salt. 
The crystalline charged complex was solved in the space group Pn21a with 
selected bond distances and bond angles in Table 3-14 and Table 3-15, 
respectively, proving that the chloride labile ligands are placed in a cis-
arrangement, the nitrogens of the quinaldic cores are trans to each other and the 
nitrogens of the aniline fragments are cis to each other, displaying a final 
configuration of cis-trans-cis. 
Table 3-14: Selected bond distances with s.u.s. of the charged complex 
described in Figure 3-29 
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Table 3-15: Selected bond angles with s.u.s. of the charged complex described 
in Figure 3-29 









Figure 3-30: Expanded Crystal Structure of the side product cis-dichloride  
bis-(2,5-difluoroquinaldamide) Ru(III) charged complex. 
3.12 Side product of the base free reaction: complex 3.33a 
The base free reaction lead to the main compound (neutral bisquinaldamide 
ruthenium complex), however, the slow crystallisation of the mother liqueurs 
yielded an unexpected product that could potentially be either the first step of the 
complexation or a decomposition product. The compound is the trichloride 
monosubstituted quinaldamide ruthenium (III) complex – the ruthenium complex 
containing three chloride ligands, one quinaldamide ligand and one molecule of 
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ethanol as shown in Figure 3-31. The quinaldamide ligand has a planar geometry 
and the ruthenium opts for an octahedral geometry. Several attempts were made 
in to form this class of compounds, but they were only obtained from the mother 
liqueurs of the reaction mixture. The compounds analysed by HRMS proved the 
mass for those species. Further investigations should be done into these 
reactions as little it is known about anticancer metallodrugs containing three labile 
ligands. The attempts made to synthesise these sorts of complexes involved the 
variation of the number of moles of the ligand, however, diluted conditions could 
favour the isolation of these complexes. 
 
Figure 3-31: (Left) chemical structure of side product of the base free reaction 
with 4-bromoquinaldamide ligand; (right) crystal structure of the compound 
isolated. 
Mother liqueurs of other reactions were left to crystallise but only a fine powder 
was isolated. The reaction involving the unsubstituted quinaldamide 2.1 was 
analysed by HRMS (Figure 3-32) observing the main peak at an m/z of 455.9578 
corresponding to the [M+H]+, calculated to be at 455.9127 u.m.a. 
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Figure 3-32: (Top) experimental HRMS spectrum obtained of the complex from 
the mother liqueurs of the reaction with the unsubstituted ligand 2.1; (Bottom) 
simulated pattern of the compound. 
The synthesis (Scheme 3-2) of the mono N-phenyl-2-quinolinecarboximade 
(ligand 2.1) ruthenium (III) trichloride complex proved to be unsuccessful, as the 
solid isolated was the initial bisquinaldamide ruthenium complex. 
 
Scheme 3-2: Reaction scheme followed to synthesis the monoquinaldamide 
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3.13 Compound fragmentation, complex 3.15a 
The reaction carried by an MChem student Daniel Kowalski that involves the 
complexation of 2-tbutylquinaldamide yielded one compound (left complex in 
Figure 3-33): the expected neutral complex which is not discussed in this 
chapter. However, after crystallisation from DMF, the desired complex and an 
unexpected neutral complex were solved by X-ray crystallography. The two 
complexes were found in the same crystallisation batch meaning, most likely, it 
could be a decomposition product formed by one quinaldamide bound anionically 
[N,O], two chlorides and two molecules of DMF coming from the crystallisation 
solvent (Figure 3-34). The crystal structure is shown in Figure 3-34 and solved 
using the triclinic space groups P -1 in which the asymmetric unit contains a single 
molecule of the complex and one molecule of DMF. Table 3-16 and Table 3-17 
summarise the main bond distances and angles respectively, showing the 
integrity of the trans dichloride ligands remain intact (176.04(2)º) and the neutrally 
coordinated ligand is being displaced by the DMF molecules. 
 
Figure 3-33: Chemical structure of bisquinaldamide neutral complex and 
decomposition product. 
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Figure 3-34: Labelled crystal structure of the proposed decomposition product. 
Table 3-16: Selected bond distances of the labelled complex in Figure 3-34 
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Table 3-17: Selected bond angles of the labelled complex in Figure 3-34 








A wide library of novel trans-dichloride bis-functionalised quinaldamide ruthenium 
(III) complexes have been successfully synthesised and characterised by means 
of IR, HRMS, elemental analysis, magnetic susceptibility and when suitable by  
X-ray crystallography and X-ray powder diffraction. The focus was given to the 
eight ‘Lead Compounds’ chosen due to their biological anticancer activity which 
is thoroughly described in chapter 4.  
It was indicated by X-ray powder diffraction that only one isomer was obtained by 
comparing the diffractogram simulated from the crystal structures and the bulk 
sample. Importantly, the two main lead compounds 3.23 (R = 2-F) and 3.32 (R = 
2,5-diCl) show  stacking between the aryl moieties, feature not seen for the 
other compounds analysed.  
All the compounds show a trans-trans-trans arrangement breaking the rules of 
metal-based drugs. Increasing ligand size by adding fused rings plays a key role 
in obtaining purely one isomer out of five potential isomers, when the labile halide 
ligand is a chloride.  
Furthermore, two unexpected compounds: a neutral trischloride 
monoquiladamide ruthenium (III) complex and a charged cis-chloride 
bisquinaldamide ruthenium (III), opening two other interesting projects. 
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3.15 Further work 
In terms of characterisation, further analysis will be studied to determine the 
behaviour in solution by Electron Paramagnetic Resonance spectroscopy (EPR) 
as it would complement a new biological approach, how paramagnetism affects 
anticancer studies.10 Stability studies using UV-vis at different temperatures will 
be done. Complementary analysis will be focused on the fluorescence of the 
ruthenium complexes, as the highly conjugated aromatic rings have the potential 
to increase this feature that could show where the compounds accumulate inside 
the cells. 
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Chapter 4  
Biological Investigations on the neutral trans-dichloride 
bisquinaldamide Ruthenium (III) complexes
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4.1 Introduction to the Drug Discovery Process 
Society is constantly demanding for new drugs that are more effective, selective 
and potent. Academia and industry joint together in the search of the ‘Holy Grail,’ 
to cure new and old diseases, in a process that divides into two parts: drug 
discovery and development process. Small molecules have been identified and 
screened against a known biological target, identified as Lead Compounds with 
the desired therapeutic effects and optimised to enhance their properties. 
Successful candidates may be taken further into preclinical trials where biological 
aspects like pharmacokinetics, pharmacodynamics and toxicity are investigated. 
New candidates fail in clinical trials due to either being less effective than current 
treatments or are unsafe, or both. Hence validating Lead Compounds in vitro and 
determining their biological properties in preclinical stages are critical in order to 
put forward a new drug for in vivo analysis or clinical trials. The first stage of 
preclinical anticancer studies is the in vitro cytotoxicity screening. These assays 
were mentioned in Chapter 1 and, briefly, are used worldwide to measure the 
effectiveness of a drugs against some human cell lines to identify Lead 
Compounds. The screening used and described in this chapter is the MTT assay. 
It falls in the category of ‘Phenotypic Approach’ within the Drug Discovery process 
which assumes there are compounds capable of targeting several pathways that 
yield a desirable phenotypical effect, in this case cancerous cell death. The next 
step is called target deconvolution where the mechanism(s) of action are 
determined.1 The outcome of the MTT assay is a number called IC50 value which 
classifies a drug as highly active, active, moderately active or inactive.2-7 
4.2 Cytotoxicity: MTT assay 
The robust and direct MTT assay is a colorimetric assay based on the reduction 
of the yellow water-soluble salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) MTT to give the purple/dark blue water insoluble formazan 
crystals. This assay, initially described by Mosmann6 in 1983 and later optimised 
by Sylvester,8 depends on NAD(P)H reductases within the cell. Originally, it was 
thought that this redox reaction took place in the membranes of the mitochondria, 
as the mitochondrial dehydrogenase enzymes were implicated. However, recent 
studies have shown that cytosolic enzymes NAD(P)H-dependent are also 
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responsible for the MTT reduction (Figure 4-1).9 The formazan crystals are 
dissolved and read using a multiwell scanning spectrophotometer (TECAN 
reader). The amount of crystals formed are proportional to the number of living 
cells that are metabolically active, meaning this method could also be used to 
differentiate the measurement of cell proliferation and activation.10 
 
Figure 4-1: Mechanism of reduction of the water soluble yellow MTT salt to the 
insoluble violet formazan neutral molecule by NAD(P)H. 
4.3 Normoxia cytotoxic studies of trans-dichloride 
bisquinaldamide Ruthenium complexes 
4.3.1 Rationale behind the cell lines studied 
In 2012 it was recorded 1.36 million new cases of colorectal cancer across the 
globe and 500.000 of those were diagnosed alongside Europe, being around 
40.000 cases in the United Kingdom. In 2015, colorectal cancer was the 4th most 
common in the UK and it is expected that in 2035, 100.000 people will be affected 
by this deadly disease. Statistics say that only 50% of the patients will survive. 
Having this in mind, colorectal cancer is a desirable target in terms of 
development of new cures.11 HCT 116 is used in this project and the cell line is 
from an adult male colorectal carcinoma.12 Those used in this project have been 
genetically manipulated to mimic cancers in clinic. This mutation is located in the 
gene p53, which is a tumour suppressor. When cells behave correctly, the gene 
p53 would stop any sorts of anomalies to happen, however, if cells start to 
reproduce uncontrollably, the gene p53 will not be expressed (knockdown) hence 
the expression of cancer. This mutation causes the cell line HCT 116 to be 
divided into HCT 116 p53 (+/+) or wild type and HCT 116 p53 (-/-) or knockdown. 
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Any mutation on this gene would allow to understand the potential mechanism of 
action for this family of complexes. 
Pancreatic cancer is not as recurrent in society as colorectal cancer, but there is 
only 1% survival. This is due to the late diagnosis and the not-known treatment. 
The NHS estimated that in 2012 there were 338.000 cases worldwide, being 
around 104.000 cases reported in Europe. In the UK, this cancer does not affect 
as much as in the rest of Europe, but it is estimated 9.800 new cases per year, 
being 37% preventable and less than 1% have survived. These numbers 
represent a very invasive cancer without a treatment, hence the interest on 
understanding the physiology of the pancreatic cancer and how to defeat it.13  
MIA PaCa_2 is the cell line chosen for the studies and it comes from a  
65 year-old Caucasian male suffering pancreatic carcinoma.14 
Cytotoxic studies must be carried out against a non-cancerous cell line in order 
to determine if compounds are selective towards cancerous cell lines. ARPE-19 
is the healthy cell line in these studies and it comes from the retinal pigmented 
epithelium of a 19 years-old male.15 
4.3.2 Normoxia cytotoxic results and discussion 
From the 40 compounds reported in this thesis (Chapter 3), three did not satisfy 
the desired purity given by elemental analysis (>95%) and seven were not tested 
due to either the lack of completing the series in terms of functionality  
(complexes 3.2, 3.3 and 3.4) and not enough sample to evaluate the anticancer 
activity. The remaining thirty compounds were screened against three cancerous 
cell lines: HCT116 p53 (+/+) (human colon carcinoma with tumour suppressor 
gene present) HCT116 p53 (-/-) (human colon carcinoma with knockdown tumour 
suppressor gene), MIA PaCa_2 (human pancreatic carcinoma) and a non-
cancerous cell line, ARPE-19 (human retinal pigmented epithelial cell).  
The general structure of the trans-dichloride bisquinaldamide ruthenium 
complexes is shown in Figure 4-2, R-substituents and numbering are 
summarised in Table 4-1. All the biological work of this thesis (unless otherwise 
stated) and chemosensitivity studies from the past two years for the McGowan 
group were carried by the author at the University of Huddersfield under the 
supervision of Professor Roger M. Phillips.  
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Figure 4-2: General structure of the trans-dichloride ruthenium (III) 
bisquinaldamide complexes. Grey dashed lines and black highlighted parts were 
drawn for 3D clarity. 
Table 4-1: Summary of the complex codes and R groups 
 
 
Complex R Complex R 
3.1 H 3.25 4-F 
3.5 2-Me 3.26 2,4-diF 
3.6 3-Me 3.27 2,5-diF 
3.7 4-Me 3.28 2-Cl 
3.9 2-Et 3.29 3-Cl 
3.10 3-Et 3.30 4-Cl 
3.11 4-Et 3.31 2,4-diCl 
3.12 2-iPr 3.32 2,5-diCl 
3.13 3-iPr 3.33 2-Br 
3.15 2,6-diiPr 3.34 3-Br 
3.16 2-Me-6-iPr 3.35 4-Br 
3.17 2-tBu 3.36 2,4-diBr 
3.18 4-tBu 3.38 2-I 
3.23 2-F 3.39 3-I 
3.24 3-F 3.40 4-I 
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The complexes (dissolved in DMSO at a final concentration of 100 mM, diluted 
further in cell media from 100 M to 0.045 M) were incubated with the cell lines 
at 37 ºC in an atmosphere of 5% CO2 for 72 hours. After incubation with MTT for 
three hours, the inhibition of cell survival was measured at 540 nm and by plotting 
the percentage cell survival (%) versus drug concentration (M). All cytotoxic 
assays were performed a minimum of three times or as many times until the 
standard deviations or standard errors were acceptable. The accepted standard 
deviations/errors to publish are determined by the following calculation: standard 
deviation or standard error must be equal or smaller than the IC50 value divided 
by three. 
The results for the cytotoxicity screening of the trans-dichloride bis-quinaldamide 
Ru(III) complexes compared against current therapeutic drugs: cisplatin, 
carboplatin and oxaliplatin as comparison were tested against HCT 116 p53 (+/+), 
HCT 116 p53 (-/-) and MIA PaCa_2 cancer cells lines and ARPE-19 are as shown 
in Figure 4-3 and all the values are summarised in Table 4-2 for complexes 
between 3.1 – 3.24, Table 4-3 for complexes 3.25 – 3.40 and Table 4-4 for the 
current FDA chemotherapeutic agents (cisplatin, carboplatin and oxaliplatin). The 
complexes show a wide variety in anticancer potency and the values in the tables 
are colour coded to facilitate the visual understanding of the results; highly active 
complexes highlighted in green (IC50 < 10 M), active complexes highlighted in 
blue (10 M < IC50 < 20 M), moderately active highlighted in orange (20 M < IC50 
< 50 M) and non-highlighted when (50 M < IC50). Additionally, the opposite 
effect is desired against ARPE-19 meaning the higher the IC50 value the less 
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Table 4-2: IC50 values ± S.E. (M) of the complexes 3.1 – 3.24 expressed as the mean IC50 ± S.E. for three independent experiments 
Complex R HCT 116 p53 (+/+) HCT 116 p53 (-/-) MIA PaCa_2 ARPE-19 
3.1 H 10.69 ± 0.42 15.75 ± 1.56 21.32 ± 3.08 36.37 ± 4.65 
3.5 2-Me 6.78 ± 1.06 10.63 ± 1.16 77.5 ± 13.91 35.35 ± 2.90 
3.6 3-Me 4.87 ± 0.92 8.13 ± 0.52 78.41 ± 13.73 21.95 ± 7.42 
3.7 4-Me 24.57 ± 3.37 78.95 ± 11.10 80.79 ± 13.44 100 
3.9 2-Et 13.37 ± 2.06 23.18 ± 2.81 99.11 ± 0.89 63.99 ± 2.29 
3.10 3-Et 35.95 ± 5.80 45.55 ± 2.45 84.83 ± 11.49 90.72 ± 9.27 
3.11 4-Et 16.11 ± 1.17 14.31 ± 1.14 81.28 ± 12.48 53.40 ± 8.12 
3.12 2-iPr 12.65 ± 2.82 9.46 ± 0.14 19.39 ± 2.92 21.38 ± 1.91 
3.13 3-iPr 7.39 ± 0.92 5.41 ±0.09 12.43 ± 1.42 5.39 ± 0.54 
3.15 2,6-diiPr 100 100 100 100 
3.16 2-Me-6-iPr 18.38 ± 2.38 12.26 ±1.15 26.36 ± 0.90 23.82 ± 1.37 
3.17 2-tBu 17.97 ± 1.48 16.50 ± 3.00 28.80 ± 1.01 21.03 ± 2.32 
3.18 4-tBu 5.79 ± 0.87 5.93 ± 0.89 15.95 ± 3.01 8.82 ± 1.35 
3.23 2-F 8.10 ± 1.30 11.74 ± 1.44 18.30 ± 3.38 29.64 ± 0.26 
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Table 4-3: IC50 ± S.E. values (M) of the complexes 3.25 – 3.40 expressed as the mean IC50 ± S.E. for three independent experiments 
Complex R HCT 116 p53 (+/+) HCT 116 p53 (-/-) MIA PaCa-2 ARPE-19 
3.25 4-F 18.78 ± 3.43 28.22 ± 4.76 84.25 ± 9.12 9.04 ± 0.49 
3.26 2,4-diF 13.94 ± 2.36 25.26 ± 2.92 82.10 ± 13.35 41.89 ± 7.82 
3.27 2,5-diF 14.41 ± 2.44 16.79 ± 2.65 29.95 ± 1.79 50.19 ± 9.10 
3.28 2-Cl 20.28 ± 3.00 27.64 ± 4.28 74.76 ± 8.79 80.08 ± 3.72 
3.29 3-Cl 5.01 ± 0.75 8.18 ± 1.06 26.38 ± 0.95 21.08 ± 1.80 
3.30 4-Cl 16.75 ± 2.28 18.19 ± 2.44 31.53 ± 0.39 16.82 ± 1.18 
3.31 2,4-diCl 52.75 ± 8.12 35.56 ± 6.32 84.62 ± 11.50 88.36 ± 8.38 
3.32 2,5-diCl 12.87 ± 2.15 11.71 ± 1.32 28.73 ± 0.58 91.09 ± 8.90 
3.33 2-Br 100 100 100 100 
3.34 3-Br 16.13 ± 2.24 17.28 ± 2.58 71.34 ± 11.23 52.57 ± 2.29 
3.35 4-Br 57.72 ± 10.59 21.72 ± 3.90 81.12 ± 11.11 45.42 ± 6.76 
3.36 2,4-diBr 7.33 ± 1.24 4.92 ± 0.89 9.45 ± 0.25 13.64 ± 2.12 
3.38 2-I 7.56 ± 1.30 7.25 ± 1.05 21.93 ± 2.58 25.54 ± 1.41 
3.39 3-I 84.27 ± 15.73 100 100 87.22 ± 12.77 
3.40 4-I 60.37 ± 9.11 55.38 ± 9.16 96.53 ± 2.58 52.56 ± 9.40 
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Table 4-4: IC50 values (M) of the current clinical chemotherapeutic drugs 
(cisplatin, carboplatin and oxaliplatin) expressed as the mean IC50 ± S.E. for three 
independent experiments after 72 hours exposure 
Complex HCT 116 (+/+) HCT 116 (-/-) MIA PaCa_2 ARPE-19 
Cisplatin 7.37 ± 0.58 9.78 ± 1.20 1.61 ± 0.19 19.03 ± 1.78 
Carboplatin >60 58.07 ± 1.92 43.15 ± 1.81 >60 
Oxaliplatin 0.61 ± 0.06 1.85 ± 0.17 0.64 ± 0.07 1.43 ±0.25 
 
From the IC50 values obtained, few trends can be observed. The compounds 
 3.15 (R = 2,6-diiPr), 3.33 (R = 2-Br) and 3.39 (R = 3-I) do not display any 
anticancer activity or affect the healthy cell line. The remaining complexes target 
predominantly the colorectal cell lines, showing some toxicity against the 
pancreatic cell line, and with a variety of values for the non-cancerous cell line. 
Compound 3.1 (R = H) is the benchmark to compare the remaining complexes, 
it shows IC50 values of 10.69 ± 0.42 (M), 15.75 ± 1.56 (M) and 21.32 ± 3.08 
(M) for HCT 116 p53 (+/+), HCT 116 p53 (-/-) and MIA PaCa-2, respectively. It 
also shows an IC50 value of 36.37 ± 4.65 (M) against the  
ARPE-19. This is an interesting result as, rarely, an unsubstituted ligand tends to 
have from the least to average anticancer potency. This compound will be used 
to find structural activity relationships when varying the electronics of the aniline 
ring and see if this affects more than the ruthenium benchmark complex 3.1  
(R = H). Chemically speaking, in terms of position of the R groups, when 
increasing the bulkiness of the EDG in the position 2 of the aniline ring, the IC50 
values increase or show equitoxic potency (Me < Et < iPr < tBu) whereas when 
decreasing the size of the EWG the anticancer activity enhances (I > Cl > F) as 
shown in Figure 4-4, this behaviour is observed for the cancerous cell lines, 
except for the pancreatic cell lines (green line) where 2-Me possesses little 
activity. In terms of coordination, the complexes bearing EDG coordinate to the 
Ru(III) in an [N,O] anionic manner, whereas the EWG coordinate in a [N,N] 
anionic manner. This reinforces that coordination is not as important but the 
disposition of the labile ligands. 
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Figure 4-4: Comparison of the activity of the complexes functionalised in the 
position 2. 
Complexes containing functional groups in the 3rd position present a different 
behaviour (Figure 4-5) than in position 2. In order of anticancer activity (IC50), iPr 
<Me ≈ Cl < Et ≈ F ≈ Br < I. It shows an alternating behaviour depending on the 
bulkiness of the substituents being the 3-iPr substituted complex (3.13), the most 
active across the series. 
 
Figure 4-5: Comparison of the activity of the complexes functionalised in the 
position 3. 
The potency of the complexes containing functional groups in the 4th position 
converge when the substituent is 4-tBu. This means, the smaller the EDG and 
the bigger the EWG the higher the IC50 against all cell lines, this potency is 
enhanced by increasing the bulkiness of the EDG and by decreasing the size of 
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Figure 4-6: Comparison of the activity of the complexes functionalised in the 
position 4. 
The di-substituted bisquinaldamide complexes decrease their activity when 
replacing di-fluoro for di-chloro, but when R is 2,4-diBr (3.36), the anticancer 
activity shows a three-fold increase in activity than the 2,4-diF, as shown in 
Figure 4-7. When comparing the 2,5-disubsituted, the activity increases when 
replacing 2,5-diF for 2,5-diCl. These complexes show low IC50 values against the 
cancerous cells and high IC50 values against a non-cancerous cell line favouring 
the selectivity ratio, which is a parameter discussed in section (4.3.3). 
 
Figure 4-7: Comparison of the activity of the complexes functionalised in the 
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Figure 4-8: Comparison of the activity of the complexes functionalised in the 
position 2 and 5. 
The final set of compounds that shows a remarkable variation are substituted in 
position 2 and 6. Compound 3.15 is constituted by two isopropyl groups (2,6-
diiPr) and compound 3.16 is constituted by one methyl and one isopropyl (2-Me-
6-iPr). Interestingly, 3.15 shows not effect at all, whereas 3.16 is classified as one 
of the most active compounds, as shown in (Figure 4-9). 
 
Figure 4-9: Comparison of the activity of the complexes functionalised in the 
position 2 and 6. 
Determining the cytotoxicity values exposes the potency of the complexes 
against the different cell lines, and also shows how chemical modifications can 
affect the preference towards cancerous cell lines. Importantly, these molecules 
showed less toxicity against non-cancerous cells. This characteristic is very 
interesting in bioinorganic medicinal chemistry as, in general, most of the  







































Chapter 4 Biological Investigations 
- 102 - 
   
towards healthy cell lines. However, after proving that not many trends can be 
outlined by using a chemical approach, the next step is to understand the 
anticancer activity from a biological point of view. 
4.3.3 Selectivity of the ruthenium complexes 
There is a well-established parameter called selectivity factor (s. f.) used to obtain 
the Lead Compounds apart from analysing the IC50 values and the chemical 
structures. This factor is defined as the IC50 value of the non-cancerous cell lines 
divided by the IC50 value of the cancerous cells. The outcome is a unit-less 
number which should be higher than one and the current chemotherapeutic drugs 
(cisplatin, carboplatin and oxaliplatin). In terms of phenotypic outcome, the 
selectivity shows the preference of the compounds towards cancerous cell lines 
causing little damage to healthy cells. In other words, the dose of the drugs can 
be increased to eradicate the tumour mass while avoiding side effects. 
All the selectivity factor (s. f.) values for the trans-dichloride bisquinaldamide 
ruthenium (III) complexes tested can be found in Table 4-5 and Table 4-6, and 
the selectivity factor values for the current chemotherapeutic compounds 
(cisplatin, carboplatin and oxaliplatin) are reported in Table 4-7. After 96 hours of 
drug exposure, the clinical platinum-based compounds drop significantly in 
selectivity. The colour code follows the same rationale as the IC50, highly selective 
complexes in green (s. f. < 3), moderate selectivity highlighted in blue (2 < s. f. < 
3), moderately active highlighted in orange (1 < s. f. < 2) and no highlighted when 
s. f. < 1. When plotting selectivity (s. f.) versus the functional groups (R)  
(Figure 4-10), it is very clear the compounds are mainly selective towards the 
human colorectal carcinoma cell lines both dependent and independent on the 
tumour suppressor gene p53. The platinum drugs do not show much selectivity 
against the HCT 116 cell lines. Across the panel of complexes tested, compounds 
bearing 2-iPr (3.12), 3-iPr (3.13), 2,6-diiPr (3.15), 2-Me-6-iPr (3.16), 2-tBu (3.17), 
4-tBu (3.18), 4-F (3.25), 4-Cl (3.30), 2-Br (2.33), 3-I (2.39) and 4-I (2.40) show no 
selectivity against any cancer cell lines. Some of the compounds (R = H (3.1),  
2-F (3.23), 2,5-diF (3.37), 2,5-diCl (3.32) and 2,4-diBr (3.36)) target the pancreatic 
adenocarcinoma cells but with less potency. However, from the thirty compounds 
tested, there is one which its substituent is the 2,5-diCl group (complex 3.32) that 
has a remarkable selectivity. When compared against the current 
chemotherapeutic benchmarks, it increases up to four times against the 
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colorectal cell lines after 72 hours exposure and the potency is double against 
oxaliplatin and carboplatin. Cisplatin shows a good selectivity against the 
pancreatic cell line which drops before reaching 96 hours of exposure when it 
becomes extremely toxic towards non-cancerous cell lines. Opposed to this 
selectivity, if R is a 4-F (complex 3.25) the damage to non-cancerous cells is 
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Table 4-5: Selectivity factor (s. f) values for the compounds 3.1 – 3.24 
Complex R HCT 116 p53 (+/+) HCT 116 p53 (-/-) MIA PaCa_2 
3.1 H 3.4 2.3 1.7 
3.5 2-Me 5.2 3.3 0.5 
3.6 3-Me 4.5 2.7 0.3 
3.7 4-Me 4.1 1.3 1.2 
3.9 2-Et 4.7 2.8 0.6 
3.10 3-Et 2.5 2.0 1.1 
3.11 4-Et 3.3 3.7 0.7 
3.12 2-iPr 1.6 2.3 1.1 
3.13 3-iPr 0.7 1.0 0.4 
3.15 2,6-diiPr 1.0 1.0 1.0 
3.16 2-Me-6-iPr 1.3 1.9 0.9 
3.17 2-tBu 1.2 1.3 0.7 
3.18 4-tBu 1.5 1.5 0.6 
3.23 2-F 3.7 2.5 1.6 
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Table 4-6: Selectivity factor (s. f) values for the compounds 3.25 – 3.40 
Complex R HCT 116 p53 (+/+) HCT 116 p53 (-/-) MIA PaCa_2 
3.25 4-F 0.5 0.3 0.1 
3.26 2,4-diF 3.0 1.7 0.5 
3.27 2,5-diF 3.5 3.0 1.6 
3.28 2-Cl 3.9 2.9 1.1 
3.29 3-Cl 4.2 2.6 0.8 
3.30 4-Cl 1.0 0.9 0.5 
3.31 2,4-diCl 1.7 2.5 1.0 
3.32 2,5-diCl 7.1 7.8 3.2 
3.33 2-Br 1.0 1.0 1.0 
3.34 3-Br 3.3 3.0 0.7 
3.35 4-Br 0.8 2.1 0.6 
3.36 2,4-diBr 1.9 2.8 1.4 
3.38 2-I 3.4 3.5 1.2 
3.39 3-I 1.0 0.9 0.9 
3.40 4-I 0.9 0.9 0.5 
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Table 4-7: Selectivity factor (s. f.) values of the current chemotherapeutic drugs 
(cisplatin, carboplatin and oxaliplatin) after 72 hours exposure 
Complex HCT 116 p53 (+/+) HCT 116 p53 (-/-) MIA PaCa_2 
Cisplatin 2.6 1.9 0.5 
Carboplatin 1.0 1.0 11.8 
Oxaliplatin 2.3 0.8 2.2 
 
In order to choose Lead Compounds of this family, the following factors were 
considered: selectivity, IC50 values, functional group and comparison against 
bench marks after 72 hours drug exposure. To validate the activity of the most 
promising drug candidates, compounds with very poor selectivity were added to 
the list in order to establish activity structure relationships when molecules are 
constituted with different EDG and EWG. Finally, eight complexes were chosen 
as Lead Compounds and further biological analysed; they are formed by the 
following functional groups: H (3.1); 3-iPr (3.13); 4-tBu (3.18); 2-F (3.23); 3-Cl 
(3.29); 2,5-diCl (3.32); 2,4-diBr (3.36) and 2-I (3.38). The summary of the IC50 
values lie within the standard error (Figure 4-11) and the selectivity (Figure 4-12) 
of the Lead Compounds are shown. In the literature, it is well described how 
ligand functionality plays a big role and having a slight alteration of both the 
electronics and the steric hindrance of the R groups affects profoundly the 
anticancer activity. Figure 4-2 shows the general structure of the compounds and 
the discussion crystal structures in Chapter 3.  
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Figure 4-11: Bar-chart summary of the IC50 ± S E. values of the Lead Compounds 
analysing the colorectal cell lines HCT 116 p53 (+/+),HCT 116 p53 (-/-) and  
MIA PaCa_2 after 72h drug exposure. 
 
Figure 4-12: Bar-chart summary of the selectivity factor of the Lead Compounds 
analysing the colorectal cell lines HCT 116 p53 (+/+), HCT 116 p53 (-/-) and  
MIA PaCa_2 after 72h drug exposure. 
4.3.4 Expansion of the cancer cell panel 
As a general trend, the compounds tested showed more cytotoxicity against 
colorectal cancers (CRC) than the pancreatic cell line (MIA PaCa_2), thus further 
tests were carried out on the ‘Lead Compounds’ to investigate the potency 
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colorectal HCT 116, but targeting a different gene. The proto-oncogene Kras, 
formed by two alleles, is the antagonist of the tumour suppressor p53. Once cells 
start to mutate, Kras gets activated by replacement of one amino acid in one 
allele, which is the oncogene responsible for tumour/cancer growth.16 Due to 
scarcity of the complexes, 2,4-diBr and 2-I were not evaluated. Due to logistics, 
(five compounds per plate), the ruthenium control complex 3.1 (R = H) was not 
evaluated either. The remaining five Lead Compounds were tested against three 
isogenic human colorectal cancer cell lines: HCT 116 Kras parent, HCT 116 Kras 
Wild Type and HCT 116 Kras mutant. In order of relevancy, Kras parent 
resembles the regulated proportion of the proto-oncogene in normal cells (one 
wild-type allele and one mutant allele), Kras mutant has no wild-type allele and 
one mutant, whereas the Kras WT or (+) shows the wild-type allele and no mutant 
allele.16 In simple terms, compounds that have a preferential activity against the 
cell line HCT 116 Kras mutant would be desirable, as this is the stage when the 
cancer is being more aggressive. 
 
Figure 4-13: Bar-chart summary of the IC50 values of the compounds 3.13, 3.18, 
3.23, 3.29, 3.32, cisplatin, carboplatin and oxaliplatin tested against the Kras 
oncogene family, and the non-cancerous cell line ARPE-19. 
Table 4-8 shows all the IC50 values with their respective standard errors. The 
values for ARPE-19 were shown previously in Table 4-2 and Table 4-3. From the 
plot, IC50 against functional group, (Figure 4-13), all compounds apart from the 
4-tBu complex, display similar potency against the three isogenic cancerous cell 
lines. The complex bearing the substituent 4-tBu (3.18) shows more potency 






















HCT116 Kras WT (+)
ARPE 19
Chapter 4 Biological Investigations 
- 110 - 
   
the complex with R = 2,5-diCl, the compounds exhibit greater potency than 
cisplatin and carboplatin. In terms of selectivity (Figure 4-14), complexes 2-F 
(3.23) and 2,5-diCl (3.32) show more selectivity than the platinum benchmarks. 
Table 4-8: IC50 ± S.E. values (M) of compounds 3.13, 3.18, 3.23, 3.29, 3.32, 
cisplatin, carboplatin and oxaliplatin against the Kras oncogene family 
Complex R Kras Parent Kras WT Kras Mutant 
3.13 3-iPr 11.27 ± 1.33 11.77 ± 0.77 12.60 ± 0.61 
3.18 4-tBu 3.46 ± 0.40 5.43 ± 0.93 3.45 ± 0.59 
3.23 2-F 7.78 ± 0.47 10.09 ± 0.70 9.05 ± 1.18 
3.29 3-Cl 7.91 ± 0.13 8.54 ± 0.78 10.79 ± 0.85 
3.32 2,5-diCl 20.11 ± 2.29 21.47 ± 0.96 22.67 ± 3.62 
Cisplatin 5.86 ± 0.89 5.59 ± 0.26 9.94 ± 1.13 
Carboplatin 59.64 ± 0.35 58.56 ± 0.83 >60 
Oxaliplatin 0.48 ± 0.06 0.59 ± 0.04 0.59 ± 0.02 
 
Figure 4-14: Bar-chart summary of the selectivity of the Lead Compounds and 
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Table 4-9: Selectivity factor (s. f.) values of 3.13, 3.18, 3.23, 3.29, 3.32, cisplatin, 
carboplatin and oxaliplatin against the Kras colorectal cell lines 
Complex R Kras Parent Kras WT Kras Mutant 
3.13 3-iPr 0.47 0.46 0.43 
3.18 4-tBu 2.55 1.62 2.56 
3.23 2-F 3.81 2.94 3.27 
3.29 3-Cl 2.66 2.47 1.95 
3.32 2,5-diCl 4.53 4.24 4.02 
Cisplatin 3.24 3.40 1.91 
Carboplatin 1.01 1.02 2.41 
Oxaliplatin 2.94 2.42 2.41 
 
4.3.5 Gene Preference of the ruthenium metal complexes 
The selectivity or preferential activity of the ruthenium metal complexes was 
focused on tumour suppressor gene p53 (-/-) or knockdown/mutant and the 
oncogene Kras mutant. These two genes are antagonists to each other, the 
tumour suppressor gene p53, in cancerous cells, is inhibited and the gene Kras 
oncogene is overexpressed. In terms of impact, the cell lines constituted by these 
genes show more resistance and potential cancer relapse, making them more 
challenging to eradicate. 
The selectivity is determined by the division of the IC50 of the natural occurrence 
gene and the mutant, yielding a unit-less number. If the value is more than one 
means preference towards the mutant variant and vice versa. For the tumour 
suppressor gene this means IC50 of HCT 116 p53 (+/+) divided by IC50 of HCT 116 
p53 (-/-). Figure 4-15 shows that few complexes display some preference towards 
the p53(-/-) being compound 3.35 (R = 4-Br) the most selective showing a selectivity 
factor of 2.66. Generally, the compounds are slightly more toxic towards HCT 116 p53 
(+/+) inferring the complexes are equipotent against both cell lines. Results are 
colour coded in Table 4-10, blue highlighted means compounds are selective 
towards p53 (-/-) and compound 3.35 in green as is the most selective. 
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Table 4-10: Preferential activity values towards the colonic cancer cell line  
HCT 116 p53 (-/-) 
Complex R p53  Complex R p53  
3.1 H 0.68 3.25 4-F 0.67 
3.5 2-Me 0.64 3.26 2,4-diF 0.55 
3.6 3-Me 0.60 3.27 2,5-diF 0.86 
3.7 4-Me 0.31 3.28 2-Cl 0.73 
3.9 2-Et 0.58 3.29 3-Cl 0.61 
3.10 3-Et 0.79 3.30 4-Cl 0.92 
3.11 4-Et 1.13 3.31 2,4-diCl 1.48 
3.12 2-iPr 1.34 3.32 2,5-diCl 1.10 
3.13 3-iPr 1.36 3.33 2-Br 1.00 
3.15 2,6-diiPr 1.00 3.34 3-Br 0.93 
3.16 2-Me-6-iPr  1.50 3.35 4-Br 2.66 
3.17 2-tBu 1.09 3.36 2,4-diBr 1.49 
3.18 4-tBu 0.98 3.38 2-I 1.04 
3.23 2-F 0.69 3.39 3-I 0.84 
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For the activated proto-oncogene Kras is translated to the IC50 of HCT Kras WT 
or (+) divided by the IC50 of HCT Kras mutant. Figure 4-16 shows that complex 
3.29 (R = 3-Cl ), highlighted in green, is more potent towards the mutated cell line 
which is the more difficult to defeat, and also, it can participate in cancer relapse. 
In terms of p53 selectivity, compound 3.29 has preference for the HCT 116 p53 
(+/+) gene. Interestingly, complexes 3.32 (2,5-diCl) and 3.13 (R = 3-iPro) shows a 
preference for both HCT p53 (-/-) and HCT 116 Kras mutant. These is a very 
positive result as, potentially, it could be establish that compounds substituted in 
position 3 could interact at different levels with the proto-oncogene Kras. 
 
Figure 4-16: Bar-chart of the ruthenium Lead Compounds preferential activity for 
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Table 4-11: Preferential activity values towards the colonic cancer cell line  
HCT 116 Kras Mutant. In green highlighted shows the most selective and blue 
highlighted means the selectivity factor is above 1 
Complex R Kras  
3.13 3-iPr 1.07 
3.18 4-tBu 0.64 
3.23 2-F 0.89 
3.29 3-Cl 1.26 





4.3.6 Summary of the normoxia cytotoxicity cell work 
Thirty compounds were tested against three cancerous cell lines  
(HCT 116 p53 (+/+), HCT 116 p53 (-/-) and MIA PaCa_2) and one non-cancerous 
cell line (ARPE-19). The variety of IC50 values ranging from over  
100 M to 5 M probed challenging to obtain the Lead Compounds, hence the 
introduction of the selectivity factor based on how preferable a drug is toxic 
against tumorigenic/tumoral cells. Eight Lead Compounds were identified after 
obtaining the selectivity, comparing them to the current chemotherapeutic drugs 
and considering additional factors previously discussed. However, only five 
compounds were tested against a wider panel of colorectal cancer cell lines 
differing from the first ones on the gene mutated, (in the first ones, the target was 
a tumour suppressor gene, and the panel expansion considers three isogenic cell 
lines based on an the proto-oncogene Kras, non-activated and activated) 
showing activities between 20 M and 4 M. Figure 4-17 and Figure 4-18 shows 
that the compounds substituted with electron-donating groups show low IC50 
values but less selectivity. Complexes 3.23 and 3.29, the IC50 values are 
generally below 10 M for the colorectal cell lines and between 15 – 30 M for 
the pancreatic cell lines. When analysing complex 3.32 (R = 2,5-diCl), the IC50 
values rise when compared to complexes 3.23 and 3.29. In terms of gene 
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preference, the compound bearing the 4-Br substituent (complex 3.34) has the 
best selectivity towards the knockdown tumour suppressor gene p53, whereas 
the compound bearing 3-Cl (complex 3.13) has a preference towards the 
oncogene Kras mutant. 
 
Figure 4-17: Bar chart of IC50 values of compounds 3.13, 3.18, 3.23, 3.29, 3.32, 
cisplatin, carboplatin and oxaliplatin. 
 
Figure 4-18: Summary of the selectivity factors of 3.13, 3.18, 3.23, 3.29, 3.32, 
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4.4 Hypoxia cytotoxic studies of trans-dichloride 
bisquinaldamide Ruthenium complexes 
Hypoxic cells are considered to be resistant to several chemotherapeutic drugs.17 
Healthy mammalian tissues need to regulate the homeostasis of molecular 
oxygen (O2) for cell survival and to maintain intracellular energy, typically existing 
between values of 2–9% oxygen known as normoxia. The difference in 
percentage is accounted depending on the blood vessel network and 
metabolism. The pioneering work lead by Peter Vaupel has shown that tumours 
larger than 1 mm3 are characterised by areas containing very low concentration 
of oxygen and containing a more reducing environment due to the overexpression 
of the sulphur containing tripeptide, glutathione. This inner sphere is known as 
hypoxic region. When healthy cells start to behave wrongly, they clamp together 
forming spheres divided into two sections: the outer sphere behaving like a 
regular healthy cell and the inner sphere which is a thick mass that does not allow 
molecular oxygen to diffuse through, creating a gradient of oxygen concentration. 
These hypoxia environments can exist at ≤ 2% oxygen and severe hypoxia 
(anoxia) as ≤ 0.02% oxygen, which is cell line dependent.18,19 
The survival of tumours depends on a process call angiogenesis where 
cancerous cells use host cell vessels to create a network of new ones. Such a 
quick process comes with disadvantages, forming abnormal vessels that disrupt 
the correct blood supply, hence restricting the normal oxygen diffusion.20 This 
explains how cancer can metastasise so quickly and how easy is to invade 
healthy cells by creating a fascinating new vascular system. Recently, it was 
reported that cancerous cells survive their hypoxic state through activation of 
hypoxia-inducible factor-1 (HIF-1). This transcription factor is constituted by the 
heterodimeric subunits:  and . In normoxic conditions, the  subunit is 
degraded by a cytosolic proteasome, whereas under hypoxic conditions, the 
specific enzyme is inhibited, thus the -subunits accumulate.18,2124 The intact 
HIF-1 can bind to the hypoxia responsive element (HRE) and upregulate the 
transcription of a number of genes involved in cell survival such as coding-genes 
for proteins involved in glycolysis, angiogenesis and the inflammatory 
response.25,26 HIF-1 is implicated in a number of cancers and there is also a 
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strong correlation between HIF-1 overexpression and the tumour grade and 
vascularisation.25 An overview of HIF-1 regulation is shown in Figure 4-19. 
 
Figure 4-19: Mechanism of HIF-1 regulation within the cell.27 
Hypoxic tumours are a strong prognostic factor for many cancers. The bigger the 
hypoxic mass (tumour) the more reduced the chemotherapeutic drug delivery, 
the more cancer inherent resistance to radiotherapy, the more 
neovascularisation, the greater metastatic capacity and the increase of apoptotic 
resistance. The depletion of oxygen in the hypoxic environment of cells can lead 
to upregulation of genes involved in drug resistance and promotion of cancerous 
cell growth.20 Furthermore, the more reducing environment of hypoxic cancerous 
cells is thought to help the stabilisation of HIF- when compared to healthy cells. 
This provides the potential of targeting the centre of hypoxic cancer cells 
selectively. 
Nowadays, the chemotherapeutic resistance of hypoxic cells to cancer therapies 
is targeted by using bio-reductive prodrugs or hypoxia activated drugs. These 
drugs possess the unique property of getting activated once entered in the 
reducing environment. For such a feature, metal-based drugs perfectly suit such 
a strategy, due to the variations in coordination number, geometry and accessible 
oxidation states.28 This activation was proposed as follows, a prodrug get 
activated by one-electron enzymatic reaction yielding a radical anion. In 
normoxia, molecular oxygen will react with it deactivating the drug, but in hypoxia 
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this radical is slightly more stabilised and spontaneously fragmented or further 
reduced yielding cytotoxic species. It is known that DNA alkylation and kinase 
inhibition occur through the last process.28-30 
 
Figure 4-20: Mechanism proposed for pro-drug activation by hypoxia.31 
4.4.1 Hypoxia cytotoxic results 
The five Lead Compounds (Figure 4-21) were tested against the main three 
cancerous cell lines, HCT116 p53 (+/+), HCT116 p53 (-/-) and MIA PaCa_2. The 
studies were performed in a Whitley H35 Hypoxystation where the oxygen level 
is set to 0.1%. This is the level which yields drug resistance in both radiotherapy 
and chemotherapy activating the HIF-1 complex under physiological cancerous 
conditions. Cells were cultured in 96-well plates, allowed to adhere for 24 hours 
under normoxia conditions, and for other 24 hours to acclimatise to the hypoxic 
conditions. They were exposed to different concentrations of the Lead 
Compounds ranging from 60 M till 0.468 M and incubated for 72 hours. IC50 
values were calculated after analysing the MTT readings after 3 hours. 
The biological evaluation of these compounds will show if they are good 
candidates to develop new hypoxia scaffolds. 
 
Figure 4-21: General structure of complexes: 3.13 (R= 3-iPr), 3.18 (R = 4-tBu), 
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Figure 4-22: Bar-chart of compounds 3.13 (R= 3-iPr), 3.18 (R = 4-tBu), 3.23 (R = 2-F), 3.29 (R = 3-Cl) and 3.23 (R = 2,5-diCl) tested against 
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Figure 4-22 (top left chart) shows the potency of the compounds under normoxic 
and hypoxic conditions against the colorectal cell line HCT 116 p53 (+/+). 
Compound 3.13 (R = 3-iPr) shows a decrease in activity of almost six times lower 
than the normoxia result. When the R group is 4-tBu (complex 3.18), the 
compound loses its activity from 5.79 M to 10.92 M. Compound 3.29 (R = 3-
Cl) shows the same trend as the previous one increasing the IC50 value from 5.01 
M to 8.32 M. On the other hand, compounds with R = 2,5-diCl and 2-F the 
activity increases from 12.87 M to 8.22 M, and from 8.10 M to 4.21 M, 
respectively. This feature is consistent with the already published compounds 
within the McGowan group32 showing that the trans-dihalide ruthenium scaffold 
can be a relevant strategy to tackle hypoxic cancerous cells. 
Figure 4-22 (top right chart) shows the comparison between normoxic and 
hypoxic results against the colorectal cell line HCT 116 p53 (-/-). In this case, 
compounds 3.13 (R = 3-iPr), 3.18 (R = 4-tBu) and 3.29 (R = 3-Cl) show the same 
trend as the potency against HCT 116 p53 (+/+), however with a bigger increase 
of drug deactivation. Compound 3.32 (R = 2,5-diCl) shows equipotent activity as 
under normoxic conditions. Interestingly, compound 3.23 (R = 2-F) increases its 
activity from 11.75 M to 8.00 M, although it is not as effectve as against the 
HCT 116 p53 (+/+). This suggest that compounds 3.32 (R = 2,5-diCl) and 3.23  
(R = 2-F) are good candidates for further biological studies. 
Figure 4-22 (bottom chart) shows the normoxia and hypoxia IC50 values against 
the pancreatic adenocarcinoma cell line MIA PaCa_2. Only compound 3.13  
(R = 3-iPr) decreases its activity under hypoxic conditions. Complexes 3.18  
(R = 4-tBu) and 3.29 (R = 3-Cl) show similar potency within the standard errors 
as the normoxic studies. Remarkably, compounds 3.32 (R = 2,5-diCl) and 3.23 
(R = 2-F) show a threefold increase and four fold increase in potency under 
hypoxic conditions, respectively. The IC50 value of complex 3.32 (R = 2,5-diCl) 
decreases from 28.74 M to 10.85 M, and compound 3.23 (R = 2-F) decreases 
from 18.30 M to 4.97 M. In terms of IC50 intervals, these compounds go from 
active to be highly active under hypoxic conditions. 
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Table 4-12: Summary of the IC50 under hypoxic conditions of complexes 3.13, 
3.18, 3.23, 3.29 and 3.32. (Blue highlighted show compounds anticancer activity 
under these conditions) 
Complex R p53 (+/+) p53 (-/-) MIA PaCa_2 
3.13 3-iPr 40.31 ± 10.76 53.71 ± 4.13 45.41 ±10.48 
3.18 4-tBu 10.92 ± 2.86 31.89 ± 6.85 12.62 ± 1.01 
3.23 2-F 4.21 ± 1.07 8.00 ± 1.42 4.97 ± 1.44 
3.29 3-Cl 8.32 ± 0.91 27.67 ± 8.39 26.11 ± 4.18 
3.32 2,5-diCl 8.22 ± 2.17 13.92 ± 3.03 10.85 ± 2.74 
 
4.4.2 Hypoxia Cytotoxicity Ratio 
The IC50 value of the drug in normoxia divided by the IC50 value in hypoxic 
conditions against a given cell line yields a unit-less number that expresses the 
preference of drug to target the oxygen depleted cells or the normoxia cells. The 
purpose of this ratio is to show if the compounds tested could potentially be used 
in 3D cancer models. This means that cells clump together forming the inside of 
the tumour and the outside behaves like a normal cell based on spheroids and 
mammospheres. 
Figure 4-23 shows compounds 3.13 (R = 3-iPr), 3.18 (R = 4-tBu) and 3.29  
(R = 3-Cl) display no enhancement unless for complex 3.18 (R = 4-tBu) against 
MIA PaCa-2. Compound 3.32 (R = 2,5-diCl) increases activity against HCT 116 
p53 (+/+) and MIA PaCa_2 but decreases for HCT 116 p53 (-/-). Finally, compound 
3.23 (R = 2-F) shows increase cytotoxicity in hypoxic conditions against all cell 
lines. Overall, compounds 3.32 (R = 2,5-diCl) and 3.23 (R = 2-F) display better 
activity being the best candidates for further analysis in 3D models. 
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Figure 4-23: Hypoxia cytotoxicity ratio (HCR) bar-chart of compounds 3.13 (R= 
3-iPr), 3.18 (R = 4-tBu), 3.23 (R = 2-F), 3.29 (R = 3-Cl) and 3.23 (R = 2,5-diCl). 
4.4.3 Hypoxia Enhancement Ratio 
The ‘Hypoxia Enhancement Ratio’ is defined by the IC50 value of a healthy cell 
line divided by the IC50 value of a cancerous cell line. The outcome represents 
the selectivity of the compounds towards cancerous cells. Figure 4-24 shows the 
hypoxia enhancement ratios for each compound and only compounds 3.23  
(R = 2-F) and 3.32 (R = 2,5-diCl) have shown more selectivity towards cancerous 
cells under hypoxic conditions. Figure 4-25 compares both the hypoxic and 
normoxic results. 
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Figure 4-25: Bar-chart comparison of the hypoxia enhancement ratio and the 
selectivity under normoxic conditions for 3.13 (R= 3-iPr), 3.18 (R = 4-tBu), 3.23 
(R = 2-F), 3.29 (R = 3-Cl) and 3.23 (R = 2,5-diCl) against the cell lines tested. 
4.4.4 Summary of the hypoxia cytotoxicity cell work 
From the normoxia cell work (4.3) eight Lead Compounds were identified after 
obtaining the selectivity, comparing them to the current chemotherapeutic drugs 
and considering additional factors previously discussed. Five compounds were 
tested under hypoxic conditions against HCT 116 p53 (+/+), HCT 116 p53 (-/-) and 
MIA PaCa-2. From those five compounds, 3.13 (R = 3-iPr), 3.18 (R = 4-tBu), 3.29 
(R = 3-Cl), 3.23 (R = 2-F) and 3.32 (R = 2,5-diCl) only two showed better IC50 
under hypoxic conditions, and those are 3.23 (R = 2-F) and 3.32 (R = 2,5-diCl). 
4.5 Cell recovery 
One of the many challenges in medicinal chemistry for both inorganic and biology 
is understanding if the potential drugs show cytotoxic or cytostatic properties. This 
means, if a cell is exposed to a drug, it has three modes to react against it: the 
drug does nothing to the cells, the drug affects the cells, but they recover after 
exposure (cytostatic) or the drug kills the cells and there is no recovery 
(cytotoxic). The advantage of a compound to be cytotoxic, it means that the drug 
exposure can be lower which avoids non-cancerous cell damage.  
The two Lead Compounds 3.23 (2-F) and 3.32 (2,5-diCl) were tested for the 
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assay, explained at the beginning of the chapter. However, the main changes are 
on how long the drug exposure is left for, and the recovery period which is left 
until 72 hours to match the cytotoxic normoxic results discussed previously within 
this chapter (4.3). This drug exposure periods were set at 1 hour and 24 hours 
with a recovery period of 71 hours and 48 hours respectively. Then, MTT is added 
and incubated for a further of three hours and the IC50 values were obtained. 
Figure 4-26 shows the different potencies of the two Lead Compounds tested 
against HCT 116 p53 (+/+), HCT 116 p53 (-/-) and MIA PaCa_2. In Table 4-13 all 
the values are shown with their respective standard deviations. The two 
compounds show similar activity against the cancerous cell lines, there is no 
recovery of the cells proving that they are cytotoxic complexes, and, they also 
exhibit their anticancer activity is time-dependent. Compound 3.23 (2-F) shows 
the quickest cytotoxic effects, however it is not very selective. Compound 3.32 
(2,5-diCl) only shows quicker cytotoxic activity against MIA PaCA_2 after 1h of 
exposure without compromising its selectivity. 
Figure 4-26 (top left HCT 116 p53(+/+) chart) shows that compound 3.23 (2-F) 
has its cytotoxic effect after 1h of exposure which enhances after 72h drug 
treatment. Compound 3.32 (2,5-diCl) increases its activity after prolonged times. 
The complex bearing 2-F is surprisingly interesting as, showing its cytotoxicity 
after one hour meaning the selectivity towards the cancerous cells is greater than 
after 72h and it can be removed to not cause any damage to healthy cell lines. 
Figure 4-26 (top right HCT 116 p53(-/-) chart) shows both compounds displaying 
similar behaviour where their activity increases with time and there is no cell 
recovery. Complex 3.23 (R = 2-F) shows faster cytotoxicity after 24h than 
complex 3.32 (R = 2,5-diCl). 
Figure 4-26 (bottom left MIA PaCa_2 chart) shows both compounds increase 
their anticancer activity with longer exposure times. However, compound 3.32  
(2,5-diCl) displays a better cytotoxicity after 1h exposure stabilising the toxicity 
after 24h. 
Figure 4-26 (bottom right ARPE-19 chart) shows the compound 3.23 (R = 2-F) 
increases its cytotoxicity with time, which translates to potential decrease of 
selectivity. Conversely, the IC50 values for compound 3.32 (R = 2,5-diCl) are 
similar at different time exposure. This is greatly appreciated for in vivo assays or 
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clinical trials, as this means, exposure of this drug could be done more frequently 
and for longer periods of time. 
Figure 4-27 shows the selectivity ratios of the complexes after 1h, 24h and 72h 
and all values can be found in Table 4-14. The complexes show opposite trends, 
complex 3.23 (R = 2-F) decreases its selectivity with longer time drug exposures, 
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Figure 4-26: Bar-chart of compounds 3.23 (R = 2-F in blue) and 3.32 (R = 2,5-diCl in red) for the different time exposure cytotoxic assays 
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Table 4-13: IC50 values (M) of compounds 3.23 (R = 2-F) and 3.32 (R = 2,5-diCl) for the different time exposure cytotoxic assays against 
HCT 116 p53(+/+), HCT 116 p53 (-/-), MIA PaCa_2 and ARPE-19. 
 Cell Line 
 HCT 116 p53(+/+) HCT 116 p53(-/-) MIA PaCa_2 ARPE-19 
Time 3.23 (2-F) 3.32 (2,5-diCl) 3.23 (2-F) 3.32 (2,5-diCl) 3.23 (2-F) 3.32 (2,5-diCl) 3.23 (2-F) 3.32 (2,5-diCl) 
1h 20.12 ± 3.63 55.59 ± 8.87 68.27 ± 6.08 67.08 ± 1.91 59.71 ± 4.54 39.84 ± 2.10 71.71 ± 7.02 84.49 ± 5.20 
24h 16.18 ± 1.43 28.67 ± 6.28 22.32 ± 5.07 40.60 ± 5.21 19.55 ± 3.87 26.02 ± 6.57 50.31 ± 1.54 85.60 ± 6.47 
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Table 4-14: Selectivity values of compounds 3.23 (R = 2-F) and 3.32 (R = 2,5-diCl) for the different time exposure cytotoxic assays against 
HCT 116 p53(+/+), HCT 116 p53 (-/-) and MIA PaCa_2. 
 Cell Line 
 HCT 116 p53(+/+) HCT 116 p53(-/-) MIA PaCa_2 
Time 3.23 (2-F) 3.32 (2,5-diCl) 3.23 (2-F) 3.32 (2,5-diCl) 3.23 (2-F) 3.32 (2,5-diCl) 
1h 3.6 1.5 1.1 1.3 1.2 2.1 
24h 3.1 3.0 2.25 2.1 2.6 3.3 
72h 2.5 7.1 2.40 7.8 1.3 3.2 
. 
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4.6 Cell viability and cycle analysis 
Once the compounds are evaluated and validated, the next step in the process 
of drug development is understanding/elucidating the mechanism of action.1 
Anticancer drugs are divided into cytotoxic or cytostatic drugs. A cytotoxic drug 
induces cancer cell death (cisplatin) and a cytostatic drug inhibits the proliferation 
(tamoxifen). Cell imaging techniques like the ones based on fluorescence 
imaging have revolutionised the way to analyse samples (flow cytometry). These 
techniques can discriminate between if a drug is cytotoxic or cytostatic.33-35 In 
section 4.5, it was proven there was no cell recovery, being the compound 3.23 
(2-F) cytotoxic towards the pancreatic and epithelial cell lines tested, whereas 
compound 3.32 (2,5-diCl) is only cytotoxic towards the pancreatic cancer, 
showing great selectivity. 
Eukaryotic cells have two representative processes: cell cycle and cell division. 
Cell division is the final step of a sequence of events that a cell goes through, 
also known as cell cycle (Figure 4-28). It is divided in four stages: mitosis  
(M phase), gap-1 (G1 phase), synthesis (S phase) and gap-2 (G2 phase). Normal 
non-dividing cells are quiescent (G0 phase); once within the cell cycle they enter 
in G1 phase (cells increasing in size), followed by the phase when DNA is 
replicated (S phase). A further short period of cell growth called G2 phase, follows 
the final M phase (mitosis) producing two identical daughter cells. During the 
oncogenic phase of a cell, this sequential cycle is disrupted in different pathways 
that regulate the process.36,37  
 
Figure 4-28: The eukaryotic cell cycle.38 
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Depending on the phase of the cell cycle, different drugs target the S phase, the 
M phase or all of them. Alkylating agents and cytotoxic antibiotics damage the 
DNA at all phases, e.g. cisplatin and mitomycin-C respectively. Anti-metabolites 
replace normal metabolites at the S phase interfering with the DNA replication, 
e.g. 5-fluorouracil. Topoisomerase inhibitor operate at S phase as well, but are 
involved with the DNA unwinding, e.g. etoposide. Lastly, mitotic inhibitors prevent 
the formation of the binding between tubulin subunits and the mitotic spindle, 
hence interfering in the M phase.39,40 
The two Lead Compounds 3.23 (2-F) and 3.32 (2,5-diCl) were analysed further 
by determining their effects on both, the cell viability and the cell cycle of two 
different cell lines, one cancerous, the pancreatic MIA PaCa_2, and one non-
cancerous, the epithelial ARPE-19. Due to time constraint, only two runs were 
carried out and a third one is needed in order to validate the results. These assays 
were carried out by the author under the supervision of Professor Roger M. 
Phillips at The University of Huddersfield. The complexes, at a given 
concentration (18 M), were incubated with the different cell lines at 37ºC, 5% 
CO2 and analysed for 24h, 48h and 72h. For cell viability, single cell suspensions 
of 1 mL were prepared and loaded into a Via1-CassetteTM. The inside of these 
cassettes is coated with two different dyes, Acridine Orange stains all the cell 
population and DAPI (4’-6-diamino-2-phenylindole) stains the non-viable cells 
that possess permeable cell membranes. The outcome is a number in percentage 
units that shows the number of viable cells. For cell cycle analysis, cell 
suspensions were centrifuged, treated with an acidic lysis buffer, and stained with 
DAPI for 5 min at 37ºC. After, a neutraliser basic buffer was added, and the 
cellular fluorescence was quantified by using a NC-Slide 8TM and the 
NucleoCounter® NC-3000TM. The outcome is a spectrum analysed using the 
software NucleoViewTM software, that, after using the markers it will show if the 
compounds interact with the cell cycle at any stage.38 
Table 4-15 summarises the cell viability results for the experiments carried out 
using the healthy cell line, ARPE-19, for the control experiments, after treatment 
with complex 3.23 (2-F) and complex 3.32 (2,5-diCl) respectively. These 
experiments are carried out using the same concentration for the complexes (18 
M) in order to observe the effect of the drugs after 24h, 48h and 72h. 
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For the control and the treatment with complex 3.23 (2-F) there is a reduction in 
the number of total cells after 72 hours and there is almost no reduction in the 
percentage of viable cells. Whereas for treatment with complex 3.32 (2-5-diCl) 
there is an increase in the number of total cells, however, there is a slight 
decrease the cell viability percentage. If a drug shows a cytotoxic behaviour, the 
number of total cells and the percentage should decrease, whereas if the drugs 
behave as cytostatic, the cell proliferation will be impeded without changing the 
percentage of cells viable. These suggest that both complexes show a cytostatic 
behaviour when using the ARPE-19 cells. These feature is consistent with the 
IC50 values against the ARPE-19 cell lines as the IC50 values are quite high, 
making these two complexes the most selective out of the thirty compounds 
tested. 
In Figure 4-29, it can be seen the optical images of the cells before analysing the 
cell viability and cell cycle. All the images are very similar apart from the 3rd row. 
The last row of Figure 4-29, involves the treatment of the cells with complex 3.32 
(R = 2,5-diCl). Interestingly, it was observed a series of needles attached to the 
cells and the walls of the T25 flasks (Figure 4-30). Several attempts were made 
in order to get some of the crystals and analyse them by x-ray crystallography, 
but, unfortunately, these crystals are very tiny and very fragile. Different 
crystallisations were set up under the same conditions as the treatment of the 
cells, but no crystals were formed. This suggests that in order to obtain the 
crystals the cells might play an important role. This could potentially be attributed 
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Time (Control) Time (3.23 (2-F)) Time (3.32 (2,5-diCl)) 
24h 48h 72h 24h 48h 72h 24h 48h 72h 
Total Cells 3.68 x 105 9.40 x 105 6.87 x 105 2.93 x 105 6.24 x 105 2.34 x 105 1.91 x 105 8.16 x 105 2.57 x 106 
Cell viability / % 98.1 98.1 94.8 98.4 97.5 94.7 98.9 98 91.9 
Cell diameter / m 16.4 ± 7.9 >20 ± * 16.0 ± 8.3 16.7 ± 8.1 17.5 ± 8.7 17.0 ± 8.7 17.1 ± 8.2 17.1 ± 8.3 13.7 ± 9.5 
Aggregates of >5 
cells 
0 4 15 11 1 3 5 2 71 
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Figure 4-29: Representative optical microscopy images (x10) of ARPE-19 cells 
after 24h, 48h and 72h in: (top) control experiment, (medium) treatment with 
complex 3.23 (2-F) and (bottom) treatment with complex 3.32 (2,5-diCl).  
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Figure 4-30: Optical image (x10) of ARPE-19 treated with the complex 3.32  
(2,5-diCl) after 48h. Several needle-like crystals can be seen when using 
polarised light. 
Table 4-16 collects all the data for the cell cycle analysis for ARPE-19. After 24h 
of drug exposure, cell cycle analysis shows two different behaviours for the 
complexes. Complex 3.23 (R = 2-F) an increase of 10% in the number sub G1 
cells. The phase G0/G1 decreases in 30% and showing increased values the 
remaining both phases, S and G2/M. However, and as expected from the very 
high IC50 value, complex 3.32 (2,5-diCl) shows similar percentages as the control 
meaning little affect towards the healthy cell line. 
After 48h of drug exposure, cell cycle analysis displays, again, two different 
behaviours for the complexes. Complex 3.23 (R = 2-F) shows an increase of 30% 
in the number sub G1 cells. The phase G0/G1 decreases from 89.1% to a 30% 
showing increased values for both phase, S and G2/M. For S-phase, the 
percentage increases in 10 units and for G2/M, the final result is 22.8 % that 
corresponds with almost a 20% increase. Complex 3.32 (2,5-diCl) displays similar 
percentages as the control. 
After 72h of drug exposure, cell cycle analysis shows the same patterns in the 
cell cycle for the cells treated compared to the untreated cells. In this case, 
complex 3.23 (R = 2-F) shows an increase of nearly 35% in the number sub G1 
cells. The phase G0/G1 decreases from 80.9% to a 27.3% showing increased 
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values of 10% for the S phase with a final value of 20%, and an increase of 10% 
for the G2/M with a final value of 15.1%. Complex 3.32 (2,5-diCl) displays similar 
percentages as the control. 
Figure 4-31 is a bar-chart representation of the different percentages of the cell 
cycle analysis for the different time experiments (duplicate). It can be seen that, 
only complex 3.32 (2-F) shows an increase in the Sub G1 phase (black highlighted 
in the plot). This phase is attributed to the leaching of DNA from the cell which is 
related to cell death. To corroborate this effect, another experiment using 18 M 
should be done in order to finish the triplicates. To prove the compound 
selectively increases the Sub G1 phase, another set of experiments should be 
carried out at higher concentration, to understand completely if this complex 
induces apoptosis, the following assays could be done: Annexin V assay, 
Caspase assay or Mitochondrial Potential assay.41 
Figure 4-31: Bar chart representing the proportions of the cell cycle for the cell 
line ARPE-19 after 24h, 48h and 72h, including the drug exposure experiments. 
The ruthenium complexes NAMI-A and KP-1019 were proved by cell cycle arrest 
assays, that both complexes alter the cycle in the phase G2/M which involves two 
processes: mitosis when the chromosomes condense and pulled to the sides of 
the cells by spindle fibres, and cytokinesis involving the formation of a ring which 
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In 2014, a cis-tetraammine(oxolato) ruthenium (III) dithionate complex was 
analysed against leukaemia cells showing that the cell cycle arrest was attributed 
to the sub G1 phase.44 The results against the ARPE-19 cells described in this 
section give an indicative that these compounds interact in a similar way to the 
complex dithionate complex. However, little it is known about the trans-dihalide 
arrangement of the chloride labile ligands when coordinated to a metal, hence 
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Table 4-16: ARPE-19 cell cycle analysis after 24h, 48h and 72h, showing the control, drug treatment with complex 3.23 (2-F) and complex 





Time (Cell Population (%) 
Control) 
Time (Cell Population (%)3.23 (2-F)) Time (Cell Population (%).32 (2,5-diCl)) 
24h 48h 72h 24h 48h 72h 24h 48h 72h 
Sub G1 4.9 1.9 2.4 14.9 31.8 36.0 3.2 2.6 2.9 
G0/G1 67.2 89.1 80.9 34.7 29.4 27.3 61.9 91.2 91.1 
S 12.0 4.3 9.3 21.8 14.4 20.0 15.6 2.1 2.3 
G2/M 15.5 4.5 7.5 26.0 22.8 15.1 17.7 3.9 3.5 
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Table 4-17 contains the cell viability results for the experiments carried out using 
the cancerous cell line, MIA PaCa_2, for the control experiments, after treatment 
with complex 3.23 (2-F) and complex 3.32 (2,5-diCl) respectively. These 
experiments were carried out using the same concentration for the complexes 
(18 M) in order to observe the effect of the drugs after 24h, 48h and 72h.  
For the control experiment, the total number of cells and viability increases with 
time showing a normal behaviour. When the cells are treated with complex 3.23 
(2-F) there is a reduction in the number of total cells after 72 hours and a clear 
reduction in the percentage of viable cells what means this is a clear cytotoxic 
behaviour. Whereas after treatment with complex 3.32 (2-5-diCl) there is a 
decrease in the total number of cells with a substantial decrease in the 
percentage of cell viability after 48h, however, after 72h there is an increase in 
the number of total cells, as well as for the cell viability percentage, reaching 
similar values to the ones obtained for the control. This suggests that compound 
3.32 (2-5-diCl) has two potential modes of action, a cytotoxic behaviour before 
48h and cytostatic properties thereafter. However, this result is slightly 
contradictory to the cell recovery assay, as it was proved that pancreatic cells did 
not recover after drug exposure of 24h. 
Figure 4-32 shows the different drug exposure optical images of the cells before 
analysing the cell viability and cell cycle. Apart from the 3rd row, all the images 
are very similar showing a decrease in cell population. Figure 4-33 involves the 
treatment of the cells with complex 3.32 (R = 2,5-diCl). Interestingly, it was 
observed a series of needles attached to the cells and the walls of the T25 flasks. 
These crystals are very tiny and very fragile, with unsuccessful attempts to 
synthesise them for x-ray crystallography. The attempts made did not involve 
cells what suggests they might play an important role which could potentially be 
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Figure 4-32: Representative optical microscopy images (x10) of MIA PaCa_2 
cells after 24h, 48h and 72h in: (top) control experiment, (medium) treatment with 
complex 3.23 (2-F) and (bottom) treatment with complex 3.32 (2,5-diCl). 
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Figure 4-33: Optical image (x10) of MIA PaCa_2 treated with the complex 3.32  
(2,5-diCl) after 48h. Several needle-like crystals can be seen when using 
polarised light, displaying three different colours: blue, red and green. 
 




Chapter 4 Biological Investigations 
- 143 - 
   
Table 4-17: MIA PaCa_2 cell viability summary for control, complexes 3.23 and 3.32 after 24h, 48h and 72h (* = Not determined) 
 
MIA PaCa_2  
Time (Control) Time (3.23 (2-F)) Time (3.32 (2,5-diCl)) 
24h 48h 72h 24h 48h 72h 24h 48h 72h 
Total Cells 1.11 x 
106 
8.91 x 105 1.69 x 106 1.35 x 
106 
1.32 x 106 6.34 x 105 1.10 x 106 9.63 x 105 2.10 x 106 
Cell viability / 
% 
77.0 64.7 90.2 79.6 67.2 48.6 94.6 81.0 92.4 




15.1 ± 10.1 16.1 ± 10.5 16.5 ± 
10.9 
12.9 ± 10.0 15.1 ± 10.1 16.9 ± 9.6 15.6 ± 10.4 16.1 ± 10.9 
Aggregates of 
>5 cells 
59 43 63 62 41 32 73 58 75 
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Table 4-18 collects all the data for the cell cycle analysis for MIA PaCa_2. After 
24h of drug exposure, cell cycle analysis shows two different behaviours for the 
complexes. Complex 3.23 (R = 2-F) shows a decrease of 10% in the number of 
G0/G1 cell phase and an increase of 10% in the S phase. However, complex 3.32 
(2,5-diCl) shows a 22% decrease in the G0/G1 phase which was almost evenly 
distributed between the other three phases. From the untreated cells, Sub G1, S 
and G2/M show values of 7.6, 11.7 and 12.3, whereas for the treated cells it was 
14.6, 17.2 and 20.5, respectively. 
After 48h of drug exposure, cell cycle analyses have displayed two different 
behaviours for the complexes. Surprisingly, complex 3.23 (R = 2-F) shows an 
increase of 30% in the number sub G1 cells, 50% decrease in G0/G1 phase and 
10% decrease for both S phase and G2/M phase. Conversely to the 24h results, 
for complex 3.32 (2,5-diCl) shows no variation when compared to the untreated 
cells or control. 
After 72h of drug exposure, cell cycle analysis shows that complex 3.23  
(R = 2-F) has an increase of nearly 30% in the number sub G1 cells. The phase 
G0/G1 decreases from 71.2% to 34.9% showing increased values of 8% for both 
the S phase and the G2/M with final values of 17.8% and 15.1%, respectively. 
Complex 3.32 (2,5-diCl) shows a 10% increase in the Sub G1, a decrease of the 
G0/G1 phase of 35%; and increases of 12% and 13% for the S-phase and the 
G2/M phase, respectively. 
Figure 4-34 is a bar-chart representation of the different percentages of the cell 
cycle analysis for the different time experiments (duplicate). Both complexes 
show a significantly change in the phase Sub G1 (black highlighted in the plot). 
This is consistent with the results obtained for the ARPE-19 cell cycle analyses. 
This phase is attributed to cell death. However, to corroborate this effect, another 
experiment using 18 M should be done in order to finish the triplicates. The 
results obtained for complex 3.32 (2,5-diCl) after 48h seem odd as they do not 
follow a trend when compared to the 24h. To prove the compound selectively 
increases the Sub G1 phase for both complexes, experiments inducing apoptosis 
should be carried out. 
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Figure 4-34: Bar chart representing the proportions of the cell cycle for the cell 
line MIA PaCa_2 after 24h, 48h and 72h, including the drug exposure 
experiments. 
4.6.1 Summary of Cell viability and Cell cycle assay 
After determining the Lead compounds, complex 3.23 (2-F) and 3.32 (2,5-diCl) 
were proved to be the best candidates for further analysis. Cell viability was 
determined and proven there is no recovery after 1h and 24h drug treatment, 
suggesting these compounds have cytotoxic properties. Cell cycle arrest 
analyses proven that only complex 3.23 (2-F) shows cytotoxic effects against 
ARPE-19 at the Sub G1 phase (suggesting that this compound might induce cell 
programme death or apoptosis). When analysing the cell cycle arrest data against 
the MIA PaCa_2 cell line, both compounds showed a remarkable increase of the 
cell population in the Sub G1 phase. As this phase is linked to cell death, further 
analyses should be done in order to determine the mechanism of action, such as 
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Table 4-18: MIA PaCa_2 cell cycle analysis after 24h, 48h and 72h, showing the control, drug treatment with complex 3.23 (2-F) and 





Time (Cell Population (%) 
Control) 
Time (Cell Population (%)3.23 (2-F)) Time (Cell Population (%).32 (2,5-diCl)) 
24h 48h 72h 24h 48h 72h 24h 48h 72h 
Sub G1 7.6 5.5 10.7 8.1 38.1 29.4 14.6 6.5 19.8 
G0/G1 67.9 77.9 71.2 56.8 27.0 34.9 45.6 75.4 36.1 
S 11.7 9.3 9.9 22. 19.1 17.8 17.2 10.5 22.9 
G2/M 12.3 6.6 7.4 9.1 15.0 15.9 20.5 6.9 19.0 
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4.7 Anti-bacterial activity 
Nowadays, modern medicine is facing a critical stage of bacterial resistance. 
There are two classes of bacteria: Gram-negative and Gram-positive meaning 
the bacteria lacks or possessed an external wall, respectively; and some 
pathogens that have shown resistance in hospital-based infections. This 
combination of pathogens is called ESKAPE. This family is known for be resistant 
to several drugs and it is formed by: Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumonae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter species.45 This resistance to current drugs is due 
to the ability of bacteria of rapid proliferation and the transfer of genes both 
between generations (vertically) or in the same generation (horizontally). It can 
be active which results when bacteria counter-attack or passive when, for 
example, the bacteria develop a non-specific barrier against the drug.46 New 
antibiotics are modifications of the pre-existing ones, but this is not a solution and 
they are not very successful. In 1950s, Rubbo et al. proved that complexation of 
oxine (sanitizer) to copper and iron ions improved its antibiotic properties.47,48 
Hence, the introduction of metal-based complexes as potential drugs which will 
approach the biocidal approach through different mechanism of action.49 The 
reported metal complexes contain an existing antibacterial compound in order to 
merge the antimicrobial activity and proved to increase its activity.50 The most 
successful family of ruthenium compounds were developed by Dwyer et al. are 
focused on ruthenium (II) polypyridyl complexes showing great activity against 
Gram-positive, Gram-negative and acid-fast bacteria.51  
Recently, more focus is given to ruthenium (III) complexes constituted by 
chelating ligands which are derived from polypyridyl units, base Schiff ligands or 
thiourea building blocks and two dichloride labile ligands. 52- 54 The ruthenium (III) 
polypyridyl charged complexes have been proven to be more active than the 
ruthenium (II) neutral complexes derived by Dwyer. The biocidal activity of the 
former increases when one of the chlorides is substituted by guanide  
(Figure 4-35). This feature was attributed to the Overtone’s concept of cell 
permeability were the more liposoluble the drug the better the antibacterial 
activity,55 and Tweedy’s chelation theory which states that the polarity of the metal 
ion is reduced due to the overlap of the ligand orbital and partially sharing the 
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metal ion charge increasing the delocalization of p-electrons what enhances the 
penetration of the metal complexes in lipid membranes (Overtone’s concept) 
blocking the metal binding sites on enzymes of the microorganisms.56 
 
Figure 4-35: Chemical structures of the ruthenium (III) polypyridyl complexes 
(left) dichloride complex and (right) its Guanide (G) derivative. 
Ruthenium (III) bearing amide ligands have not yet been exploited nor any 
literature could be found to date. In this work, trans-dichloride ruthenium (III)  
bis-quinaldamide neutral complexes are proposed as candidates for selective 
antibacterial studies. 
Complexes were screened (Figure 4-36) for their anti-bacterial activity against 
two types of bacteria classified depending on the absence (Gram negative) or 
presence (Gram positive) of bacteria cell wall; Escherichia coli (E. c.), Klebsiella 
pneuomoniae (K. p.), Acinetobacter baumannii (A. b.), Pseudomonas aerugonisa 
(P. a.) and Staphylococcus aureus (S. a.) by The Community for Antimicrobial 
Drug Discovery (CO-ADD) at The University of Queensland. The complexes at a 
single concentration of 32 g/mL, were incubated with the bacterial strains at 
37ºC for 18 hours without shaking. All growth inhibition assays were performed 
in duplicate. Growth inhibition was determined by measuring absorbance at  
600 nm. Complexes with growth inhibition greater than 80% are classed as 
active, complexes in the range of 50-80% are considered partially active and 
below 50% are considered inactive. 
Antibacterial screening results for the trans-dichloride ruthenium (III) 
bisquinaldamide neutral complexes are summarised in Table 4-19 from 
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complexes 3.1 – 3.24, and Table 4-20 for complexes 3.25 – 3.40. The results are 
highlighted for ease of understanding. Green means greater than 80% and 
subject to further analysis by the same institution. Orange means between 50-
80%. 
From the results obtained, almost half of the complexes tested have shown a 
preferential activity against Staphylococcus aureus (S. a.); being selective 
towards this bacterial strain and with any other biocidal activity against the 
remaining ones. Compounds 3.5 (2-Me), 3.9 (2-Et), 3.26 (2,4-diF), 3.32 (2,5-diCl), 
3.39 (3-I) and 3.40 (4-I) are classified as moderately active with MIC values 
ranging between 52.48% until 79.08%. Compounds 3.12 (2-iPr), 3.28 (2-Cl), 3.30 
(4-Cl), 3.33 (2-Br), 3.34 (3-Br), 3.35 (4-Br) and 3.38 (2-I) classified as active 
antibacterial drugs with values ranging between 81.83% until 98.72%; they were 
analysed further by the same institution and discussed later in this chapter.  
Interestingly, both series of compounds show that the 2-substituted complexes 
have an effect on this selective biocidal activity against Staphylococcus aureus. 
Compounds with electron-donating groups show a MIC in the moderately active 
region, whereas, apart for the complex substituted with R = 2-iPr, when the 
functional groups are electron-withdrawing groups the activity falls in the region 
of active compounds. Surprisingly, compounds with fluoro groups did not show 
an effect that falls in this activity range, however when conversion to Cl, Br and I 
the MIC rises to near 98% of activity. The size of these EWG have a clear effect 
as well as the position, when the functional group of the ligand is Cl, only positions 
2 and 4 show activity; if the ligand is I, only position 2 shows potency and if the 
ligand is monofunctionalised with Br, positions 2, 3 and 4 show activity. From 
these results, it is very clear that position is a crucial factor being position 2 of the 
ligands the most relevant. In terms of functional group, only when the 
functionalised ligand is Br, it shows activity independently of the position, what 
makes bromide a key factor in the selectivity and potency.  
The ruthenium benchmark (complex 3.1 with R = H) shows no activity at all. In 
contrast with the anticancer activity, this compound shows that aryl modifications 
are important in order to increase the activity of the compounds. It also shows 
that this sort of trans-dichloride disposition effects selectivity. Unfortunately, the 
similar family published within the group32 was not tested against any bacteria 
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strains. Nonetheless, there is some work done (unpublished) in cobalt metal 
complexes having picolinamide ligands as functional groups and their 
antibacterial studies. The outcome was that the bispicolinamide cobalt complexes 
with different labile ligands showed no activity against the same bacterial strains 
used for this thesis. This shows that ruthenium metal complexes are good 
candidates as antibacterial agents, as it was seen for the Ru(III) polypyridyl 
complexes, and, also that they can be fine-tuned to be selective and very potent 
when the ligands are bulky amides. 
It is important to highlight that: the complexes tested have a trans-dichloride 
arrangement and, to date, little it is known about this metal-amide based scaffolds 
in terms of antibacterial activity neither there is a comparison between trans or 
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Figure 4-36:  Bar-chart summary of the growth inhibition (%) of the ruthenium complexes against the different bacterial strains tested by 
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Table 4-19: Growth inhibition of trans-dichloride ruthenium bisquinaldamide 3.1 – 3.24 complexes against bacterial strains expressed in % 
Complex R S. a.  E. c.  K. p. P. a. A. b. 
3.1 H -15.17 10.74 1.85 3.57 0 
3.5 2-Me 65.53 16.37 5.71 12.67 2.91 
3.6 3-Me -51.18 1.69 -6.4 -3.88 -18.4 
3.7 4-Me 14.25 20.61 14.01 17.4 18.35 
3.9 2-Et 52.48 17.88 8.41 5.75 4.26 
3.10 3-Et 6.83 17.63 4.95 4.73 -3.33 
3.11 4-Et 8.34 22.32 9.77 6.64 7.49 
3.12 2-iPr 91.42 8.96 4.16 6.58 -2.86 
3.13 3-iPr 22.64 15.05 6.18 6.92 6.94 
3.15 2,6-diiPr 18.41 16.32 11.89 12.2 20.9 
3.16 2-Me-6-iPr 39.8 7.76 2.47 5.67 9.72 
3.17 2-tBu -3.54 27.31 12.72 12.81 4.37 
3.18 4-tBu 7.79 17.82 3.9 6.71 6 
3.23 2-F 18.09 10.59 4.32 5.75 3.78 
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Table 4-20: Growth inhibition of trans-dichloride ruthenium bisquinaldamide 3.25 – 3.40 complexes against bacterial strains expressed in % 
Complex R S. a.  E. c.  K. p. P. a. A. b. 
3.25 4-F 16.84 22.87 12.33 0.64 9.68 
3.26 2,4-diF 79.08 5.7 0.81 1.16 5.6 
3.27 2,5-diF 15.79 20.16 9.33 4.35 20.86 
3.28 2-Cl 98.76 13.27 10.97 4.35 15.08 
3.29 3-Cl 32.44 -3.51 -9.15 -11.54 -10 
3.30 4-Cl 94.93 7.51 -0.15 -2.66 -5.14 
3.31 2,4-diCl 48.63 -5.6 -5.29 -5.31 -3.44 
3.32 2,5-diCl 65.88 14.75 -0.95 -11.87 -4.35 
3.33 2-Br 84.07 13.26 -2.93 1.26 -1.43 
3.34 3-Br 86.28 7.88 1.92 -2.87 -0.53 
3.35 4-Br 81.83 12.27 8.6 1.41 -1.97 
3.36 2,4-diBr 42.81 -8.05 -10.71 -10.08 -8.86 
3.38 2-I 88.35 18.27 5.87 0.64 6.9 
3.39 3-I 62.04 16.86 3.02 -3.58 10.71 
3.40 4-I 66.95 0.52 -6.88 -6.17 -13.29 
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Complexes showing antibacterial activity (3.12, 3.28, 3.30 – 3.35 and 3.38) and 
classed as active were tested further, undergoing the hit confirmation process, 
which yields a number called minimum inhibitory concentration (MIC). MIC refers 
to the lowest drug concentration which displays visible growth of a given 
pathogen; the five antibacterial strains in this case, focusing on Staphylococcus 
aureus. This hit confirmation assay was carried by the same institution (CO-ADD) 
at The University of Queensland. The active trans-dichloride bisquinaldamide 
ruthenium (III) complexes were incubated, at eight concentrations, with the cells 
suspensions of the bacteria strains at 35 ºC for 18 hours without shaking. All 
growth inhibition assays were performed in duplicate. Inhibition of bacterial 
growth was determined by measuring the absorbance at 600 nm. The MIC was 
determined as the lowest concentration at which the growth was fully inhibited, 
defined by an inhibition greater than 80%. Complexes with MIC values less than 
32 g/mL are classed as confirmed active hits.  
In order to determine if these complexes are toxic to humans, they were also 
tested for their cytotoxicity against a non-cancerous cell line HEK 293 which is a 
human embryonic kidney. The cells were incubated with the complexes (eight 
different concentrations) at 37 ºC for 20 hours in an atmosphere of 5% CO2. In 
this case, the cytotoxicity was not measured by the addition of MTT, but after 3 
hours incubation of the addition of resazurin (excitation wavelength of 560 nm 
and emission of 590 nm), under the same conditions as the assay was carried 
out. In this case, a value called CC50 is obtained and is defined as the 
concentration of drug required to kill 50% of cells.  
Haemolysis assays were also carried out using human blood. The active 
complexes, at different concentrations, were shaken with the cells for then 
minutes prior to incubation at 37 ºC for one hour. The degree of haemolysis was 
determining by measuring the absorbance of the supernatant at 405 nm of the 
centrifuged samples, then it is expressed in term of HC10. The HC10 is a number 
that expressed the amount of the drug required to cause 10% haemolysis. 
The antibacterial MIC values, cytotoxicity and haemolysis results for complexes 
3.12 (2-iPr), 3.28 (2-Cl), 3.30 (4-Cl), 3.33 (2-Br), 3.34 (3-Br), 3.35 (4-Br) and 3.38 
(2-I) are summarised in Table 4-21. 
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Table 4-21: Antibacterial toxicity (MIC), cytotoxicity (CC50) and haemolysis (HC10) 
of 3.12, 3.28, 3.30, 3.33 – 3.35 and 3.38, all data expressed in g/ml (M) 
Complex R 
MIC CC50 HC10 
S. a. E. c. K. p. P. a. A. b. HEK  Hm 
3.12 2-iPr 16 >32 >32 >32 >32 12.62 >32 
3.28 2-Cl >32 >32 >32 >32 >32 >32 >32 
3.30 4-Cl >32 >32 >32 >32 >32 >32 >32 
3.33 2-Br >32 >32 >32 >32 >32 >32 >32 
3.34 3-Br 8 >32 >32 >32 >32 13.46 >32 
3.35 4-Br >32 >32 >32 >32 >32 >32 >32 
3.38 2-I 32 >32 >32 >32 >32 >32 >32 
 
The first screening showed that the complexes 3.12, 3.28, 3.30 – 3.35 and 3.38 
possessed a positive growth inhibition against Staphylococcus aureus, however 
only two complexes 3.12 (R = 2-iPro) and 3.34 (R = 3-Br) display sufficient activity 
to be completely classed as active hits, showing MIC values of 16 g/mL and  
8 g/mL, respectively. Interestingly, only these two complexes showed 
cytotoxicity values towards the non-cancerous cell line HEK 293, showing CC50 
values of 12.62 M for complex 3.12 (R = 2-iPro) and 13.46 M 3.34 (R = 3-Br). 
These values are actually very interesting when compared to the IC50 values 
obtained for the non-cancerous cell ARPE-19 (retinal pigmented epithelium). This 
suggest that non-cancerous cell lines should be expanded as well as the 
cancerous ones. The fact that the two hit Lead Compounds show CC50 against 
kidney cells suggest this family of trans-dichloride ruthenium complexes could be 
nephrotoxic. On the other hand, haemolysis results showed that the selection of 




     
Chapter 4 Biological Investigations 
- 156 - 
   
4.8 Anti-fungal activity 
Fungal infections can be classified as superficial or invasive, being the latter life-
threatening. The pathogens which cause invasive infections are Candida 
albicans, Cryptococcus neoformans and Aspergillus fumigates.57 There are only 
four classes of drugs based on organic molecules: polyenes, azoles, allylamines 
and echinocandins. 
Modern medicine has evolved very quickly in terms of surgery and treatment of 
different illness. However, these advantages sometimes compromise the 
immunological system. Surgical procedures that involve transplantation, and 
treatments against cancer or HIV/AIDS are linked to the weakness of the immune 
system making patients to be vulnerable against fungal infections.58 Furthermore, 
these infections have increased with a worrying mortality rate.59  
Organometallic and coordination metal complexes are slowly proving to be 
excellent candidates in terms of anticancer agents. Recently, the applications of 
those metal complexes have shifted to the antibiotic field, however, there are not 
many publications on the use of ruthenium (III) metal complexes as antifungal 
agents. 
The main complexes proved to show anti-fungal activities are based on the 
metals of the first row, and generally it was found that their activity is dose 
dependant, the higher the dose concentration the better the activity. Historically, 
Schiff bases were the first ligands used as organic moieties that showed an 
increase in activity when complexed to metals, especially copper.60 However, little 
it is known about the use of a bigger metal like ruthenium. Ruthenium (III) 
complexes are not as well studied as, for example, the piano-stool ruthenium (II) 
complexes. It can be found that the ligands bound to the ruthenium (III) centre 
are based on cycle Schiff bases61 acyclic hydrazones,62 catecholamine63 or sulfur 
derivatives.64 
The trans-dichloride bisquinaldamide ruthenium complexes will expand another 
functionality, the amide bond coordinated to the ruthenium (III) as novel anti-
fungal family. 
Complexes were screened for their anti-fungal activity against Candida albicans 
(C. a.) and Cryptococcus neoformans (C. n.) by CO-ADD at the University of 
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Queensland. The complexes were tested at single concentration of 32 g/mL, 
incubated with the fungal strains at 35 ºC for 24 hours without shaking. All growth 
inhibition assays were performed by duplicate. Growth inhibition of Candida 
albicans was determined by measuring the absorbance at 530 nm. Growth 
inhibition of Cryptococcus neoformans was determined by measuring the 
difference in absorbance between 580 nm and 600 nm following the addition of 
resazurin and incubation at 35 ºC for a further two hours. Complexes are divided 
in active is inhibition is higher than 80% or moderately active if the inhibition 
ranges between 50% and 80%.  
Antifungal screening results for the complexes are summarised in Table 4-22 and 
the compounds are highlighted in orange if moderately active and in green if 
active. 
Only one complex possesses some activity against one of the fungal strains 
screened, Candida albicans; all other complexes were inactive or helped to 
proliferate the strains. Complex 3.26 (R = 2,4-diF) was moderately active and 
very selective against Candida albicans, showing an inhibition growth of 67.35%. 
Any alteration on the position of the substituents and on the number of them 
would affect dramatically. This disposition seems to be fundamental to show the 
moderate but selective antifungal activity. Haemolysis analysis have shown that 
these compounds are potentially not toxic to humans. 
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Table 4-22: Growth inhibition of trans-dichloride ruthenium bisquinaldamide 3.1 – 3.40 complexes against fungal strains expressed in % 
Complex R C. a.  C. n.  Complex R C. a.  C. n.  
3.1 H -0.57 21.8 3.25 4-F 21.1 1.62 
3.5 2-Me 7.39 -6.61 3.26 2,4-diF 67.35 -33.47 
3.6 3-Me -7.75 0.32 3.27 2,5-diF 7.75 -0.53 
3.7 4-Me 7.46 -5.09 3.28 2-Cl 9.38 -7.26 
3.9 2-Et 12.16 -11.58 3.29 3-Cl 9.67 -21.14 
3.10 3-Et 29.01 -12.03 3.30 4-Cl 2.7 -3.5 
3.11 4-Et 43.45 -7.33 3.31 2,4-diCl -6.1 -14.98 
3.12 2-iPr 29.58 -12 3.32 2,5-diCl 39.48 9 
3.13 3-iPr 46.58 -12.22 3.33 2-Br 46.23 -8.35 
3.15 2,6-diiPr 35.89 -1.16 3.34 3-Br 24.39 -11.37 
3.16 2-Me-6-iPr 37.55 0.95 3.35 4-Br 11.62 -19.65 
3.17 2-tBu 4.26 23.75 3.36 2,4-diBr 32.3 -26.67 
3.18 4-tBu 17.44 10.95 3.38 2-I 8.25 -10.94 
3.23 2-F 36.68 3.14 3.39 3-I 27.73 -14.13 
3.24 3-F 13.72 2.71 3.40 4-I -8.89 -30.28 
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4.9 Conclusions  
Thirty ruthenium (III) trans-dichloride bis-quinaldamide complexes were tested for 
anti-cancer potency. Eight complexes were classified as Lead Compounds 
targeting two isogenic colorectal cancer cell lines based on tumour supresor 
genes and one pancreatic cell line. Five of the Lead Compounds were studied 
further by expanding the colorectal cell line panel, targeting a proto-oncogene 
family. This work represents the first time a wide library of pure trans-dihalide 
complexes have a great potency under normoxic studies targeting several 
isogenic cell lines. The Lead Compounds were also screened under hypoxic 
conditions observing that compounds 3.23 (R = 2-F) and 3.32 (R = 2,5-diCl) 
enhance their activity. The two aforementioned compounds were studied further 
to understand their mechanism of action against the pancreatic cell line. Short 
time drug exposure showed the compounds are cytotoxic and cell cycle analysis 
proved that compounds arrest in the Sub G1 DNA phase. 
All complexes were screened for their anti-fungal and anti-bacterial properties, 
showing that the complexes bearing the functional group in position 2 are toxic 
towards Staphylococcus aureus and only compound 3.26 displayed a moderate 
activity against Candida albicans. 
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5.1 Introduction 
Pharmaceutical drugs are in constant development in order to improve three 
features: higher potency, lower toxicity and improved selectivity. This is achieved 
by chemical modifications of the potential drug. To do so, the key point is 
understanding the relationship and behaviour between the molecular structure of 
a drug and its biological activity. After determining the anticancer activity of the 
ruthenium complexes described in Chapter 3, the main approaches to determine 
the structural-activity relationships are based on hydrolysis and hydrophobicity 
tests. 
 
5.2 Hydrolysis Studies 
An established mechanism of action for any anti-cancer drug with labile ligands 
is the activation by hydrolysis, probed for cisplatin (Chapter 1),1,2 NAMI-A 
(Chapter 1),3 and KP-1019.4 Once these complexes are administered 
intravenously into the blood plasma, they remain inert due due to the high chloride 
concentration, what prevents the halide labile ligand attached to the metallic core. 
Once inside the cells, the low chloride concentration triggers the aquation 
reaction (inducement of hydrolysis) hence activating the molecules by replacing 
the halide ligand by a water molecule. It was reported that, under physiological 
conditions, dichloride ruthenium complexes hydrolyse yielding cationic 
monoaqua or diaqua intermediates.5  
It is assumed the trans-dichloride bis-quinaldamide ruthenium complexes will 
undergo a hydrolysis reaction (proposed in Scheme 5-1) showing a similar 
aquation process to cisplatin and NAMI-A. A neutral dichloride ruthenium (III) 
complex undergoes a monohalide substitution with water forming a charged 
monoaqua intermediate which hydrolyses further by substituting the second 
halide by another molecule of water yielding a 2+ charged diaqua complex. As 
previously discussed, the aqua derivatives are supposed to be the active species 
that have the potential to bind to DNA damaging its structure.6  
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Scheme 5-1: Proposed hydrolysis mechanism for the trans-dichloride bis-
quinaldamide ruthenium complexes 
Complexes 3.1, 3.15, 3.18, 3.23, 3.27, 3.29, 3.32 and 3.33 display different 
cytotoxicity ranging from highly active to inactive, hence, were selected to study 
their hydrolysis rate. The samples were prepared according to conditions used in 
hydrolysis studies previously reported in the literature and within the McGowan 
group for the bis-picolinamide complexes.7,8 The complexes were prepared in 
10% DMF/90% H2O to give a final concentration of 100 µM. These solutions were 
scanned using UV-vis spectrophotometry at different time points: 0 h, 1 h, 12 h, 
24 h, 48 h and 72 h at 293 K to correlate with the 3-day drug incubation cytotoxic 
studies and cell recovery studies. After 72 h incubation, the samples were 
analysed by ESI-HRMS and there is no sign of any aquated species nor 
decomposition of the chloride ruthenium complexes. Figure 5-1 collects the uv-
vis spectra recorded from hydrolysis studies for the ruthenium trans-dichloride. 
The arrows on the graphs indicate the change of intensities of the peaks from 
time 0 h to 72 h. There are three different types of behaviour, in general, at 0h, 
each complex shows an intense absorption band in the ultraviolet region around 
280 nm and two small bands between 300 and 350 nm. Compounds with 
electron-donating groups shows a slight decrease in intensities. There is no 
change in the spectra for the compounds bearing electron-withdrawing groups, 
except for compound 3.32 (the most selective as explained in Chapter 5), where 
there is a significant change after 1 h. The slight changes in the absorption bands 
suggest there are ligand substitution reactions occurring in aqueous solution.9 
The ruthenium trans-dichloride complexes seem stable to hydrolysis meaning the 
mechanism of action would not involve a hydrolysed compound as active species. 
In summary, the UV-vis spectra show an intense ligand based absorbance (π-
π*) at approximately 290 nm and two broad and less intense bands at 300-400 
nm arising from metal-to-ligand charge transfer transitions. Table 5.1 lists the 
wavelength where the maxima of each absorption bands are seen in the 
complexes tested. 
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R = H (3.1) R = 2,6-diiPr (3.15) 
  
R = 4-tBu (3.18) R = 2-F (3.23) 
  
R = 2,5-diF (3.27) R = 3-Cl (3.29) 
 
 
R = 2,5-diCl (3.32) R = 2-Br (3.33) 
Figure 5-1: Recorded spectra for time-evolution hydrolysis studies and functional 
groups for the selected trans-dichloride Ru complexes.
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Table 5.1: Absorption wavelength bands (λmax) for the Ru complexes  
RuCl2(L)2 R λmax / nm 
3.1 H 292, 315, 331 
3.15 2,6-diiPr 292, 314, 328 
3.18 4-tBu 291, 315, 332 
3.23 2-F 291, 314, 330 
3.27 2,5-diF 288, 313, 329 
3.29 3-Cl 291, 316, 331 
3.32 2,5-diCl 292, 317, 330 
3.33 2-Br 289, 313, 328 
 
Ruthenium complexes 3.1, 3.15, 3.18, 3.23, 3.27, 3.29, 3.32 and 3.32 follow the 
same trend as the trans-diiodide bis-picolinamide ruthenium complexes reported 
within the McGowan group where the anticancer activity was correlated to the 
less hydrolysed products. The bis-picolinamide dichloride ruthenium complexes 
showed that the more hydrolysed the better the anticancer activity which opposed 
to the trend found within this project. This outlines a new strategy in medicinal 
research, where a trans di-halide arrange can be critical to design new anticancer 
molecules which are less prone to hydrolysis suggesting that their integrity is not 
compromised when administered to the body.8  
The equation shown below is used to estimate the final concentration in 
percentage of the aqua complex formed in solution. A calibration curve for each 
complex was used by taking the wavelength of the maximum absorbance peak 
to obtain the amount of complex hydrolysed after 72 h. 
% ℎ𝑦𝑑𝑟𝑜𝑙𝑦𝑠𝑒𝑑 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 =  (
[𝐶]𝑖𝑛𝑖𝑡𝑖𝑎𝑙 − [𝐶]𝑓𝑖𝑛𝑎𝑙
[𝐶]𝑖𝑛𝑖𝑡𝑖𝑎𝑙
)  𝑥 100% 
 
The percentage of hydrolysed complexes and the IC50 values of the compounds 
tested are shown in Table 5.2, Hydrolysis studies have demonstrated that the 
ruthenium chloride complexes show no trend. The most selective compound 3.32 
displays more hydrolysed product after 72 h than the remaining complexes. 
Although there is an striking feature, compounds tend to be stable throughout this 
assay but the most selective compounds shows a drop in the uv-vis spectra after 
between 1 h and 24 h. Finally, hydrolysis studies suggest that the mode of action 
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for these complexes might not be attributed to the displacement of the ligands. 
Additionally, these studies show this novel family is likely to be more stable under 
physiological conditions. The UV-vis hydrolysis samples were analysed by ESI-
HRMS after 72 h to investigate if the ‘aquated’ ruthenium complexes can be 
detected. As expected, all the spectra show the mean peak for each complex, 
but in the case of 3.23 and 3.32, they both show a peak around 336 m/z that was 
absent in all the other spectra. In conclusion, the mechanism of action does not 
occur through hydrolysis being demonstrated by uv-vis spectroscopic and further 
confirmed by the absence of aqua-species of the ruthenium family. 
NAMI-A and KP-1019 passed phase I clinical trials and both were demonstrated 
that the first step towards their activity was attributed to the displacement of two 
ligands arranged in a cis manner. McGowan et al. reported that trans-dihalide 
arrangement enhances the anticancer activity and, also, the less hydrolysed the 
compounds the lower the IC50. This is challenging to prove as each cancerous 
cell line shows different behaviours and different mechanism of actions. It was 
also probed that the anticancer properties of the trans-dihalide complexes 
increases under hypoxic conditions for colorectal and breast cancer. That is also 
true for this family of compounds, what means the compounds could be possible 
prone to hydrolyse once the Ru(III) is reduced to Ru(II) being the latter more likely 
to react with water. Finally, this behaviour breaks the following rule: complexes 
with trans geometry could lead to an increase in toxicity due to due to kinetic 
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IC50 / µM 
% hydrolysed 
p53 +/+ p53 -/- Kras Mutant Kras WT Kras Parent MIA PaCa-2 ARPE-19 
3.1 10.69 ± 0.42 15.75 ± 1.56 - - - 21.32 ± 3.08 36.37± 4.65 5.06 
3.15 >100 >100 - - - >100 >100 5.08 
3.18 5.79 ± 0.87 5.93 ± 0.89 3.45 ± 0.59 5.43 ± 0.93 3.46 ± 040 15.95 ± 3.01 8.82± 1.35 4.65 
3.23 8.10 ± 1.30 11.74 ± 1.44 9.05 ± 1.18 10.09 ± 0.70 7.78 ± 0.47 18.30 ± 3.38 29.64± 0.26 0 
3.27 14.41 ± 2.44 16.79 ± 2.65 - - - 29.95 ± 1.79 50.19± 9.10 0.25 
3.29 5.01 ± 0.75 8.18 ± 1.06 10.79 ± 0.85 8.54 ± 0.78 7.91 ± 0.13 26.38 ± 0.95 21.08± 1.80 0.73 
3.32 12.87 ± 2.15 11.71 ± 1.32 22.67 ± 3.62 21.47 ± 0.96 20.11 ± 2.29 28.73 ± 0.58 91.09± 8.90 9.50 
3.33 >100 >100 - - - >100 >100 1.51 
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5.3 Hydrophobicity 
Drug resistance is a big milestone that needs to be overcome. It is believed that 
the decrease in cellular uptake of drugs is one of the main factors cause tumours 
to be resistant against chemotherapeutic drugs promoting cancer relapse.13 Cells 
possess a bilipid membrane which is hydrophobic in nature, hence, if compounds 
hydrophobic the easier they can enter the cells by passive diffusion.14 A way to 
make a drug more potent is by increasing its optimising liposolubility. Increasing 
the hydrophobicity of the drug will facilitate the cellular uptake, hence increasing 
their cytotoxicity. Furthermore, hydrophobicity has an optimum range, as a drug 
must be soluble in aqueous media and be able to cross the cell membrane, 
otherwise it decreases its potency. 
The hydrophobicity of the ruthenium compounds was determined by the shake-
flask method of octanol-water partition coefficient to obtain log P values.15 
Deionised water containing 300 mM of NaCl was used to prevent the hydrolysis 
of the complexes during the study. Complexes 3.1, 3.15, 3.18, 3.23, 3.27, 3.29, 
3.32 and 3.33 were dissolved in water-saturated octanol to be shaken with 
octanol-saturated water for 4 hours to ensure equilibrium. The organic layer of 
the samples before and after the experiment were analysed by uv-vis obtaining 
the concentration of the complex. Using pre-calibration curve of the respective 
complex, it was possible to calculate the concentration of the compounds hence 
determining the Log P values by using the following formula, 




The organic phase in a shake-flask method models the hydrophobic layers of the 
cell membrane. A complex is defined as hydrophobic when the concentration in 
the organic phase is higher than in the aqueous phase, what yields a positive Log 
P value. If log P is negative it means the drug concentration in the aqueous phase 
is higher, like cisplatin. The Log P values for the trans- dichloride ruthenium 
complexes selected are as shown in Figure 5-1. The complexes tested are found 
to be hydrophobic with their partition coefficients preferentially in the organic layer 
with values between 0.78 – 1.79. Lipinski’s ‘rule of five’ were developed to 
understand what the requirements are for a molecule to be a successful 
chemotherapeutic drug, stating that poor absorption can be expected when the 
molecular weight is over 500 Da, Log P value is greater than 5, number of H-
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bond donors is more than 5, and number of H-bond acceptors is more than 10.16 
The bisquinaldamide ruthenium complexes are more hydrophobic – as expected 
– than the complexes previously published within the McGowan group, due to the 
extra fused ring in the ligand.8 Generally, transition metal drugs have proved to 
break some of the Lipinski’s rules, as many compounds tend to weight more than 
stated. As hydrophobicity is concerned, complementing Lipinski rule, the 
Hansch’s principle of minimum hydrophobicity states that a Log P should be lower 
than 2.0 to avoid related side effects with the central nervous system (CNS).17 
The two lead ruthenium trans-dichloride compounds 3.23 and 3.32 have log P 
values of 1.50 and 1.79 respectively are the two most hydrophobic in the series. 
The remaining complexes do not follow really a trend but that can be explained 
as not all the complexes were tested for hydrophobicity. The compounds with 
moderate to none anticancer activity fall in the region between 1 and 1.25, and 
the compounds with some activity tend to be less hydrophobic.  
 
Figure 5-2: Log P values of the trans-dichloride bis-quinaldamide ruthenium 
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Some platinum complexes have shown that by increasing their hydrophobicity 
correlates with the increase in their anti-cancer activity, unless for cisplatin.18 
Figure 5-3 shows the correlation between the cytotoxicity values and Log P 
values of the selected trans-dichloride ruthenium complexes against all the cell 
lines. There are some interesting correlations, the complexes that have been 
tested against HCT 116 Kras (mutant, WT and parent) show a quasi-linear 
relationship. The compounds that have high IC50 for the non-cancerous cell line 
follow a nice linear trend, but half of the complexes are outliers from the 
correlation (given by R2) and have showed irregularities of Log P values in the 
order of their cytotoxic activity. 
The observations suggest that these hydrophobic complexes can easily enter the 
cells by passive diffusion. The correlations seen between the partition coefficient 
values and some cancerous cell lines suggest that these compounds have more 
preference to get into colorectal cell lines with the overexpression of oncogenes. 
Although, with only few correlations seen between their cytotoxicity and log P 
values, their cellular uptake mechanism may not influence their anti-cancer 
activity to these specific cell lines tested. Studies have shown the cellular uptake 
of KP-1019 occurs via overexpressed protein transferrin receptor within the 
cancer cell membrane.19 As ruthenium is in the same group as iron, it could be 
these family of ruthenium dichloride complexes may bind to a specific transporter, 
thus relating their anti-cancer activity to active cellular uptake. 
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6.1 General Experimental Procedures 
All ligands and complexes are air stable and all reactions were carried out in air. 
Chemicals were obtained from Sigma-Aldrich Chemical Co., Acros Organics, Alfa 
Aesar, Fisher Chemicals and FluoroChem and were all used as supplied. 
Deuterated NMR solvents were purchased from Sigma-Aldrich Chemical Co. or 
Argos Organics.  
6.2 Characterisation techniques and Instrumentation 
6.2.1 IR spectroscopy 
Infra-red spectra were recorded using a Bruker platinum-ATR FT-IR 
spectrophotometer on a crystal plate. The samples were analysed using the 
software OPUS. 
6.2.2 Mass spectrometry 
High resolution mass spectrometry data were collected on a Bruker Daltonics 
(micrOTOF) instrument using positive and negative ion electrospray as ionization 
technique. Samples of 1g/mL were directly injected and acquired over an m/z 
range of 50 – 1500. The HRMS measurements are accurate within 5ppm. 
6.2.3 NMR spectroscopy 
1H spectra were recorded on a Bruker DPX300 spectrometer, where the operating 
frequency was 300.1MHz for 1H and 75MHz for 13C. 13C{1H} spectra were recorded 
on a Bruker Avance500 spectrometer where the operating frequency was 500.13 
MHz for 1H and 125.80 MHz for 13C. 19F{1H} spectra were recorded on a Bruker 
AscendTM400 spectrometer whose operating frequency was 400.13 for 1H and 
376.46 MHz for 19F. All spectra were recorded at 300 K in deuterated solvents (see 
individual experiment). Chemical shift values () are quoted in parts per million 
(ppm) and the coupling constants (J) are quoted in Hertz (Hz). 
6.2.4 Elemental Analysis 
Microanalyses were acquired by Mr. Stephen Boyer at the London Metropolitan 
University Elemental Analysis Service using a Carlo Erba 1108 Elemental 
Analyser instrument being the value the average of two independent 
measurements. 
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6.2.5 Magnetic Susceptibility 
Magnetic susceptibility measurements were determined by using a Sherwood 
Scientific Susceptibility at room temperature. 
6.2.6 X-Ray Crystallography 
Single crystal X-ray diffraction data for the neutral trans-dichloride complexes 
were collected by Dr. Christopher Pask, the positively charged complex by Dr. 
Matthew Allison, and the novel ligands by the author. An Agilent SuperNova 
diffractometer fitted with an Atlas CCD detector with Mo-K radiation  
(λ = 0.71073 Å) or Cu-Kα radiation (λ = 1.54184 Å) was used. For a general 
procedure, a suitable crystal was selected, immersed in an inert oil and mounted 
under Fomblin on nylon loops. The experiments were run at 120K using an 
Oxford Cryosystems low temperature device1 during both unit cell determination 
and data collection. The full data set was recorded and the images processed 
using CrysAlis Pro2. Structure solution by direct methods was achieved by using 
SHELXT3 program, and the structure model refined by full matrix least squares 
on F2 using ShelXL. Molecular graphics were plotted using Olex2-1.24. Editing of 
CIFs and construction of tables of bond lengths and angles were achieved using 
Olex2-1.2. Unless stated, hydrogen atoms were placed using idealised geometric 
positions (with free rotation for methyl groups) and allowed to move alongside 
with the atom adjacent. The overall structures were refined anisotropically.  
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6.3 Preparation of Arene Functionalised Quinaldamide Ligands 
Some of the ligands synthesised were previously reported and were prepared 
using the same synthetic route, however some alterations were made from the 
published procedure by Bhattacharya et al.5 Ligands 2.8, 2.12-2.14, 2.22 & 2.40 
can be found in the database Scifinder, however, all the analytical data, spectra 
and properties are predicted. 
6.3.1 N-(2,4-dimethoxyphenyl)quinoline-2-carboxamide, (2.3)  
2,4-Dimethoxyaniline (1 eq., 5 mmol, 
0.7659 g) was added to a solution of  
2-quinolinecarboxylic acid (1 eq.,  
5 mmol; 0.8659 g) in pyridine (4 mL) 
and warmed for 15 minutes. While 
warming, triphenylphosphite (1 eq., 5 mmol; 1.31 mL) was added. The reaction 
was heated overnight at 110°C and cooled to room temperature. Addition of water 
(20 mL) yielded a precipitate, which was filtered and washed with distilled water 
and methanol. The product was recrystallised from chloroform.  
Yield: 73%; 1H NMR (CDCl3, 300 MHz, 300 K): δ 10.54 (bs, 1H, NH), 8.46 (d, 
1H, 3J(1H-1H)= 9.3 Hz, H16), 8.33 (d, 1H, 3J(1H-1H)= 8.5 Hz, H8), 8.28 (d, 1H, 
3J(1H-1H)= 8.7 Hz, H7), 8.14 (d, 1H, 3J(1H-1H)= 8.9 Hz, H2), 7.84 (dd, 1H, 
3J(1H-1H)= 8.2 Hz, 0.9 Hz, H5), 7.72 (ddd, 1H, 3J(1H-1H)= 6.9 Hz, 1.5 Hz, H3), 7.57 
(ddd, 1H, 3J(1H-1H)= 6.9 Hz, 1.4 Hz, H4), 6.51 (d, 1H, 4J(1H-1H)= 2.4 Hz, H15), 
6.49 (d, 1H, 4J(1H-1H)= 2.7 Hz, H13), 3.92 (s, OMe18), 3.75 (s, OMe17); 13C{1H} 
NMR: (CDCl3, 126 MHz 300 K): δ 161.8 (C10), 156.7 (C1), 150.4 (C6), 150.3 (C14), 
146.4 (C12), 137.6 (C7), 130.1 (C2), 130.0 (C3), 129.3 (C9), 127.9 (C4), 127.8 (C5), 
121.3 (C11), 120.6 (C16), 118.8 (C8), 103.8 (C15), 98.9 (C13), 56.0 (OMe18), 55.6 
(OMe17); IR (cm-1): 3364 (s) 3100-2785 (m), 1681 (s), 1630-1400 (m), 1300-1000 
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6.3.2 N-(2,5-dimethoxyphenyl)quinoline-2-carboxamide, (2.4) 
2,5-Dimethoxyaniline (1 eq., 5 mmol, 
0.7659 g) was added to a solution of  
2-quinolinecarboxylic acid (1 eq., 5 mmol; 
0.8659 g) in pyridine (4 mL) and warmed for 
15 minutes. While warming, 
triphenylphosphite (1 eq., 5 mmol; 1.31 mL) 
was added. The reaction was heated overnight at 110°C, then cooled to room 
temperature. Addition of water (20 mL) yielded a precipitate, which was filtered 
and washed with distilled water and methanol. The product was recrystallised 
from chloroform. 
Yield: 86%;1H NMR: (CDCl3, 300 MHz, 300 K): δ 10.84 (bs, 1H, NH), 8.40 (d, 1H, 
3J(1H-1H)= 3.1 Hz, H16), 8.37 – 8.34 (m, 2H, H7/8), 8.21 (dt, 1H, 3J(1H-1H)= 8.5 Hz, 
0.5 Hz, H2), 7.90 (dd, 1H, 3J(1H-1H)= 8.2 Hz, 0.9 Hz, H5), 7.80 (ddd, 1H, 
3J(1H-1H)= 8.4 Hz, 6.9 Hz, 1.5 Hz, H3), 7.64 (ddd, 1H 3J(1H-1H)= 8.9 Hz, 6.9 Hz, 
1.2 Hz, H4), 6.89 (d, 1H, 3J(1H-1H)= 8.9 Hz, H14), 6.65 (dd, 1H, 3J(1H-1H)= 8.9 Hz, 
3.0 Hz, H13), 3.98 (s, OMe18), 3.86 (s, OMe17); 13C{1H} NMR (CDCl3, 126 MHz 
300 K): δ 162.3 (C10), 154.0 (C1), 150.0 (C6), 146.4 (C15), 143.2 (C12), 137.7 (C7), 
130.2 (C2), 130.0 (C3), 129.4 (C9), 128.3 (C4), 128.1 (C5), 127.8 (C11), 118.8 (C16), 
111.2 (C8), 109.2 (C14), 105.8 (C13), 56.6 (OMe18), 55.9 (OMe17); IR (cm-1): 3336 
(s) 3005-2831 (m), 1680 (s), 1599 (s), 1561-1476 (m), 1338 (s), 1277-1199 (m), 
1164 (s), 1140 (s), 913-443 (m); H.R.M.S. [ESI+] (m/z) in methanol (Theoretical/ 
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6.3.3 N-(2,4-difluorophenyl)quinoline-2-carboxamide, (2.26) 
2,4-Difluoroaniline (1 eq., 5 mmol,  
0.51 mL) was added to a solution of  
2-quinolinecarboxylic acid (1 eq.,  
5 mmol; 0.8659 g) in pyridine (4 mL) 
and warmed for 15 minutes. While 
warming, triphenylphosphite (1 eq., 5 mmol; 1.31 mL) was added. The reaction 
was heated overnight at 110°C, then cooled to room temperature. Addition of 
water (20 mL) yielded a white precipitate, which was filtered and washed with 
distilled water and methanol. The product was recrystallised from chloroform. 
Yield: 32%; 1H NMR (CDCl3, 300 MHz, 300 K): δ 10.38 (bs, 1H, NH), 8.51 (ddd, 1H, 
3J(1H-1H)= 9.1 Hz, 6.0 Hz, H13), 8.31 (s, 2H, H7/8), 8.14 (d, 1H, 3J(1H-1H)= 8.5 Hz, H2), 
7.85 (ddd, 1H, 3J(1H-1H)= 8.1Hz, 1.4 Hz, 0.6 Hz, H5), 7.75 (ddd, 1H, 3J(1H-1H)= 8.5 
Hz, 6.9Hz, 1.5 Hz, H3), 7.60 (ddd, 1H, 3J(1H-1H)= 8.1 Hz, 6.9Hz, 1.2 Hz, H4),  
6.94 – 6.83 (m, 2H, H14/16); 13C{1H} NMR (CDCl3, 126 MHz, 300 K): δ 162.3 (C10), 
159.7 (C1), 157.8 (C6), 149.0 (C14), 146.4 (C12), 137.9 (C7), 130.4 (C2), 129.9 (C3), 129.5 
(C9), 128.4 (C4), 127.8 (C5), 122.9 (C11), 122.2 (dd, 2J(13C-19F)= 9.1 Hz, 2.3 Hz, C16), 
118.6 (C8),111.3 (dd, 2J(13C-19F)= 21.6 Hz, 3.77 Hz, C15 ), 103.8 (dd, 2J(13C-19F)= 26.6 
Hz, C13); 19F{1H} NMR (CDCl3, 376 MHz, 300 K): δ -115.14 (d, 1F, F2), -125.85 (d, 
1F, F1); IR (cm-1): 3326 (s) 3076-3017 (m), 1682 (s), 1607 (s), 1534 (s), 1504 (s), 
1423 (s), 1284-1086 (m), 962-689 (m), 537 (s); H.R.M.S. [ESI+] (m/z) in methanol 
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6.3.4 N-(2,5-difluorophenyl)quinoline-2-carboxamide, (2.27) 
2,5-Difluoroaniline (1 eq., 5 mmol, 0.50 
mL) was added to a solution of  
2-quinolinecarboxylic acid (1 eq.,  
5 mmol; 0.8659 g) in pyridine (4 mL) 
and warmed for 15 minutes. While 
warming, triphenylphosphite (1 eq., 5 mmol; 1.31 mL) was added. The reaction 
was heated overnight at 110°C, then cooled to room temperature. Addition of 
water (20 mL) yielded a precipitate, which was filtered and washed with distilled 
water and methanol. The product was recrystallised from chloroform. 
Yield: 69%; 1H NMR (CDCl3, 300 MHz, 300 K): δ 10.61 (bs, 1H, NH), 8.52-8.42 
(m, 1H, H13), 8.42 - 8.34 (m, 2H, H7/8), 8.21 (d, 1H, 3J(1H-1H)= 8.1 Hz, H2), 7.92 
(dd, 1H, 3J(1H-1H)= 8.2 Hz, 0.8 Hz, H5), 7.82 (ddd, 1H, 3J(1H-1H)= 8.5 Hz, 6.9 Hz, 
1.4 Hz, H3), 7.72 - 7.63 (m, 1H, H4), 7.13 (ddd, 3J(1H-1H)= 10.3 Hz, 9.1 Hz, 4.9 
Hz 1H, H14),6.83 - 6.73 (m, 1H,H16); 13C{1H} NMR (CDCl3, 126 MHz, 300 K): δ 
162.4 (C10), 159.7 (C1), 157.8 (C6), 149.0 (C15), 146.4 (C12), 138.0 (C7), 130.5 
(C2), 130.0 (C3), 129.6 (C9), 128.5 (C4), 127.8 (C5), 127.4 (C11), 118.6 (C8),115.3 
(dd, 2J(13C-19F)= 21.7 Hz, 9.76 Hz, C14 ), 110.2 (dd, 2J(13C-19F)= 24.7 Hz, 7.8 Hz, 
C13), 108.4 (d, 2J(13C-19F)= 30.1 Hz, C16); 19F{1H} NMR (CDCl3, 376 MHz, 300 
K): δ -116.07 (d, 1F, F2), -136.49 (d, 1F, F1); IR (cm-1): 3338 (s), 3103-3057 (m), 
1697 (s), 1632 (s), 1530 (s), 1503-1442 (m), 1246 (s), 1159 (s), 1124 (s), 969-
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6.3.5 N-(2,4-dichlorophenyl)quinoline-2-carboxamide, (2.31) 
2,4-Dichloroaniline (1 eq., 5 mmol, 
0.8101 g) was added to a solution of  
2-quinolinecarboxylic acid (1 eq.,  
5 mmol; 0.8659 g) in pyridine (4 mL) 
and warmed for 15 minutes. While 
warming, triphenylphosphite (1 eq., 5 mmol; 1.31 mL) was added. The reaction 
was heated overnight at 110°C, then cooled to room temperature. Addition of 
water (20 mL) yielded a precipitate, which was filtered and washed with distilled 
water and methanol. The product was recrystallised from chloroform. 
Yield: 67%; 1H NMR (CDCl3, 300 MHz, 300 K) δ 10.87 (bs, 1H, NH), 8.59 (d, 1H, 
3J(1H-1H)= 8.9 Hz, H16), 8.34 - 8.23 (m, 2H, H7/8), 8.11 (d, 1H, 3J(1H-1H)= 8.4 Hz, 
H2), 7.83 (d, 1H, 3J(1H-1H)= 8.1 Hz, H5), 7.78 – 7.68 (m, 1H, H3), 7.59 (dd, 1H, 
3J(1H-1H)= 11.0 Hz, 4.0 Hz, H4), 7.38 (d, 1H, 3J(1H-1H)= 2.3 Hz, H15), 7.23 (dt, 1H, 
3J(1H-1H)= 10.2 Hz, 5.1 Hz, H13); 13C{1H} NMR (CDCl3, 126 MHz, 300 K): δ 162.3 
(C10), 153.7 (C1), 149.1 (C6), 146.3 (C14), 138.0 (C12), 133.6 (C7), 130.4 (C2), 
130.0 (C3), 129.6 (C9), 129.0 (C4), 128.4 (C5), 127.9 (C11), 127.7 (C13), 124.0 
(C13), 121.6 (C15), 118.6 (C16); IR (cm-1) 3293 (s), 3098-3038 (m), 1695 (s), 1591-
1099 (m), 953-830 (m), 766 (s), 730-552 (m); H.R.M.S. [ESI+] (m/z) in methanol 
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6.3.6 N-(2,5-dichlorophenyl)quinoline-2-carboxamide, (2.32) 
2,5-Dichloroaniline (1 eq., 5 mmol,  
0.53 mL) was added to a solution of  
2-quinolinecarboxylic acid (1 eq.,  
5 mmol; 0.8659 g) in pyridine (4 mL) 
and warmed for 15 minutes. While 
warming, triphenylphosphite (1 eq., 5 mmol; 1.31 mL) was added. The reaction 
was heated overnight at 110°C and cooled to room temperature. Addition of water 
(20 mL) yielded a precipitate, which was filtered and washed with distilled water 
and methanol. The product was recrystallised from chloroform. 
Yield: 55%; EA (Theoretical/Found)(%): C (60.59/60.60), H (3.18/3.20) & N 
(8.83/8.50); 1H NMR (CDCl3, 300 MHz, 300 K): δ 11.01 (bs, 1H, NH), 8.81 (d, 
1H, 3J(1H-1H)= 2.5 Hz, H13), 8.45 - 8.36 (m, 2H, H7/8), 8.21 (d, 1H, 3J(1H-1H)= 8.5 
Hz, H2), 7.93 (dd, 1H, 3J(1H-1H)= 8.2 Hz, 0.8 Hz, H5), 7.82 (ddd, 1H, 3J(1H-1H)= 
8.5 Hz, 6.9 Hz, 1.5 Hz, H3), 7.68 (ddd, 1H, 3J(1H-1H)= 8.1 Hz, 6.9 Hz, 1.2 Hz, H4), 
7.38 (d, 1H, 3J(1H-1H)= 8.6 Hz, H14), 7.08 (dd, 1H, 3J(1H-1H)= 8.6Hz, 2.5 Hz, H16); 
13C{1H} NMR (CDCl3, 126 MHz, 300 K): δ 162.4 (C10), 149.1 (C1), 146.3 (C6), 
138.0 (C14), 135.7 (C12), 133.6 (C7), 130.5 (C2), 130.1 (C3), 129.9 (C9), 129.6 (C4), 
128.5 (C5), 127.8 (C11), 124.5 (C13), 121.6 (C13), 120.8 (C15), 118.7 (C16);  
IR (cm-1) 3304-3288 (d), 3098-3039 (m), 1694 (s), 1589-1204 (m), 1122-1050 
(m), 913-841 (m), 766 (s), 730-525 (m); H.R.M.S. [ESI+] (m/z) in methanol 
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6.3.7 N-(2,4-dibromophenyl)quinoline-2-carboxamide, (2.36) 
2,4-Dibromoaniline (1 eq., 5 mmol, 
1.2546 g) was added to a solution of  
2-quinolinecarboxylic acid (1 eq.,  
5 mmol, 0.8659 g) in pyridine (4 mL) 
and warmed for 15 minutes. While 
warming, triphenylphosphite (1 eq., 5 mmol, 1.31 mL) was added. The reaction 
was heated overnight at 110°C, then cooled to room temperature. Addition of 
water (20 mL) yielded a precipitate, which was filtered and washed with distilled 
water and methanol. The product was recrystallised from chloroform. 
Yield: 54%; 1H NMR: (CDCl3, 300 MHz, 300 K) δ 11.00 (bs, 1H, NH), 8.62 (d, 
1H, 3J(1H-1H)= 8.9 Hz, H13), 8.38 (d, 2H, 3J(1H-1H)= 1.9 Hz, H7/8), 8.21 (d, 1H, 
3J(1H-1H)= 8.5 Hz, H2), 7.93 (d, 1H, 3J(1H-1H) = 8.2 Hz, H5), 7.86 – 7.79 (m, 1H, 
H3), 7.78 (d, 1H, 3J(1H-1H)= 2.2 Hz, H16), 7.68 (dd, 1H, 3J(1H-1H)= 11.1 Hz, 4.0 
Hz, H4), 7.52 (dd, 1H, 3J(1H-1H)= 8.8 Hz, 2.2 Hz, H15); 13C{1H} NMR (CDCl3, 126 
MHz, 300 K): δ 163.0 (C10), 149.5 (C1), 146.3 (C6), 138.0 (C14), 135.3 (C12), 134.7 
(C7), 131.5 (C2), 130.5 (C3), 130.1 (C9), 128.5 (C4), 127.8 (C5), 122.1 (C11), 118.6 
(C13), 118.1 (C8), 116.6 (C15), 111.1 (C16); IR (cm-1) 3288 (s), 3101-2961 (m), 
1690 (s), 1585-1205 (m), 1124-1079 (m), 914-545 (m);H.R.M.S. [ESI+] (m/z) in 
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6.3.8 N-(2,5-dibromophenyl)quinoline-2-carboxamide, (2.37) 
2,5-Dibromoaniline (1 eq., 5 mmol, 1.2546 
g) was added to a solution of  
2-quinolinecarboxylic acid (1 eq., 5 mmol, 
0.8659 g) in pyridine (4 mL) and warmed 
for 15 minutes. While warming, 
triphenylphosphite (1 eq., 5 mmol, 1.31 
mL) was added. The reaction was heated overnight at 110ºC, then cooled down 
to room temperature; addition of water (20 mL) yielded to a precipitate, which was 
filtered and washed with distilled water and methanol. The product was 
recrystallised from chloroform. 
Yield: 42%; 1H NMR (CDCl3, 300 MHz, 300 K): δ 11.01 (bs, 1H, NH), 8.93 (d, 
1H, 3J(1H-1H)= 2.3 Hz, H13), 8.44 – 8.32 (m, 2H, H7/8), 8.21 (dd, 1H, 3J(1H-1H)= 
8.0 Hz, 0.5 Hz, H2), 7.93 (dd, 1H, 3J(1H-1H)= 8.2 Hz, 0.9Hz, H5), 7.85 – 7.78 (m, 
1H, H3), 7.68 (ddd, 1H, 3J(1H-1H)= 8.1 Hz, 6.9 Hz, 1.2 Hz, H4), 7.48 (d, 1H, 
3J(1H-1H)= 8.5 Hz, H14), 7.16 (d, 1H, 3J(1H-1H)= 8.5 Hz, 2.4 Hz, H16); 13C{1H} NMR 
(CDCl3, 126 MHz, 300 K): δ 162.4 (C10), 149.1 (C1), 146.4 (C6), 138.0 (C15),  
137.1 (C12), 133.4 (C7), 130.5 (C2), 130.1 (C3), 129.6 (C9), 128.5 (C4), 128.0 (C5), 
127.8 (C11), 123.9 (C13), 122.1 (C8), 118.62 (C14), 112.3 (C16); IR (cm-1) 3299 (s), 
3105-3056 (m), 1699 (s), 1578-1425 (m), 1401-1205 (m), 1124-850 (m), 767 (s), 
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6.3.9 N-(2-iodophenyl)quinoline-2-carboxamide, (2.38) 
2-Iodoaniline (1 eq., 5 mmol, 1.0951 g) was 
added to a solution of 2-quinolinecarboxylic 
acid (1 eq., 5 mmol; 0.8659 g) in pyridine  
(4 mL) and warmed for 15 minutes. While 
warming, triphenylphosphite (1 eq.,  
5 mmol; 1.31 mL) was added. The reaction was heated overnight at 110°C, then 
cooled to room temperature. Addition of water (20 mL) yielded a precipitate, 
which was filtered and washed with distilled water and methanol. The product 
was recrystallised from chloroform. 
Yield: 60%; 1H NMR (CDCl3, 300 MHz, 300 K): δ 10.78 (bs, 1H, NH), 8.52  
(dd, 1H, 3J(1H-1H)= 8.3 Hz, 1.5 Hz, H13), 8.30 (s, 2H, H7/8), 8.16 (d, 1H, 3J(1H-1H)= 
8.4 Hz, H2), 7.84 (dd, 1H, 3J(1H-1H)= 8.2 Hz, 0.8 Hz, H5),7.80 (dd, 1H, 3J(1H-1H)= 
7.9 Hz, 1.4Hz, H16) 7.73 (ddd, 1H, 3J(1H-1H)= 8.4 Hz, 6.9 Hz, 1.4 Hz, H14), 7.58 
(ddd, 1H, 3J(1H-1H)= 11.0 Hz, 6.1 Hz, 2.6 Hz, H3), 7.40 – 7.28 (m, 1H, H4), 6.89 – 
6.70 (m, 1H, H15); 13C{1H} NMR (CDCl3, 126 MHz, 300 K): δ 162.5 (C10), 149.4 (C1), 
146.3 (C6), 139.2 (C12), 137.9 (C7), 130.3 (C2), 130.1 (C3), 129.6 (C9), 129.5 (C4), 
129.3 (C5), 128.3 (C11), 127.7 (C13), 125.8 (C8), 121.1 (C14), 118.62 (C15), 89.7 
(C16); IR (cm-1) 3299 (s), 3057 (s), 1679 (s), 1574-1424 (m), 1298-835 (m), 766-
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6.3.10 N-(3-iodophenyl)quinoline-2-carboxamide, (2.39) 
3-Iodoaniline (1 eq., 5 mmol, 0.60 mL) was 
added to a solution of  
2-quinolinecarboxylic acid (1 eq., 5 mmol; 
0.8659 g) in pyridine (4 mL) and warmed 
for 15 minutes. While warming, 
triphenylphosphite (1 eq., 5 mmol;  
1.31 mL) was added. The reaction was heated overnight at 110°C, then cooled 
to room temperature. Addition of water (20 mL) yielded a precipitate, which was 
filtered and washed with distilled water and methanol. The product was 
recrystallised from chloroform. 
Yield: 81%; 1H NMR (CDCl3, 300 MHz, 300 K): δ 10.85 (bs, 1H, NH), 8.63 (d, 
1H, 3J(1H-1H)= 8.2 Hz, H12), 8.45 (s, 2H, H7/8), 8.25 (d, 1H, 3J(1H-1H)= 7.9 Hz, H2), 
8.12 (dd, 1H, 3J(1H-1H)= 8.3 Hz, 1.0 Hz, H5), 7.99 (ddd, 1H, 3J(1H-1H)= 8.2 Hz, 
2.0 Hz, 0.9 Hz, H4), 7.93 (ddd, 1H, 3J(1H-1H)= 8.5 Hz, 6.9 Hz, 1.5 Hz, H3), 7.76 
(ddd, 1H, 3J(1H-1H)= 8.1 Hz, 6.9 Hz, 1.2 Hz, H14), 7.51 (ddd, 1H, 3J(1H-1H)=  
7.8 Hz, 1.6 Hz, 0.9 Hz, H16), 7.21 (dd, 1H, 3J(1H-1H)= 8.0 Hz, H15); 13C{1H} NMR 
(CDCl3, 126 MHz, 300 K): δ 168.2 (C10), 154.9 (C1), 151.1 (C6), 145.0 (C13), 143.5 
(C12), 137.7 (C7), 136.0 (C2), 135.9 (C3), 134.5 (C9), 134.2 (C4), 133.7 (C5), 133.42 
(C11), 124.8 (C12), 124.0 (C8), 103.84 (C14), 99.71 (C15); IR (cm-1) 3331 (s), 3150-
3063 (m), 1673 (s), 1581-1380 (m), 1290-816 (m), 773-679 (m), 658-581 (m); 
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6.3.11 N-(2-methoxy-4-nitrophenyl)quinoline-2-carboxamide, (2.41) 
2-Methoxy-4-nitroaniline (1 eq.,  
5 mmol, 0.8408 g) was added to a 
solution of 2-quinolinecarboxylic acid 
(1 eq., 5 mmol; 0.8659 g) in pyridine  
(4 mL) and warmed for 15 minutes. 
While warming, triphenylphosphite (1 eq., 5 mmol; 1.31 mL) was added. The 
reaction was heated overnight at 110°C, then cooled to room temperature. 
Addition of water (20 mL) yielded a precipitate, which was filtered and washed 
with distilled water and methanol. The product was recrystallised from chloroform. 
(Yield: 25%; 1H NMR (CDCl3, 300 MHz, 300 K): δ 11.09 (bs, 1H, NH), 8.84 (d, 
1H, 3J(1H-1H)= 9.0 Hz, H16), 8.39 (s, 2H, H7/8), 8.22 (d, 1H, 3J(1H-1H)= 8.5 Hz, 
H15), 8.00 (d, 1H, 3J(1H-1H) = 9.0 Hz, 2.4 Hz, H2), 7.93 (dd, 1H, 3J(1H-1H)= 8.2 
Hz, 0.9 Hz, H5), 7.87 – 7.80 (m, 1H, H3), 7.68 (ddd, 1H, 3J(1H-1H)= 8.1 Hz, 6.9 
Hz, 1.2 Hz, H4), 4.14 (s, OMe17); 13C{1H} NMR (CDCl3, 126 MHz, 300 K): δ 162.8 
(C10), 149.2 (C1), 148.5 (C6), 146.4 (C14), 143.3 (C12), 138.0 (C7), 133.8 (C2), 
130.5 (C3), 130.0 (C9), 129.6 (C4), 128.5 (C5), 127.9 (C11), 118.7 (C16), 118.3 (C8), 
117.8 (C15), 106.4 (C13), 56.6 (OMe17); IR (cm-1) 3320 (s), 3090-2926 (m), 1641 
(s), 1613-1514 (m), 1128-1032 (m), 895-585 (m); H.R.M.S. [ESI+] (m/z) in 
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6.3.12 N-(2-methoxy-5-nitrophenyl)quinoline-2-carboxamide, (2.42) 
2-Methoxy-5-nitroaniline (1 eq., 5 mmol, 
0.8408 g) was added to a solution of  
2-quinolinecarboxylic acid (1 eq., 5 mmol, 
0.8659 g) in pyridine (4 mL) and warmed 
for 15 minutes. While warming, 
triphenylphosphite (1 eq., 5 mmol; 1.31 
mL) was added. The reaction was heated overnight at 110°C and cooled to room 
temperature. Addition of water (20 mL) yielded a precipitate, which was filtered 
and washed with distilled water and methanol. The product was recrystallised 
from chloroform. 
Yield: 58%; 1H NMR (CD3CN, 300 MHz, 300 K): δ 10.73 (bs, 1H, NH), 9.32 (d, 1H, 
3J(1H-1H)= 2.8 Hz, H13), 8.39 (d, 1H, 3J(1H-1H)= 7.9 Hz, H2), 8.19 (d, 1H, 
3J(1H-1H)= 8.5 Hz, H8), 8.08 (d, 1H, 3J(1H-1H)= 8.5 Hz, H7), 7.94 - 7.88 (m, 1H, 
H14), 7.74 (t, 1H, 3J(1H-1H)= 7.8 Hz, H3), 7.58 (t, 1H, 3J(1H-1H)= 7.0, H4), 7.07 (d, 
1H, 3J(1H-1H)= 9.2 Hz, H5), 4.00 (s, OMe17); 13C{1H} NMR (CDCl3, 100.6 MHz, 
300 K): δ 162.5 (C10), 153.4 (C1), 149.4 (C6), 146.4 (C15), 141.2 (C12), 138.0 (C7), 
130.4 (C2), 129.9 (C3), 129.6 (C9), 128.4 (C4), 128.0 (C5), 127.9 (C11), 120.1 (C16), 
118.8 (C8), 115.0 (C14), 109.3 (C13), 56.7 (OMe17); IR (cm-1) 3316 (s), 3100-2946 
(m), 1681 (s), 1615-1424 (m), 1328-1022 (m), 897-565 (m); H.R.M.S. [ESI+] (m/z) 
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6.3.13 N-(4-methoxy-2-nitrophenyl)quinoline-2-carboxamide, (2.43) 
4-Methoxy-2-nitroaniline (1 eq.,  
5 mmol, 0.8408 g) was added to a 
solution of 2-quinolinecarboxylic acid 
(1 eq., 5 mmol, 0.8659 g) in pyridine 
(4 mL) and warmed for 15 minutes. 
While warming, triphenylphosphite (1 eq., 5 mmol; 1.31 mL) was added. The 
reaction was heated overnight at 110°C, then cooled to room temperature. 
Addition of water (20 mL) yielded a precipitate, which was filtered and washed 
with distilled water and methanol. The product was recrystallised from chloroform. 
Yield: 36%; 1H NMR (CDCl3, 300 MHz, 300 K): δ 10.19 (bs, 1H, NH), 8.36 (s, 
2H, H7/8), 8.25 (dd, 1H, 3J(1H-1H)= 1.8 Hz, H13), 8.17 (d, 1H, 3J(1H-1H)= 8.5 Hz, 
H16), 7.94 - 7.84 (m, 1H, H2), 7.87 - 7.78 (m, 1H, H5), 7.65 (ddd, 1H, 3J(1H-1H)= 
8.1 Hz, 6.9 Hz, 1.2 Hz, H4), 7.49 (ddd, 1H, 3J(1H-1H)= 7.9 Hz, 1.5 Hz, 1.0Hz, H3), 
7.13 (dd, 1H, 3J(1H-1H)= 8.0 Hz, H15), 3.75 (s, OMe17); 13C{1H} NMR (CDCl3, 76 
MHz, 300 K): δ 162.2 (C10), 155.4 (C12), 149.2 (C1), 146.3 (C14), 143.3 (C6), 139.0 
(C7), 133.3 (C2), 130.6 (C3), 134.0 (C9), 130.0 (C4), 129.5 (C5), 128.4 (C11), 128.3 
(C16),127.85 (C13), 118.9 (C8), 118.7 (C15), 94.3 (OMe17); IR (cm-1) 3277 (s), 
3107-3058 (m), 1679 (s), 1563-1345 (m), 1263-1014 (m), 920-547 (m); H.R.M.S. 
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6.4 Preparation of trans-dichloride bis-quinaldamide ruthenium 
(III) neutral complexes 
As explained in Chapter 3, following the protocol established within the 
McGowan group6 the final product was a mixture of different complexes. Hence, 
the focus is given to the synthesis that yielded to the neutral complexes, 
otherwise it will be stated in the protocol. 
6.4.1 Synthesis and Characterisation of trans-dichloride  
bis-quinaldamide ruthenium (III) complexes 
The procedure was as follows: a functionalised 
quinaldamide ligand (R) (2 eq., 0.765 mmol) was 
dissolved in 20 mL of ethanol. The solution was heated 
up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a 
solution of RuCl3·3H2O (1 eq., 0.382 mmol, 0.1 g) in  
5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A reddish solid 
(general structure shown on the left) was isolated which recrystallised from DMF 
or DMSO, and the mother liqueurs were left to crystallise. 
6.4.2 Bis-(N-phenylquinaldamide) ruthenium dichloride, 
C32H23O2N4RuCl2, (3.1) 
Ligand 2.1 (2 eq., 0.765 mmol, 0.1886 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 60°C until the ligand was completely dissolved. After 
30 min, it was added to a solution of RuCl3·3H2O (1 eq., 0.382 mmol, 0.1 g) in 5 
mL of ethanol and left to reflux overnight. The reaction was cooled down to 65°C 
and filtered immediately. A red solid was isolated, recrystallised from DMF, and 
the mother liqueurs were left to crystallise. 
Yield: 0.1507 g, 0.23 mmol, 59 %; eff = 1.85.; EA (Theoretical/Found)(%): 
C (56.66/56.54), H (3.89/3.68) & N (8.01/7.88) [3.1+0.5H2O+0.5EtOH]; IR (cm-1) 
3277 (s), 3107-3058 (m), 1679 (s), 1563-1345 (m), 1263-1014 (m), 920-547 (m); 
H.R.M.S. [ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 
668.0302/668.0306. 
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6.4.3 Bis-(N-2-Methoxyphenylquinaldamide) ruthenium dichloride, 
C34H27O4N4RuCl2, (3.2) 
Ligand 2.2 (2 eq., 0.765 mmol, 0.2129 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 80°C until the ligand was completely dissolved. After 
30 min, the functionalised ligand was added to a solution of RuCl3·3H2O (1 eq., 
0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The reaction 
was cooled down to 65°C and filtered immediately. A violet powder was isolated, 
recrystallised from DMF and the mother liqueurs were left to crystallise. (Not 
tested for anticancer properties) 
Yield: 0.0626 g, 0.09 mmol, 24 %; eff = 1.76; EA (Theoretical/Found)(%): 
C (52.24/52.20), H (4.75/3.88) & N (6.77/6.93) [3.2+3H2O+EtOH]; IR (cm-1), 
3207-2858 (m), 1635 (s), 1563-1345 (m), 764 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 728.0526/728.0522. 
6.4.4 Bis-(N-2,4-diMethoxyphenylquinaldamide) ruthenium 
dichloride, C36H31O6N4RuCl2, (3.3)  
Ligand 2.3 (2 eq., 0.765 mmol, 0.2358 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 80°C until the ligand was completely dissolved and 
then N(Et)3 was added (1 eq., 0.382 mmol, 0.053 mL). After 30 min, the 
functionalised ligand was added to a solution of RuCl3·3H2O (1 eq., 0.382 mmol, 
0.1 g) in 5 mL of ethanol and left to reflux overnight. The reaction was filtered 
immediately isolating a black powder. The mother liqueurs were left to crystallise. 
(Characterisation on going) 
Yield: 0.0245 g, 0.031 mmol, 8 %; H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 788.0737/not found. 
6.4.5 Bis-(N-2,5-diMethoxyphenylquinaldamide) ruthenium 
dichloride, C36H31O6N4RuCl2, (3.4)  
Ligand 2.4 (2 eq., 0.765 mmol, 0.2358 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 80°C until the ligand was completely dissolved and 
then N(Et)3 was added (1 eq., 0.382 mmol, 0.053 mL). After 30 min, the 
functionalised ligand was added to a solution of RuCl3·3H2O (1 eq., 0.382 mmol, 
0.1 g) in 5 mL of ethanol, and left to reflux overnight. The reaction was filtered 
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immediately, and a black powder was isolated which recrystallised from DMF, 
and the mother liqueurs were left to crystallise. (Characterisation ongoing) 
Yield: 0.0374 g, 0.047 mmol, 12 %; IR (cm-1) -; H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 788.0737/787.0737. 
6.4.6 Bis-(N-2-Methylphenylquinaldamide) ruthenium dichloride, 
C34H27O2N4RuCl2, (3.5) 
Ligand 2.5 (2 eq., 0.765 mmol, 0.2006 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 70°C until the ligand was completely dissolved. After 
30 min, the functionalised ligand was added to a solution of RuCl3·3H2O (1 eq., 
0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The reaction 
was cooled down to 65°C and filtered immediately. A reddish solid was isolated 
which recrystallised from DMF or DMSO, and the mother liqueurs were left to 
crystallise. 
Yield: 0.1235 g, 0.18 mmol, 47 %; eff = 1.74; EA (Theoretical/Found)(%):  
C (55.82/55.80), H (4.27/3.57) & N (7.66/7.72) [3.5+2H2O]; IR (cm-1) 3277 (s), 
3107-3058 (m), 1679 (s), 1563-1345 (m), 1263-1014 (m), 920-547 (m); H.R.M.S. 
[ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 696.0627/696.0630. 
6.4.7 Bis-(N-3-Methylphenylquinaldamide) ruthenium dichloride, 
C34H27O2N4RuCl2, (3.6) 
Ligand 2.6 (2 eq., 0.765 mmol, 0.2006 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 80°C until the ligand was completely dissolved. After 
30 min, the functionalised ligand was added to a solution of RuCl3·3H2O (1 eq., 
0.382 mmol; 0.1 g) in 5 mL of ethanol and left to reflux overnight. The reaction 
was cooled down to 65°C and filtered immediately. A reddish solid was isolated 
which recrystallised from DMF and the mother liqueurs were left to crystallise. 
Yield: 0.0856 g, 0.12 mmol, 32 %; eff = 1.78; EA (Theoretical/Found)(%): 
C (57.23/57.34), H (4.10/3.79) & N (7.85/7.91) [3.6+1H2O]; IR (cm-1) 3059-2873 
(m), 1629-1509 (m), 1370-1335 (m), 764 (s); H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 696.0627/696.0631. 
 
 
Chapter 6 Experimental 
- 194 - 
 
6.4.8 Bis-(N-4-Methylphenylquinaldamide) ruthenium dichloride, 
C34H27O2N4RuCl2, (3.7) 
Ligand 2.7 (2 eq., 0.765 mmol, 0.2006 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 80°C until the ligand was completely dissolved. After 
30 min, the functionalised ligand was added to a solution of RuCl3·3H2O (1 eq., 
0.382 mmol; 0.1 g) in 5 mL of ethanol and left to reflux overnight. The reaction 
was cooled down to 65°C and filtered immediately. A reddish solid was isolated 
and the mother liqueurs were left to crystallise. 
Yield: 0.1046 g, 0.15 mmol, 39 %; eff = 1.77; EA (Theoretical/Found)(%): 
C (55.82/55.87), H (4.27/3.74) & N (7.66/7.67) [3.7+2H2O]; IR (cm-1) 3139-2852 
(b), 1616 (s), 1571-1510 (m), 1409-1372 (m), 764 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 696.0627/696.0612. 
6.4.9 Bis-(N-2,4,6-triMethylphenylquinaldamide) ruthenium 
dichloride, C38H35O2N4RuCl2, (3.8) 
Ligand 2.8 (2 eq., 0.765 mmol, 0.2218 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 80°C until the ligand was completely dissolved. After 
30 min, the functionalised ligand was added to a solution of RuCl3·3H2O (1 eq., 
0.382 mmol; 0.1 g) in 5 mL of ethanol and left to reflux overnight. The reaction 
was cooled down to 65°C and filtered immediately. A reddish solid was isolated 
which recrystallised from DMSO, and the mother liqueurs were left to crystallise. 
(E.A. impure, more characterisation on going) 
Yield: 0.0788 g, 0.105 mmol, 27 %; eff = 1.78; H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 752.1253/752.1256. 
6.4.10 Bis-(N-2-Ethylphenylquinaldamide) ruthenium dichloride, 
C36H31O2N4RuCl2, (3.9) 
Ligand 2.9 (2 eq., 0.765 mmol, 0.2114 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 60°C until the ligand was completely dissolved. After 
30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A red powder was 
isolated which recrystallised from DMF and the mother liqueurs were left to 
crystallise. 
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Yield: 0.2011 g, 0.28 mmol, 73 %; eff = 1.69; EA (Theoretical/Found)(%): 
 C (56.92/56.78), H (4.64/4.22) & N (7.38/7.45) [3.9+2H2O]; IR (cm-1) 3132-2875 
(m), 1611-1507 (m), 760 (s); H.R.M.S. [ESI+] (m/z) in methanol (Theoretical/ 
Found) [M+H]+ 726.0916/726.0947. 
6.4.11 Bis-(N-3-Ethylphenylquinaldamide) ruthenium dichloride, 
C36H31O2N4RuCl2, (3.10) 
Ligand 2.10 (2 eq., 0.765 mmol, 0.2114 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 60°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. After the 
reaction was cooled down to 65°C, it was filtered immediately. A reddish solid 
was isolated which recrystallised from DMF and the mother liqueurs were left to 
crystallise. 
Yield: 0.0973 g, 0.13 mmol, 35 %; eff = 1.70; EA (Theoretical/Found)(%):  
C (59.75/59.53), H (4.32/4.24) & N (7.74/7.65) [3.10]; IR (cm-1) 3277 (s), 3107-
3020 (m), 2957-2869 (m), 1627-1513 (m), 760 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 726.0916/726.0936. 
6.4.12 Bis-(N-4-Ethylphenylquinaldamide) ruthenium dichloride, 
C36H31O2N4RuCl2, (3.11) 
Ligand 2.11 (2 eq., 0.765 mmol, 0.2114 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 70°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 75°C and filtered immediately. A red solid was 
isolated which recrystallised from DMF and the mother liqueurs were left to 
crystallise. 
Yield: 0.150 g, 0.21 mmol, 55 %. eff = 1.80;. EA (Theoretical/Found)(%):  
C (59.75/59.62), H (4.32/4.24) & N (7.74/7.66) [3.11]; IR (cm-1) 3052 (s), 2961-
2836 (m), 1601 (s), 1574-1511 (m), 1370-1337 (m), 764 (s); H.R.M.S. [ESI+] 
(m/z) in methanol (Theoretical/ Found) [M+H]+ 724.0940/724.0922. 
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6.4.13 Bis-(N-2-iPropylphenylquinaldamide) ruthenium dichloride, 
C38H35O2N4RuCl2, (3.12) 
Ligand 2.12 (2 eq., 0.765 mmol, 0.2221 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 50°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol; 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A red powder was 
isolated which recrystallised from DMF and the mother liqueurs were left to 
crystallise. 
Yield: 0.2078 g, 0.28 mmol, 73 %; eff = 1.68; EA (Theoretical/Found)(%): 
C (55.41/55.45), H (5.26/4.52) & N (6.80/6.60) [3.12+4H2O]; IR (cm-1) 3420 (s), 
3159-2867 (m), 1611-1545 (m), 754 (s); H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 752.1073/752.1249. 
6.4.14 Bis-(N-3-iPropylphenylquinaldamide) ruthenium dichloride, 
C38H35O2N4RuCl2, (3.13) 
Ligand 2.13 (2 eq., 0.765 mmol, 0.2221 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 50°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A dark green solid 
was isolated which recrystallised from DMF and the mother liqueurs were left to 
crystallise. 
Yield: 0.0206 g, 0.03 mmol, 7 %; eff = 1.69; EA (Theoretical/Found)(%):  
C (54.11/55.45), H (5.79/4.18) & N (6.31/6.07) [3.13+5H2O+EtOH]; IR (cm-1) 
3239-3189 (m), 3136-3016 (m), 2955-2865 (m), 1607-1558 (m), 1490 (s), 762 
(s); H.R.M.S. [ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 
752.1073/752.1250. 
6.4.15 Bis(N-4-iPropylphenylquinaldamide) ruthenium dichloride, 
C38H35O2N4RuCl2, (3.14) 
Ligand 2.14 (2 eq., 0.765 mmol, 0.2221 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
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(1 eq., 0.382 mmol; 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A reddish solid was 
isolated which recrystallised from DMF or DMSO, and the mother liqueurs were 
left to crystallise. (Analytically impure) 
Yield: 0.1331 g, 0.177 mmol, 46 %; H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 752.1073/324.0981. 
6.4.16 Bis-(N-2,6-diiPropylphenylquinaldamide) ruthenium dichloride, 
C44H47O2N4RuCl2, (3.15) 
Ligand 2.15 (2 eq., 0.765 mmol, 0.2543 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 60°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol; 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A reddish solid was 
isolated which recrystallised from DMF and the mother liqueurs were left to 
crystallise. 
Yield: 0.0739 g, 0.09 mmol, 23 %;. eff = 1.65;. EA (Theoretical/Found)(%): 
C (59.99/60.19), H (5.95/5.31) & N (6.36/6.58) [3.15+2.5H2O]; IR (cm-1), 3143-
2478 (b), 3139 (s), 3012 (s), 2957 (s), 2929 (s), 2868 (s), 1601 (s), 748 (s); 
H.R.M.S. [ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 
836.2012/836.2204. 
6.4.17 Bis-(N-2-Methyl-6-iPropylphenylquinaldamide) ruthenium 
dichloride, C40H39O2N4RuCl2, (3.16) 
Ligand 2.16 (2 eq., 0.765 mmol, 0.2329 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was filtered immediately. A reddish solid was isolated which 
recrystallised from DMF and the mother liqueurs were left to crystallise. 
Yield: 0.2172 g, 0.28 mmol, 73 %; eff = 1.70; EA (Theoretical/Found)(%):  
C (52.01/51.82), H (6.34/4.75) & N (5.78/5.76) [3.16+8H2O+EtOH]; IR (cm-1) 
3496 (s), 3226-3142 (m), 2962 (s), 2928 (s), 1582-1537 (m), 767 (s); H.R.M.S. 
[ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 780.1566/780.1569. 
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6.4.18 Bis-(N-2-tButylphenylquinaldamide) ruthenium dichloride, 
C40H39O2N4RuCl2, (3.17) 
Ligand 2.17 (2 eq., 0.765 mmol, 0.231 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 80°C until the ligand was completely dissolved. After 
30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol; 0.1 g) in 5 mL of ethanol, and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A reddish solid was 
isolated which recrystallised from DMF, and the mother liqueurs were left to 
crystallise. 
Yield: 0.0293 g, 0.04 mmol, 10 %. eff = 1.85;. EA (Theoretical/Found)(%): 
 C (58.59/58.71), H (5.31/5.42) & N (6.87/7.02) [3.17+2H2O]; IR (cm-1) 3428 (b), 
3159-3059 (m), 1606 (s), 1586-1504 (m), 1258 (s), 772-762 (d); H.R.M.S. [ESI+] 
(m/z) in methanol (Theoretical/ Found) [M+H]+ 780.1556/780.1620. 
6.4.19 Bis-(N-4-tButylphenylquinaldamide) ruthenium dichloride, 
C40H39O2N4RuCl2, (3.18) 
Ligand 2.18 (2 eq., 0.765 mmol, 0.231 g) was dissolved in 20 mL of ethanol. The 
solution was heated up to 80°C until the ligand was completely dissolved. After 
30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol; 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A reddish solid was 
isolated which recrystallised from DMF or DMSO, and the mother liqueurs were 
left to crystallise. 
Yield: 0.0372 g, 0.048 mmol, 13 %. eff = 1.90; EA (Theoretical/Found)(%): C 
(60.22/60.26), H (5.18/4.6) & N (7.02/7.20) [3.18+H2O]; IR (cm-1) 3420 (b), 3172-
3070 (m), 1610 (s), 1576-1524 (m), 1268 (s), 776-763 (d); H.R.M.S. [ESI+] (m/z) 
in methanol (Theoretical/ Found) [M+H]+ 780.1556/780.2360. 
6.4.20 Bis-(N-2-triFluoromethylphenylquinaldamide) ruthenium 
dichloride, C34H21O2N4F6RuCl2, (3.19)  
Ligand 2.19 (2 eq., 0.765 mmol, 0.2419 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol; 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
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reaction was cooled down to 65°C and filtered immediately. A reddish solid was 
isolated which recrystallised from DMF, and the mother liqueurs were left to 
crystallise.  
Yield: 0.0151 g, 0.018 mmol, 5 %; IR (cm-1) 3240 (s), 3059 (s), 1612-1574 (m), 
762 (s); H.R.M.S. [ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 
804.0062/804.0069. 
6.4.21 Bis-(N-3-triFluromethylphenylquinaldamide) ruthenium 
dichloride, C34H21O2N4F6RuCl2, (3.20) 
Ligand 2.20 (2 eq., 0.765 mmol, 0.2419 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A green powder was 
isolated, and the mother liqueurs were left to crystallise. 
Yield: 0.0283 g, 0.04 mmol, 9 %; IR (cm-1) 3249 (s), 3210 (s), 3067 (s), 1611-
1594 (m), 763 (s); H.R.M.S. [ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 
804.0062/804.0064. 
6.4.22 Bis-(N-4-triFluorophenylquinaldamide) ruthenium dichloride, 
C34H21O2N4F6RuCl2, (3.21) 
Ligand 2.21 (2 eq., 0.765 mmol, 0.2419 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A green solid was 
isolated which recrystallised from DMF, and the mother liqueurs were left to 
crystallise.  
Yield: 0.0590 g, 0.073 mmol, 19 %; H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 804.0062/804.0084. 
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6.4.23 Bis-(N-3,5-ditriFluoromethylphenylquinaldamide) ruthenium 
dichloride, C36H19O2N4F12RuCl2, (3.22) 
Ligand 2.22 (2 eq., 0.765 mmol, 0.2940 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A green solid was 
isolated which recrystallised from DMF or DMSO, and the mother liqueurs were 
left to crystallise. 
Yield: 0.0409 g, 0.044 mmol, 12 %; H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 939.9810/939.9820. 
6.4.24 Bis-(N-2-Fluorophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4F2RuCl2, (3.23) 
Ligand 2.23 (2 eq., 0.765 mmol, 0.2037 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 55°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered. A reddish solid was isolated which 
recrystallised from DMF and the mother liqueurs were left to crystallise. 
Yield: 0.0926 g, 0.13 mmol, 34 %; eff = 1.9; EA (Theoretical/Found)(%):  
C (53.27/53.37), H (3.21/2.62) & N (7.77/7.72) [3.23+H2O]; IR (cm-1) 3148 (s), 
3025 (s), 2785 (s), 1611 (s), 1580-1503 (m), 753 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 704.0126/704.0227. 
6.4.25 Bis-(N-3-Fluorophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4F2RuCl2, (3.24) 
Ligand 2.24 (2 eq., 0.765 mmol, 0.2037 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 50°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A black powder was 
isolated which recrystallised from DMF or DMSO, and the mother liqueurs were 
left to crystallise. 
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Yield: 0.1725 g, 0.25 mmol, 65 % eff = 1.85; EA (Theoretical/Found)(%):  
C (54.63/54.50), H (3.01/2.99) and N (7.96/7.82) [3.24]; IR (cm-1) 3334-2908 (b), 
3210 (s), 3061 (s), 1640 (s), 765 (s); H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 704.0126/704.0120. 
6.4.26 Bis-(N-4-Fluorophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4F2RuCl2, (3.25) 
Ligand 2.25 (2 eq., 0.765 mmol, 0.2037 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 35°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered. A reddish solid was isolated, 
recrystallised from DMF and the mother liqueurs were left to crystallise. 
Yield: 0.153 g, 0.217 mmol, 57 %; eff = 1.94; EA (Theoretical/Found)(%):  
C (54.63/54.51), H (3.01/3.09) and N (7.96/8.14) [3.25]; IR (cm-1) 3000 (s), 3070 
(s), 1619 (s), 1584-1510 (m), 792 (s), 761 (s); H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 704.0126/704.0115. 
6.4.27 Bis-(N-2,4-diFluorophenylquinaldamide) ruthenium dichloride, 
C32H219O2N4F4RuCl2, (3.26) 
Ligand 2.26 (2 eq., 0.765 mmol, 0.2172 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 75°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was filtered immediately. A dark powder was isolated which 
recrystallised from DMF and the mother liqueurs were left to crystallise. 
Yield: 0.0467 g, 0.063 mmol, 17 %; eff = 2.01; EA (Theoretical/Found)(%):  
C (51.98/51.72), H (2.59/2.73) & N (7.58/7.53) [3.26]; IR (cm-1) 3217 (b), 3066 
(m), 1614 (s), 1584-1512 (m), 785-764 (m); H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 739.9937/739.9930. 
6.4.28 Bis-(N-2,5-diFluorophenylquinaldamide) ruthenium dichloride, 
C32H219O2N4F4RuCl2, (3.27) 
Ligand 2.27 (2 eq., 0.765 mmol, 0.2172 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
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After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction filtered immediately. A red solid was isolated, recrystallised from DMF 
and the mother liqueurs were left to crystallise. 
Yield: 0.1054 g, 0.142 mmol, 37 %; eff = 2.04; EA (Theoretical/Found)(%):  
C (51.98/51.8), H (2.59/2.58) & N (7.58/7.41) [3.27]; IR (cm-1) 3405 (s), 3063-
3038 (m), 1647-1613 (d), 1586-1554 (d), 1496-1445 (m), 1341 (s) 760-728 (m); 
H.R.M.S. [ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 
739.9937/739.9932. 
6.4.29 Bis-(N-2-Chlorophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4RuCl4, (3.28) 
Ligand 2.28 (2 eq., 0.765 mmol, 0.2163 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 60°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered. A reddish solid was isolated, 
recrystallised from DMF and the mother liqueurs were left to crystallise. 
Yield: 0.1452 g, 0.20 mmol, 52 %; eff = 1.97; EA (Theoretical/Found)(%):  
C (52.19/51.97), H (2.87/2.80) & N (7.61/7.53) [3.28]; IR (cm-1) 3371 (b), 3148-
3059 (m), 1666 (s), 1594-1509 (m), 1471-1341 (m), 755 (s); H.R.M.S. [ESI+] 
(m/z) in methanol (Theoretical/ Found) [M+H]+ 737.4235/737.9518. 
6.4.30 Bis-(N-3-Chlorophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4RuCl4, (3.29) 
Ligand 2.29 (2 eq., 0.765 mmol, 0.2163 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 70°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A red solid was 
isolated which recrystallised from DMSO, and the mother liqueurs were left to 
crystallise. 
Yield: 0.2238 g, 0.30 mmol, 80 %. eff = 2.12; EA (Theoretical/Found)(%):  
C (50.95/51.24), H (3.07/3.14) and N (7.43/7.15) [3.27+H2O]; IR (cm-1) 3203 (b), 
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3071-2963 (m), 1568-1548 (m), 1358-1335 (d), 760 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 737.9511/737.9516. 
6.4.31 Bis-(N-4-Chlorophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4RuCl4, (3.30) 
Ligand 2.30 (2 eq., 0.765 mmol, 0.2163 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 60°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered. A reddish solid was isolated which 
recrystallised from DMF and the mother liqueurs were left to crystallise. 
Yield: 0.1885 g, 0.256 mmol, 67 %; eff =2.06; EA (Theoretical/Found)(%):  
C (52.19/52.06), H (2.87/2.72) & N (7.61/7.53) [3.30]; IR (cm-1) 3059-3012 (m), 
2890-2836 (b), 1612-1535 (m), 1487-1406 (m), 791-764 (m); H.R.M.S. [ESI+] 
(m/z) in methanol (Theoretical/ Found) [M+H]+ 737.9511/737.9514. 
6.4.32 Bis-(N-2,4-diChlorophenylquinaldamide) ruthenium dichloride, 
C32H19O2N4RuCl6, (3.31) 
Ligand 2.31 (2 eq., 0.765 mmol, 0.2423 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A reddish solid was 
isolated which recrystallised from DMF or DMSO, and the mother liqueurs were 
left to crystallise. 
Yield: 0.1226 g, 0.152 mmol, 40 %; eff = 2.14; EA (Theoretical/Found)(%):  
C (47.73/47.69), H (2.38/2.48) & N (6.96/6.87) [3.31]; IR (cm-1) 3166-3060 (m), 
1633 (s), 1593-1508 (m), 1341 (s), 767 (s); H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 805.8726/805.8727. 
6.4.33 Bis-(N-2,5-diChlorophenylquinaldamide) ruthenium dichloride, 
C32H19O2N4RuCl6, (3.32) 
Ligand 2.32 (2 eq., 0.765 mmol, 0.2423 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
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(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was filtered. A reddish solid was isolated, recrystallised from DMF and 
the mother liqueurs were left to crystallise. 
Yield: 0.103 g, 0.127 mmol, 34 %. eff = 2.04; EA (Theoretical/Found)(%):  
C (47.73/47.85), H (2.38/2.43) & N (6.96/7.05) [3.32]; IR (cm-1) 3186-3062 (m), 
1638 (s), 1597-1507 (m), 1377-1341 (m), 765 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 324.0979/324.0981. 
6.4.34 Bis-(N-2-Bromophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4Br2RuCl2, (3.33) 
Ligand 2.33 (2 eq., 0.765 mmol, 0.2503 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight and 
filtered. A reddish solid was isolated which recrystallised from DMF leaving the 
mother liqueurs to crystallise. 
Yield: 0.1035 g, 0.12 mmol, 31 %. eff = 1.98;. EA (Theoretical/Found)(%):  
C (46.57/46.41), H (2.56/2.67) & N (6.79/6.66) [3.33]; IR (cm-1) 3300-3250 (b), 
3149-2961 (m), 1590-1580 (d), 754 (s); H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 825.8505/825.8375. 
6.4.35 Bis-(N-3-Bromophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4Br2RuCl2, (3.34) 
Ligand 2.34 (2 eq., 0.765 mmol, 0.2503 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 85°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was filtered immediately. A red powder was isolated which recrystallised 
from DMF, and the mother liqueurs were left to crystallise. 
Yield: 0.2229 g, 0.27 mmol, 71 %; eff = 2.21; EA (Theoretical/Found)(%):  
C (46.57/46.29), H (2.56/2.67) and N (6.79/6.56) [3.34] IR (cm-1) 3250-3230 (b), 
3059-2965 (m), 1594-1507 (m), 1341-1335 (m), 760 (m); H.R.M.S. [ESI+] (m/z) 
in methanol (Theoretical/ Found) [M+H]+ 825.8504/825.8497. 
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6.4.36 Bis-(N-4-Bromophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4Br2RuCl2, (3.35) 
Ligand 2.35 (2 eq., 0.765 mmol, 0.2503 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A reddish solid was 
isolated which recrystallised from DMF or DMSO, and the mother liqueurs were 
left to crystallise. 
Yield: 0.1243 g, 0.150 mmol, 39 %; eff = 2.13. EA (Theoretical/Found)(%):  
C (46.57/46.75), H (2.56/2.66) and N (6.79/6.60); IR (cm-1) 3228-3163 (m), 3059-
2924 (m), 1611-1574 (m), 1537-1466 (m), 1401-1335 (m), 762 (s); H.R.M.S. 
[ESI+] (m/z) in methanol (Theoretical/ Found) [M+H]+ 825.8504/825.8503. 
6.4.37 Bis-(N-2,4-diBromophenylquinaldamide) ruthenium dichloride, 
C32H19O2N4Br4RuCl2, (3.36) 
Ligand 2.36 (2 eq., 0.765 mmol, 0.3103 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the ligand was added to a solution of RuCl3·3H2O (1 eq., 0.382 
mmol, 0.1 g) in 5 mL of ethanol and left to reflux overnight. Then, filtered 
immediately. A dark solid was isolated, recrystallised from DMF and the mother 
liqueurs were left to crystallise. 
Yield: 0.1935 g, 0.197 mmol, 52 %; eff = 2.06. EA (Theoretical/Found)(%):  
C (39.10/39.27), H (1.95/1.83) & N (5.70/5.88) [3.36]; IR (cm-1) 3200-3100 (b), 
3139-3056 (m), 1632 (s), 1585-1507 (m), 766 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 983.6674/983.6686. 
6.4.38 Bis-(N-2,5-diBromophenylquinaldamide) ruthenium dichloride, 
C32H19O2N4Br4RuCl2, (3.37)  
Ligand 2.37 (2 eq., 0.765 mmol, 0.3103 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the functionalised ligand was added to a solution of RuCl3·3H2O  
(1 eq., 0.382 mmol, 0.1 g) in 5 mL of ethanol, and left to reflux overnight. The 
reaction was cooled down to 65°C and filtered immediately. A reddish solid was 
Chapter 6 Experimental 
- 206 - 
 
isolated which recrystallised from DMF or DMSO, and the mother liqueurs were 
left to crystallise. 
Yield: 0.1579 g, 0.160 mmol, 42 %; H.R.M.S. [ESI+] (m/z) in methanol 
(Theoretical/ Found) [M+H]+ 983.6674/983.6685 (not major peak). 
6.4.39 Bis-(N-2-Iodophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4I2RuCl2, (3.38) 
Ligand 2.38 (2 eq., 0.765 mmol, 0.2862 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until the ligand was completely dissolved. 
After 30 min, the ligand was added to a solution of RuCl3·3H2O (1 eq., 0.382 
mmol, 0.1 g) in 5 mL of ethanol, left to reflux overnight and then filtered 
immediately. A dark red solid was isolated, recrystallised from DMF and the 
mother liqueurs were left to crystallise. 
Yield: 0.1053 g, 0.11 mmol, 29 %. eff =1.98; EA (Theoretical/Found)(%):  
C (41.81/41.97), H (2.30/2.29) & N (6.09/6.06) [3.38]; IR (cm-1) 3181-2867 (m), 
1592-1558 (m), 1507-1433 (m), 1372-1335 (m), 750 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 919.8247/919.8239. 
6.4.40 Bis-(N-3-Iodophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4I2RuCl2, (3.39) 
Ligand 2.39 (2 eq., 0.765 mmol, 0.2862 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 85°C until completely dissolved. After 30 min, the 
functionalised ligand was added to a solution of RuCl3·3H2O (1 eq., 0.382 mmol, 
0.1 g) in 5 mL of ethanol and left to reflux overnight. The reaction was filtered 
immediately. A dark solid was isolated which recrystallised from DMF and the 
mother liqueurs were left to crystallise. 
Yield: 0.2568 g, 0.28 mmol, 74 %. eff = 2.04; EA (Theoretical/Found)(%):  
C (41.40/41.62), H (2.39/2.65) & N (6.04/5.88) [3.39+0.5H2O]; IR (cm-1) 3279-
2963 (m), 1617-1549 (m), 1466-1333 (m), 760 (s); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 921.8218/921.8240. 
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6.4.41 Bis-(N-4-Iodophenylquinaldamide) ruthenium dichloride, 
C32H21O2N4I2RuCl2, (3.40) 
Ligand 2.40 (2 eq., 0.765 mmol, 0.2862 g) was dissolved in 20 mL of ethanol. 
The solution was heated up to 80°C until completely dissolved. After 30 min, the 
ligand was added to a solution of RuCl3·3H2O (1 eq., 0.382 mmol; 0.1 g) in 5 mL 
of ethanol, left to reflux overnight. Then, filtered immediately. A dark solid was 
isolated, recrystallised from DMF and the mother liqueurs were left to crystallise. 
Yield: 0.1811 g, 0.196 mmol, 51 %; eff = 1.99; EA (Theoretical/Found)(%):  
C (41.81/41.715), H (2.30/2.09) & N (6.09/6.13) [3.40]; IR (cm-1) 3056 (s), 3000-
2870 (m), 1585-1509 (m), 1482-1398 (m), 793-763 (m); H.R.M.S. [ESI+] (m/z) in 
methanol (Theoretical/ Found) [M+H]+ 921.8218/921.8245. 
6.5 Cell Culture Work 
6.5.1 General Experimental Procedures 
The in vitro training was performed at the University of Huddersfield under the 
supervision of Prof. Roger M. Phillips, Dr. Simon J. Allison and their PhD student 
Samantha Shepherd. The cells used were MIA PaCa-2 (human pancreatic 
carcinoma), HCT116 p53(+/+) and HCT116 p53(-/-) (human colorectal carcinoma 
with p53 upregulated and knockdown, respectively) and ARPE-19 (human retinal 
epithelium – non cancerous) cell lines. These were purchased from ATCC. 
Standard sterile techniques were used throughout this work. Unless otherwise 
stated, chemicals were purchased from Sigma Aldrich, consumables from 
Sarstedt and were used as supplied. The stock cultures were grown in T-75 flasks 
containing DMEM and DMEM:F12 complete cell medium (15 mL) for the 
cancerous and non-cancerous cell lines respectively, and incubated at 37 ºC with 
5.0% of CO2. The complete media was prepared from DMEM high glucose 
without L-glutamine Incomplete Media (450 mL), L-Glutamine 2 mM (5 mL, 200 
mM) and foetal bovine serum 10% (50 mL). The complete media was prepared 
from DMEM:F12 (1:1) (450 mL), L-Glutamine 2 mM (5 mL, 200 mM) and foetal 
bovine serum 10% (50 mL). Phosphate Buffer Saline (PBS) buffer sterile solution 
was used to wash the cells, Trypsin-EDTA (1x) was used to detach the cells from 
the flask. DMEM (complete and incomplete), DMEM:F12 (complete and 
incomplete), MTT (Alfa Aesar) and MTT stock solutions (5 mg/mL), trypsin-EDTA 
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(1x) were all stored at 4ºC. L-Glutamine, foetal bovine serum and trypsin-EDTA 
stock solutions were stored at -20ºC. All chemicals except the MTT solution were 
incubated in a water bath at 37ºC prior to use. 
6.5.2 Thawing Cells and from Cryo-Preservation 
Cell stocks are kept in liquid nitrogen to preserve them. Once cells were taken 
from the liquid nitrogen, they were defrosted quickly in a water bath at 37ºC, after 
that, 20 mL of culture media (dependant on the cell line) were added to dilute the 
amount of DMSO in the freezing medium. The suspension was centrifuged at 
1500 rpm for 3 minutes forming a pellet. The media containing DMSO was 
carefully removed, the pellet was re-suspended in the desired media and an 
adequate volume of cell suspension added to the cell culture flask. 
6.5.3 Sub culturing by trypsination of Monolayer Cultures 
After carefully removing the media from the T-75 flasks, cells were washed with 
PBS buffer solution (1 x 5 mL) and carefully removed. Trypsin-EDTA (1x) (1 x 5 
mL) was added and the T-75 flask was incubated for 3 min. When the cells were 
detached from the flask wall, if needed for cell counting, 3 mL were taken and put 
in a falcon tube (50 mL) and 12 mL of media (different depending on the cell line) 
added to the falcon tube and 13 mL to the T-75 flask to allow cells to recover and 
be confluent. 
6.5.4 Cell Counting 
Cells were detached using trypsin as above and centrifuged to 1000 rpm. for  
3 minutes to form a cell pellet. Media was then carefully removed without 
disturbing the pellet, and depending on cell pellet size resuspended in 1-10 mL 
of fresh media added to make a homogenous cell suspension. From the 
suspension 10 L were taken and carefully placed onto each side of the glass 
slide of a haemocytometer. Cells were counted under the microscope in four 
squares of the haemocytometer and an average was taken with units of 104 
cell/mL. 
6.5.5 Cryo-preservation (cell stock) 
After trypsination, if needed, cells were re-suspended in culture media containing 
20% FBS and 10% DMSO and 1 mL of this suspension placed in pre-labelled 
cry-vial. The cryo-vials were frozen by a gradient of freezing using a NaIgene ® 
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‘Mr Frosty ™’ system loaded with isopropyl alcohol. Once the cryo-vials are 
inserted into the ‘Mr Frosty ™’ container at room temperature, this was placed in 
a -80ºC freezer overnight prior to transferring the cryo-vials into the liquid 
nitrogen. The exact location, number of vials, date and cell line details were 
entered into the liquid nitrogen storage logging system. 
6.5.6 MTT stock solution 
The MTT stock solution (5 mg/mL) was prepared by dissolving MTT  
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 250 mg in PBS 
sterile (50 mL), this was then vortexed and then passing through a 0.2 m sterile 
filter. 
6.5.7  Validation of pipetting technique 
A single cell suspension cell/mL was prepared to a final concentration of 5 x 104. 
A 96 well plate was seeded at varying volumes of cell suspension and media, 
lane 1 had only media and lane 12 left as blank. From lane 2 to lane 11, a final 
volume of 200 l remained constant decreasing the amount of cell suspension in 
20 L and increasing the cell media in 20 l. 20 l of MTT stock solution was 
immediately added and incubated for 4 hours. After 4h, the solution was carefully 
removed from each well to not disturb the crystals and dissolve them in 150 L 
of DMSO (Fisher Scientific). The plates were read by a Tecan plate reader set at 
540 nm. Finally, the mean absorbance was calculated (differing the mean of the 
blank) for each line and plotted against the cell number, the R value is then 
calculated in order to quantify the accuracy of the user pipetting technique. 
6.5.8 Chemo-sensitivity MTT assays (Normoxic Conditions) 
After cell counting, a suspension with a concentration of 2 x 104 cell/mL was 
prepared. A 96-well plate was used and 200 L was added to a lane one, to serve 
as a blank. 200 L of the diluted cell suspension was then added to lanes 2 to 
12, and were incubated for 24h at 37ºC in an atmosphere of 5.0% of CO2 prior to 
drug exposure. The drugs to be tested were dissolved in DMSO and diluted 
further with media to obtain drug solutions ranging from 100 M to 0.046 M. The 
final DMSO concentration was 0.2% (v/v) which is non-toxic to cells. The second 
lane was left as a blank meaning no drug was added to see the effect of the anti-
cancer molecules. Drug solutions were added to cells and incubated for 96h at 
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37ºC in an atmosphere of 5% CO2. Cell survival was determined using the MTT 
assay and MTT (20 L of a 5 mg/mL stock) was added to each well and incubated 
for 4h at 37ºC in an atmosphere of 5.0% of CO2. The solutions were then removed 
and 150 L of DMSO was added to each well plate to dissolve the formazan 
crystals. 
6.5.9 Data Analysis 
A Tecan plate reader was used to measure the absorbance at 540 nm. Lanes 
contained medium only and cell suspension (no drug) were used as blanks and 
100% cell survival respectively. Cell survival was determined as the absorbance 
of treated cells divided by the true absorbance of controls and expressed as 
percentage. The IC50 values were determined from choosing where the 50% of 
survival against drug concentration. Each experiment was repeated a minimum 
of three times, to give the mean of IC50 and standard deviations. 
6.5.10 Chemo-sensitivity MTT assays (Hypoxic Condititions) 
The hypoxic studies were carried out in a Hypoxic chamber (Whitley H35 
hypoxystation) with 0.1% of O2, 5.0% of CO2, 94.9% of N2 and 81% of humidity, 
on MIA PaCa-2 (human pancreatic carcinoma) and HCT116 (human colon 
carcinoma p53 upregulated) cell lines. DMEM complete media was conditioned 
for at least 24h in the hypoxic chamber prior to start of the experiment in order to 
purge the oxygen from the media. The cells were seeded as for the 5-day 
cytotoxic assay in section 6.5.8 and after 24h they were moved the hypoxic 
chamber where the cells were exposed to the lead compounds (IC50 below 20 
M) from concentrations starting at 100 M until 0.048 M. In this assay, it was 
seeded one compound per plate in order to decrease the potential cell infection. 
Cell survival was then determined using the MTT assay described in section 
6.5.8. 
6.5.11 Viability assay and drug induced Cell Cycle Arrest using 
the NucleoCounter (NC-3000) cytometer 
The NucleCounter (NC) 3000 is an advanced cytometer which uses fluorescence 
imaging to characterise cell properties. For each of the compounds selected (two 
Lead Compound 3.23 and 3.32) four T-25 flasks with 1 x106 cells were placed in 
the incubator to allow them to adhere (1 serving as a control and the other 3 for 
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time point experiments).The seeding density of the flasks reflected the same 
density as in the 96-well plate used for the MTT assay (number of cells per cm2 
is the same). Cells were exposed to the same IC50 and the final concentration of 
DMSO (used to dissolve the complexes) was kept constant 0.1% v/v. The 
compounds were then incubated for 24h, 48h and 72h. After drug exposure, 
images were taken (Evos XL digital microscope) of each flask for visual 
comparison prior to trypsination. Then, cells were analysed using the NC3000 
using the viability assay and the cell cycle arrest assay. For the two assays, the 
original medium was always kept and re-added prior to centrifugation to create a 
cell suspension with all living, apoptotic and necrotic populations present. 
6.5.11.1 Viability Assay 
Following the preparation of a single cell suspension, cells were drawn into the 
Via1-cassette by inserting the tip of the cassette into the cell suspension and 
pressing the piston. This cassette was pre-loaded with Acridine Orange staining 
the entire population and DAPI which stained only the non-viable cells. Then, the 
cassettes were placed in the NC3000 for analysis. The cell suspension should be 
in the range of 5 x104-5 x106 cells/mL to assure reliable results and manageable 
cell densities for potential further analysis. This assay not only determines the 
cell viability of cell suspension but provides an accurate cell count as well. 
6.5.11.2 Cell Cycle Arrest Assay 
To determine the degree of cell cycle arrest of a compound, a cell suspension at 
1 x106 cells/mL was prepared. Cells were washed twice in PBS prior to the 
addition of 250 L of solution 10 (lysis buffer, Chemometec) supplemented with 
10 g/mL DAPI. The cell suspension was then incubated for 5 minutes at 37ºC 
followed by the addition of 250 L of solution 11 (stabilisation buffer, 
Chemometec). The resultant sample was analysed using A8 slides. The principle 
of the assay was quantifying the amount of DNA stained by DAPI. In a single 
population, cells are distributed among three major phases: G1/G0 with one set of 
paired chromosomes per cell, S phase where DNA is synthesised (variable in 
DNA content) and G2/M phase where there are two sets of paired chromosomes 
per cell. Sub G1 populations are apoptotic with higher fluorescent intensities than 
G2/M phase being polyploid. DAPI intensity directly relates to DNA content. 
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6.5.12 Antimicrobial Studies 
Antimicrobial screening was performed by CO-ADD (The Community for 
Antimicrobial Drug Discovery), funded by the Wellcome Trust (UK) and The 
University of Queensland (Australia). 
6.5.13 Antibacterial Evaluation 
Complexes were prepared in DMSO and water to a give a final concentration of 
32 μg mL-1 in a 384-well non-binding surface (NBS) plate. The final DMSO 
concentration was at a maximum of 1.0 %. All bacteria were cultured in Cation 
Adjusted Mueller Hinton broth (CAMHB) at 37 °C overnight. A sample of each 
culture was diluted 40-fold in fresh broth and incubated at 37 °C for 1.5 - 3 hours. 
The resultant mid-log phase cultures were diluted (CFU mL-1 measured by 
OD600), then added to each well of the compound containing plates, giving a cell 
density of 5 × 105 CFU mL-1 and a total volume of 50 μL. Colistin and vancomycin 
were used as positive bacterial inhibitor standards for Gram-negative and Gram-
positive bacteria, respectively. Each standard was provided in 4 concentrations, 
with 2 above and 2 below its MIC or CC50 value, and plated into the first 8 wells 
of column 23 of the 384-well NBS plates. All of the plates were covered and 
incubated at 37 °C for 18 hours without shaking. All experiments were carried out 
in duplicate. Inhibition of bacterial growth was determined measuring absorbance 
at 600 nm (OD600), using a Tecan M1000 Pro monochromator plate reader. The 
percentage of growth inhibition was calculated for each well, using the negative 
control (media only) and positive control (bacteria without inhibitors) on the same 
plate as references. The significance of the inhibition values was determined by 
modified Z-scores, calculated using the median and MAD of the samples (no 
controls) on the same plate. Samples with inhibition value above 80 % and Z-
Score above 2.5 for either replicate were classed as actives. Samples with 
inhibition values in the range 50 to 80 % and Z-Score above 2.5 for either replicate 
were classed as partial actives. 
6.5.14 Antibacterial Hit Confirmation 
Complexes were prepared in DMSO and water to a give a final concentration of 
32 μg mL-1 and serially diluted two fold for eight times. Each sample concentration 
was prepared in a 384-well non-binding surface (NBS) plate for each bacterial 
strain or tissue-culture treated plates for mammalian cell types. The final DMSO 
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concentration was at a maximum of 0.5 % DMSO. All bacteria were cultured in 
Cation Adjusted Mueller Hinton broth (CAMHB) at 37 °C overnight. A sample of 
each culture was then diluted 40-fold in fresh broth and incubated at 37 °C for 
1.5-3 h. The resultant mid-log phase cultures were diluted (CFU mL-1 measured 
by OD600), then added to each well of the compound containing plates, giving a 
cell density of 5105 CFU mL-1 and a total volume of 50 µL. Colistin and 
vancomycin were used as positive bacterial inhibitor standards for Gram-negative 
and Gram-positive bacteria, respectively. Each standard was provided in 4 
concentrations, with 2 above and 2 below its MIC or CC50 value, and plated into 
the first 8 wells of column 23 of the 384-well NBS plates. All the plates were 
covered and incubated at 37 °C for 18 h without shaking. All experiments were 
performed in duplicate. Inhibition of bacterial growth was determined measuring 
absorbance at 600 nm (OD600), using a Tecan M1000 Pro monochromator plate 
reader. The percentage of growth inhibition was calculated for each well, using 
the negative control (media only) and positive control (bacteria without inhibitors) 
on the same plate as references. The MIC was determined as the lowest 
concentration at which the growth was fully inhibited, defined by an inhibition  
≥ 80%. In addition, the maximal percentage of growth inhibition is reported as 
DMax, indicating any compounds with partial activity. Hits were classified by  
MIC ≤ 16 μg mL-1 or MIC ≤ 10 μM in either replicate. 
6.5.15 Antifungal Evaluation 
Complexes were prepared in DMSO and water to a give a final concentration of 
32 μg mL-1 in a 384-well non-binding surface (NBS) plate. The final DMSO 
concentration was at a maximum of 1.0 %. Fungal strains were cultured for three 
days on yeast extract-peptone dextrose (YPD) agar at 30 °C. A yeast suspension 
of 1 x 106 to 5 x 106 CFU mL-1 (as determined by OD530) was prepared from five 
colonies. The suspension was diluted and added to each well of the compound-
containing plates giving a final cell density of fungi suspension of 2.5 × 103 CFU 
mL-1 and a total volume of 50 μL. Fluconazole was used as a positive fungal 
inhibitor standard and provided in 4 concentrations, with 2 above and 2 below its 
MIC or CC50 value, and plated into the first 8 wells of column 23 of the 384-well 
NBS plates. All the plates were covered and incubated at 35 °C for 36 hours 
without shaking. All experiments were carried out in duplicate. Growth inhibition 
of C. albicans was determined measuring absorbance at 630 nm (OD630) and the 
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growth inhibition of C. neoformans was determined measuring the difference in 
absorbance between 600 and 570 nm (OD600-570), after the addition of 0.001 % 
resazurin and incubation at 35 °C for an additional 2 hours. The absorbance was 
measured using a Biotek Synergy HTX plate reader. The percentage of growth 
inhibition was calculated for each well, using the negative control (media only) 
and positive control (fungi without inhibitors) on the same plate. The significance 
of the inhibition values was determined by modified Z-scores, calculated using 
the median and MAD of the samples (no controls) on the same plate. Samples 
with inhibition value above 80 % and Z-Score above 2.5 for either replicate were 
classed as actives. Samples with inhibition values in the range 50 to 80 % and Z-
Score above 2.5 for either replicate were classed as partial actives. 
6.5.16 Antifungal Hit Confirmation 
Complexes were prepared in DMSO and water to a give a final concentration of 
32 μg mL-1 and serially diluted two fold for eight times. Each sample concentration 
was prepared in a 384-well non-binding surface plate for each fungal strain or 
tissue-culture treated plates for mammalian cell types. The final DMSO 
concentration was at a maximum of 0.5 % DMSO. Fungal strains were cultured 
for three days on YPD agar at 30 °C. A yeast suspension of 1 x 106 to 5 x 106 
CFU mL-1 (as determined by OD530) was prepared from five colonies. The 
suspension was subsequently diluted and added to each well of the compound-
containing plates giving a final cell density of fungi suspension of 2.5 × 103 CFU 
mL-1 and a total volume of 50 μL. Fluconazole was used as a positive fungal 
inhibitor standard and provided in 4 concentrations, with 2 above and 2 below its 
MIC or CC50 value, and plated into the first 8 wells of column 23 of the 384-well 
NBS plates. All plates were covered and incubated at 35 °C for 36 hours without 
shaking. All experiments were performed in duplicate. Growth inhibition of C. 
albicans was determined measuring absorbance at 630 nm (OD630) and the 
growth inhibition of C. neoformans was determined measuring the difference in 
absorbance between 600 and 570 nm (OD600-570) after the addition of 0.001 % 
resazurin and incubation at 35 °C for 2 hours. The absorbance was measured 
using a Biotek Multiflo Synergy HTX plate reader. The percentage of growth 
inhibition was calculated for each well, using the negative control (media only) 
and positive control (fungi without inhibitors) on the same plate. The MIC was 
determined as the lowest concentration at which the growth was fully inhibited, 
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defined by an inhibition ≥ 80% for C. albicans and an inhibition ≥ 70% for C. 
neoformans. Due to a higher variance in growth and inhibition, a lower threshold 
was applied to the data for C. neoformans. In addition, the maximal percentage 
of growth inhibition is reported as DMax, indicating any compounds with marginal 
activity. Hits were classified by MIC ≤ 16 μg mL-1 or MIC ≤ 10 μM in either 
replicate.  
6.5.17 Cytotoxicity Assay (CO-ADD protocol) 
To assess the cytotoxicity, HEK293 cells were counted manually in a Neubauer 
haemocytometer and then plated in the 384-well plates containing the 
compounds to give a density of 5000 cells well-1 in a final volume of 50 μL. 
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% FBS was 
used as growth media and the cells were incubated together with the compounds 
for 20 hours at 37°C in 5% CO2. Tamoxifen was used as a positive cytotoxicity 
standard in 8 concentrations in 2 fold serial dilutions with 50 µg mL-1 highest 
concentration. All experiments were performed in duplicate. Cytotoxicity was 
measured by fluorescence with excitation at 560 nm and emission at 590 nm 
(F560/590), after addition of 5 μL of resazurin (25 μg mL-1) and incubation for a 
further 3 hours at 37°C in 5% CO2. The fluorescence intensity was measured 
using a Tecan M1000 Pro monochromator plate reader, using automatic gain 
calculation. CC50 were calculated by curve fitting the inhibition values against 
log(concentration) using sigmoidal dose-response function, with variable fitting 
values for bottom, top and slope. The maximal percentage of cytotoxicity is 
reported as DMax, indicating any compounds with partial cytotoxicity. The curve 
fitting was implemented using Pipeline Pilot's dose-response component. Any 
value with > indicates a sample with no activity (low DMax value) or samples with 
CC50 values above the maximum tested concentration (higher DMax value). 
Cytotoxic samples were classified by CC50 ≤ 32 μg mL-1 or CC50 ≤ 10 μM in either 
replicate. In addition, samples were flagged as partial cytotoxic if DMax ≥ 50%, 
even with CC50 > the maximum tested concentration. 
6.5.18 Haemolysis Assay 
To assess blood toxicity, Human whole blood was washed three times with 3 
volumes of 0.9% NaCl and then resuspended in same to a concentration of 0.5 x 
108 cells mL-1, as determined by manual cell count in a Neubauer 
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haemocytometer. The washed cells were then added to the 384-well compound-
containing plates for a final volume of 50 µL. After a 10 min shake on a plate 
shaker the plates were then incubated for 1h at 37°C. Melittin was used as a 
positive haemolytic standard in 8 concentrations in 2 fold serial dilutions with 50 
µg mL-1 highest concentration. After incubation, the plates were centrifuged at 
1000g for 10 min to pellet cells and debris, 25 µL of the supernatant was then 
transferred to a polystyrene 384-well assay plate. Haemolysis was determined by 
measuring the supernatant absorbance at 405 mm (OD405). The absorbance was 
measured using a Tecan M1000 Pro monochromator plate reader. HC10 and 
HC50 (concentration at 10% and 50% haemolysis, respectively) were calculated 
by curve fitting the inhibition values vs. log(concentration) using a sigmoidal dose-
response function with variable fitting values for top, bottom and slope. In 
addition, the maximal percentage of haemolysis is reported as DMax, indicating 
any compounds with partial haemolysis. The curve fitting was implemented using 
Pipeline Pilot's dose-response component. Any value with > indicate sample with 
no activity (low DMax value) or samples with HC10 values above the maximum 
tested concentration (higher DMax value). Haemolysis samples were classified by 
HC10 ≤ 32 µg mL-1 or HC10 ≤ 10 µM in either replicate. In addition, samples were 
flagged as partial haemolytic if DMax ≥ 50%, even with HC10 > the maximum tested 
concentration. 
6.6 Mechanistic studies 
6.6.1 Hydrolysis 
A calibration curve was prepared for each complex by dissolving in 10% of DMF, 
and diluting it further with deionised water. The concentrations used were 100, 
80, 60, 40 and 20 µM. The maximum absorbance (λmax) was taken to plot the 
calibration curve of concentration against absorbance. Hydrolysis samples were 
prepared 50 µM. These aqueous solutions were scanned at different time points, 
0h, 1h, 24h, 48h and 72h by UV-Visible Spectrophotoscopy at 293 K. The 
concentration of each complex from 0h to 72 hours was determined using its 
individual calibration curve. The following formula is used to calculate the 
percentage of hydrolysed complex, 
% ℎ𝑦𝑑𝑟𝑜𝑙𝑦𝑠𝑒𝑑 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 =  (
[𝐶]𝑖𝑛𝑖𝑡𝑖𝑎𝑙 − [𝐶]𝑓𝑖𝑛𝑎𝑙
[𝐶]𝑖𝑛𝑖𝑡𝑖𝑎𝑙
)  𝑥 100% 
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6.6.2 Hydrophobicity 
A calibration curve was prepared for each complex by dissolving the complexes 
in octanol, and diluting it further to obtain the concentrations of 100, 80, 60, 40 
and 20 µM. The maximum absorbance (λmax) was taken to plot the calibration 
curve of concentration against absorbance. Equal amounts of octanol and 
deionised water (containing 300 mM NaCl to prevent complexes from undergoing 
hydrolysis) were stirred overnight for saturation and separated to obtain water-
saturated octanol and octanol-saturated water solutions. Approximately 1 mg of 
each complex tested was dissolved in 25 ml of water-saturated octanol as stock 
solution, and sonicated for complete dissolution. Six independent samples were 
prepared for each complex by adding 2 ml of octanol-saturated water, followed 
by 2 ml of the stock solution containing ruthenium complexes in each labelled 15 
ml Falcon tubes. The samples were then shaken using the IKA Vibrax VXC basic 
shaker at 500 g/min for 4 hours. Organic (octanol) layer of the stock solution and 
from the six independent samples were taken for analysis on UV-Visible 
spectrophotometry. The concentration of each complex was determined using its 
individual calibration curve. The following formula is used to calculate the partition 
coefficient of the complexes (Log P), 
𝐿𝑜𝑔 𝑃 = 𝐿𝑜𝑔 (
[𝐶]𝑜𝑟𝑔
[𝐶]𝑎𝑞
) ; [𝐶]𝑎𝑞 =  [𝐶]𝑜𝑟𝑔 𝑠𝑡𝑜𝑐𝑘 – [𝐶]𝑜𝑟𝑔 
Chapter 6 Experimental 
- 218 - 
 
6.7 References 
1 Cosier, J.; Glazer, A. M.; J. App. Crystallogr., 1986, 19, 105-107. 
2 Otwinowski, Z.; Minor, W., in ‘DENZO and SCALEPACK programs’. 1995. 
3 Sheldrick, G. M.; Acta Crystallogr. C, 2015, 71, 3-8. 
4 Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A.; Puschmann, H.; 
J. App. Crystallogr., 2009, 42, 339-341. 
5 Dutta, S.; Pal, S.; Bhattacharya, P. K.; Polyhedron, 1999, 18, 2157-2162. 
6 Basri, A. M.; Lord, R. M.; Allison, S. J.; Rodríguez-Bárzano, A.; Lucas, S. J.; 
Janeway, F. D.; Shepherd, H. J.; Pask, C. M.; Phillips, R. M.; McGowan, P. C.; 


















Chapter 7 Conclusions and Future Work 
 
 
Chapter 7 Conclusions and Future Work 
 
- 220 - 
 
7.1 Conclusions 
Amide based ligands are embedded in the field of peptide chemistry displaying 
key biological roles such as protein construction. Forty ligands were synthesised 
being twelve of them novel. Two synthetic protocols (based on amide 
condensation reactions) were followed. These ligands have been fully 
characterised by means of NMR, IR, HRMS, some by elemental analysis, and 
when suitable crystals were obtained, analysed for X-ray crystallography, as 
described in Chapter 2. In the solid state, these ligands opt for an almost planar 
configuration showing a slight twist between the quinoline and the aniline ring, 
allowing them to facilitate the coordination to metallic centres either by [N,N] or 
[N,O] coordination in an anionic or neutral form. . 
 
An umbrella of novel functionalised di-chloride bis-quinaldamide ruthenium (III) 
complexes have been successfully synthesised. The compounds that showed 
pure elemental analysis (3.1 (H), 3.5 (2-Me), 3.6 (3-Me), 3.7 (4-Me), 3.9 (2-Et), 
3.10 (3-Et), 3.11 (4-Et), 3.12 (2-iPr), 3.13 (3-iPr), 3.15 (2,6-diiPr), 3.16 (2-Me,6-iPr), 
3.17 (2-tBu), 3.18 (4-tBu), 3.23 (2-F), 3.24 (3-F), 3.25 (4-F), 3.26 (2,4-diF), 3.27, 
(2,5-diF), 3.28 (2-Cl), 3.29 (3-Cl), 3.30 (4-Cl), 3.31 (2,4-diCl), 3.32 (2,5-diCl), 3.33 
(2-Br), 3.34 (3-Br), 3.35 (4-Br), 3.36 (2,4-diBr), 3.38 (2-I), 3.39 (3-I), and 3.40 (4-I) 
were fully characterised using IR, HRMS, magnetic susceptibility, X-ray powder 
diffraction and single crystal X-Ray diffraction, when suitable, however, only the 
compounds that showed relevant biological activity are described in Chapter 3. 
Several synthetic protocols were attempted, only one protocol was thoroughly 
discussed in this thesis which yielded the ruthenium neutral complexes 
recrystallised by slow evaporation of DMF or DMSO solutions. From the five 
potential isomers only the trans-trans-trans was isolated and proved by X-ray 
powder diffraction that the whole bulk of the sample was that only isomer. The 
thirty pure complexes have been tested against various cancerous and non-
cancerous cell lines to assess their potential as anti-cancer agents, as reported 
in Chapter 4. 
 
In Chapter 3, three further complexes were obtained as secondary products from 
the reactions carried in presence of a base, crystallised from mother liqueurs and 
from the same batch of crystallisation. These side products helped to optimise 
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the reaction conditions and understanding how these complexes might lose their 
biocidal properties. Surprisingly, following the original protocol (addition of a base 
to the complexation reaction) a charged complex was isolated suggesting 
another family of complexes type [RuCl2L2]- which are negatively charged but not 
discussed in this project. 
 
Chapter 4 describes a library of functionalised trans-dichloride bis-quinaldamide 
ruthenium complexes that were tested for cytotoxicity against three cancer cell 
lines, HCT116 p53 +/+ (colorectal adenocarcinoma with upregulated tumour 
suppressor gene), HCT 116 p53 -/- (colorectal adenocarcinoma with knockdown 
of the tumour suppressor gene) and MIA PaCa-2 (pancreatic cancer), and non-
cancerous cells line ARPE-19 (retinal epithelial). Their anticancer activity was 
determined following a 72h drug exposure MTT assay. Longer incubation times 
show very low selectivity of the drug, hence 3-day incubation time was used in 
the assay as well as for cisplatin, carboplatin and oxaliplatin, allowing the 
calculation of the IC50 values of the drugs. The cytotoxicity of the complexes is 
mostly affected by the substitution of the aniline rings displaying a wide range of 
potency, from inactive to highly active. Only a few trends can be seen, complexes 
with electron withdrawing groups show more selectivity towards cancer cell lines, 
the para-substituted complexes show a general increase in activity and the 
compounds with double substituents in the aniline ring opt for slightly higher IC50 
displaying selectivity ratios higher than the platinum based drugs – FDA 
approved. The complexes tend to be selective towards colorectal cancer cell lines 
being the complex 3.35 (4-Br) (IC50 = 21.72 ± 3.90 M) selective towards HCT 
p53 -/-, and the complex 3.7 (4-Me) (IC50 = 24.57 ± 3.37 M) selective towards 
p53 +/+, hence more cytotoxicity assays were carried out against isogenic colonic 
cancerous cell lines but, in this case, targeting oncogenes. Five lead compounds 
were tested against HCT 116 Kras cell lines (Wild type, mutant and parent). It 
was proven the three complexes showed equipotent activity against the 
oncogene cell lines, complex 3.18 (R = 4-tBu) displayed higher activity than 
against the tumour suppressor gene and complex 3.32 (R = 2,5-diCl) showed 
lower toxicity. 
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The lead compounds were tested under hypoxia conditions to mimic the core of 
cancerous cells as the oxygen concentration is very low. Compounds with 
electron donating groups increased the IC50 whereas the compounds with 
electron withdrawing groups have shown better anticancer activity when 
compared to their toxicity under normoxic conditions. This feature suggests that 
two lead compounds 3.23 and 3.32 are the two most promising anti-cancer 
complexes selected for further analysis. 
 
Viability studies and cell cycle arrest studies have shown that compounds 3.23 
and 3.32 disrupt the DNA in the sub G1 phase, what means they can promote cell 
death by apoptosis, necrosis or necroptosis. Interestingly, compound 3.32 does 
not interrupt the cell cycle for healthy cells. Selected complexes (dependent on 
the anticancer potency) were chosen for further structural-activity relationship 
studies. Mechanistic studies such as hydrolysis and hydrophobicity tests have 
proved that compounds are not prone to hydrolysis suggesting the mechanism of 
action does not occur via aquated species. On the other hand, the compounds 
tend to accumulate in the octanol (organic) layer which mimics the cell 
membrane, suggesting the compounds get into the cell via passive diffusion 
showing acceptable Log P values according to Lipinski’s rule of five and Hansch’s 
principle of minimum hydrophobicity. The UV-vis hydrolysis study was carried at 
the same time points as the MTT assay in order to correlate the cytotoxicity 
studies. HRMS proved that there were not aquated species. It can be seen that 
the higher the Log P value the better the selectivity towards colonic cancer cell 
lines is. Although, few correlations can be observed between the cytotoxicity and 
Log P values these are opposed to the platinum complexes that have shown an 
increase in cytotoxicity when increasing hydrophobicity. 
 
A new approach given in this research project is using these compounds as 
antibacterial and antifungal agents, analysed by the CO-ADD at the University of 
Queensland. The compounds were tested against five types of bacteria classified 
depending on the absence (Gram negative) or presence (Gram positive) of 
bacteria cell wall, showing that compounds with substituents in position 2 have 
better MIC values being the complex 3.12 the most active. Surprisingly, all the 
active compounds were selective towards the bacteria strain Staphylococcus 
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aureus. In addition, the compounds with bromo substituent in any position shows 
good activity across the panel of bacteria tested. In terms of antifungal activity, 
the compounds were tested against two fungal strains showing the compound 
3.26 (R = 2,4-diF) displays good activity against the fungi Candida albicans. 
 
7.2 Future Work 
Further characterisation for the complexes will include Electron Paramagnetic 
Resonance (EPR) spectroscopy. This helps to understand the isomeric 
behaviour of the complexes in solution over time to elucidate if the ruthenium 
complexes isomerise in solution. 
 
Further work will be investigating their cytotoxic properties in 3D models 
(spheroids). This will be done in the colorectal cell line HT-29 under the 
supervision of Prof. Roger Philips at the University of Huddersfield. Ongoing work 
is focused on the cytotoxic properties of these complexes against cancer stem 
cells (CSCs) in collaboration with Associate Professor Kogularamanan 
Suntharalingama at King’s College/The University of Leicester as, to date, there 
is no literature about ruthenium-based anticancer stem cell agents. The work 
carried at King’s College is being funded by the mobility grant awarded by the 
RSC. The main cell lines to work with are breast cancer (Bulk and CSCs) and the 
healthy breast cell line MCF10a and healthy kidney cell line HEK293T. Cellular 
uptake and DNA cleavage will be also studied to comprehend how these new 
family of complexes behave. Cellular fractionation will be helpful to determine 
where the drug is being accumulated within the cell (cytoplasm, cell membrane, 
and nucleus). 
 
After the successful achievements, the next step is analysing in vivo drug 
accumulation in order to introduce these new family into clinical potential anti-
cancer drugs. This is appropriate for complexes 3.23 (R = 2-F) and complex 3.32 
(R = 2,5-diCl). The former shows great potency, selectivity and very good hypoxic 
enhancement ratio for pancreatic cancer (no cure to date), the latter is the most 
selective, although less potent than 3.23, its enhancement properties in hypoxic 
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 Ligand 2.3 Ligand 2.4  Ligand 2.8  
Empirical formula C18H15N2O3 C18H16N2O3 C19H18N2O 
Formula weight 307.32 308.33 290.35 
Temperature/K 120.3(6) 120.1(4) 119.97(12) 
Crystal system monoclinic orthorhombic monoclinic 
Space group C2 Pbca C2/c 
a/Å 22.7070(6) 13.4360(2) 19.3410(9) 
b/Å 3.91108(9) 12.00512(19) 8.1490(4) 
c/Å 16.9323(5) 19.1345(3) 19.3328(8) 
α/° 90 90 90 
β/° 102.619(3) 90 100.860(4) 
γ/° 90 90 90 
Volume/Å3 1467.41(7) 3086.40(9) 2992.4(2) 
Z 4 7 8 
ρcalcg/cm
3 1.391 1.161 1.289 
μ/mm-1 0.787 0.655 0.081 
F(000) 644.0 1134.0 1232.0 
Crystal size/mm3 0.31 × 0.08 × 0.02 0.632 × 0.273 × 0.273 0.611 × 0.447 × 0.215 
Radiation CuKα (λ = 1.54184) CuKα (λ = 1.54184) MoKα (λ = 0.71073) 
2Θ range for data collection/° 7.34 to 147.56 9.244 to 147.378 6.616 to 62.434 
Index ranges -27 ≤ h ≤ 27, -4 ≤ k ≤ 4, -19 ≤ l ≤ 20 -16 ≤ h ≤ 16, -14 ≤ k ≤ 14, -22 ≤ l ≤ 23 -27 ≤ h ≤ 25, -11 ≤ k ≤ 10, -27 ≤ l ≤ 28 
Reflections collected 5488 7855 10622 
Independent reflections 2508 [Rint = 0.0299, Rsigma = 0.0350] 3058 [Rint = 0.0257, Rsigma = 0.0266] 4275 [Rint = 0.0361, Rsigma = 0.0477] 
Data/restraints/parameters 2508/1/210 3058/0/210 4275/0/202 
Goodness-of-fit on F2 1.044 1.062 1.060 
Final R indexes [I>=2σ (I)] R1 = 0.0327, wR2 = 0.0826 R1 = 0.0368, wR2 = 0.0915 R1 = 0.0532, wR2 = 0.1271 
Final R indexes [all data] R1 = 0.0351, wR2 = 0.0848 R1 = 0.0437, wR2 = 0.0967 R1 = 0.0677, wR2 = 0.1369 
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 Ligand 2.19 Ligand 2.20  Ligand 2.41  
Empirical formula C17H11N2OF3  C18H10F6N2O  C17H13N3O4 
Formula weight 316.28  384.28  323.31 
Temperature/K 120.1(3)  120.0(2)  119.99(11) 
Crystal system monoclinic  monoclinic  monoclinic 
Space group P21/n  Cc  P21/n 
a/Å 14.5099(6)  20.8347(15)  7.6216(3) 
b/Å 5.8509(2)  4.7047(3)  19.9877(7) 
c/Å 17.1616(5)  17.3675(11)  9.7135(3) 
α/° 90  90  90 
β/° 105.937(4)  112.427(8)  96.662(3) 
γ/° 90  90  90 
Volume/Å3 1400.95(9)  1573.6(2)  1469.75(8) 
Z 3  4  4 
ρcalcg/cm
3 1.125  1.622  1.4610 
μ/mm-1 0.788  0.151  0.890 
F(000) 486.0  776.0  674.4 
Crystal size/mm3 0.185 × 0.129 × 0.119  0.299 × 0.13 × 0.081  0.272 × 0.104 × 0.074 
Radiation CuKα (λ = 1.54184)  MoKα (λ = 0.71073)  Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 7.086 to 147.26  7.752 to 62.528  8.84 to 147.72 
Index ranges -16 ≤ h ≤ 18, -7 ≤ k ≤ 5, -21 ≤ l ≤ 20  -29 ≤ h ≤ 29, -6 ≤ k ≤ 5, -25 ≤ l ≤ 23  -9 ≤ h ≤ 8, -20 ≤ k ≤ 24, -8 ≤ l ≤ 11 
Reflections collected 5201  10782  5632 
Independent reflections 2700 [Rint = 0.0258, Rsigma = 0.0332]  4407 [Rint = 0.0353, Rsigma = 0.0418]  2888 [Rint = 0.0240, Rsigma = 0.0321] 
Data/restraints/parameters 2700/0/208  4407/2/244  2888/0/217 
Goodness-of-fit on F2 1.028  1.050  0.987 
Final R indexes [I>=2σ (I)] R1 = 0.0421, wR2 = 0.1028  R1 = 0.0666, wR2 = 0.1687  R1 = 0.0389, wR2 = 0.1225 
Final R indexes [all data] R1 = 0.0529, wR2 = 0.1115  R1 = 0.0747, wR2 = 0.1765  R1 = 0.0480, wR2 = 0.1345 
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 Complex 3.1 Complex 3.5     Complex 3.6  
Empirical formula C35H30Cl2N5O3Ru   C37H34Cl2N5O3Ru C37H34Cl2N5O3Ru 
Formula weight 740.63   768.66 768.66 
Temperature/K 120.01(11)   120.01(10) 119.99(14) 
Crystal system triclinic   monoclinic triclinic 
Space group P-1   P21/c P-1 
a/Å 10.1760(4)   7.64577(15) 11.1744(5) 
b/Å 12.4582(5)   16.1343(3) 12.0473(6) 
c/Å 13.8175(5)   26.9130(5) 13.6903(6) 
α/° 96.766(3)   90 109.099(4) 
β/° 92.746(3)   93.8443(16) 92.921(4) 
γ/° 114.018(4)   90 95.160(4) 
Volume/Å3 1580.00(11)   3312.49(10) 1728.15(15) 
Z 2   4 2 
ρcalcg/cm
3 1.5567   1.541 1.477 
μ/mm-1 0.711   5.688 5.452 
F(000) 752.4   1572.0 786.0 
Crystal size/mm3 0.41 × 0.38 × 0.07   0.14 × 0.08 × 0.04 0.16 × 0.08 × 0.05 
Radiation Mo Kα (λ = 0.71073)   CuKα (λ = 1.54184) CuKα (λ = 1.54184) 
2Θ range for data collection/° 2.98 to 62.22   8.568 to 147.544 6.858 to 147.828 
Index ranges -14 ≤ h ≤ 12, -16 ≤ k ≤ 14, -19 ≤ l ≤ 19   -9 ≤ h ≤ 9, -19 ≤ k ≤ 13, -33 ≤ l ≤ 29 -13 ≤ h ≤ 13, -14 ≤ k ≤ 14, -15 ≤ l ≤ 17 
Reflections collected 19881   13598 13885 
Independent reflections 8794 [Rint = 0.0355, Rsigma = 0.0612]   6541 [Rint = 0.0349, Rsigma = 0.0469] 6508 [Rint = 0.0508, Rsigma = 0.0620] 
Data/restraints/parameters 8794/20/508   6541/0/441 6508/0/437 
Goodness-of-fit on F2 1.049   1.044 1.018 
Final R indexes [I>=2σ (I)] R1 = 0.0417, wR2 = 0.0741   R1 = 0.0379, wR2 = 0.0855 R1 = 0.0421, wR2 = 0.1049 
Final R indexes [all data] R1 = 0.0570, wR2 = 0.0821   R1 = 0.0514, wR2 = 0.0926 R1 = 0.0513, wR2 = 0.1134 
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 Complex 3.8 Complex 3.9      Complex 3.10  
Empirical formula C44H47Cl2N6O4Ru  C41H42Cl2N5O3Ru  C39H38Cl2N5O3Ru 
Formula weight 895.84  824.76  796.71 
Temperature/K 120.00(11)  120.2(5)  119.99(10) 
Crystal system triclinic  monoclinic  triclinic 
Space group P-1  P21/c  P-1 
a/Å 9.2414(8)  14.8410(9)  11.6858(6) 
b/Å 10.7415(8)  16.1225(7)  11.8306(6) 
c/Å 10.8201(8)  16.1394(8)  13.6476(7) 
α/° 95.506(6)  90  96.853(4) 
β/° 101.755(7)  104.058(6)  110.928(5) 
γ/° 92.436(7)  90  90.664(4) 
Volume/Å3 1044.58(15)  3746.1(3)  1746.73(16) 
Z 1  4  2 
ρcalcg/cm
3 1.424  1.462  1.515 
μ/mm-1 0.553  5.069  0.648 
F(000) 463.0  1700.0  818.0 
Crystal size/mm3 0.14 × 0.06 × 0.03  0.64 × 0.04 × 0.02  0.24 × 0.15 × 0.11 
Radiation MoKα (λ = 0.71073)  CuKα (λ = 1.54184)  MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.528 to 62.512  7.872 to 147.592  3.224 to 62.432 
Index ranges -13 ≤ h ≤ 10, -15 ≤ k ≤ 13, -15 ≤ l ≤ 13  -17 ≤ h ≤ 15, -18 ≤ k ≤ 19, -19 ≤ l ≤ 15  -13 ≤ h ≤ 17, -17 ≤ k ≤ 17, -19 ≤ l ≤ 19 
Reflections collected 10768  15691  18984 
Independent reflections 5842 [Rint = 0.0581, Rsigma = 0.1171]  7210 [Rint = 0.0674, Rsigma = 0.0858]  18984 [Rint = ?, Rsigma = 0.1545] 
Data/restraints/parameters 5842/52/311  7210/0/475  18984/0/456 
Goodness-of-fit on F2 1.141  1.019  1.062 
Final R indexes [I>=2σ (I)] R1 = 0.0725, wR2 = 0.1197  R1 = 0.0635, wR2 = 0.1625  R1 = 0.0710, wR2 = 0.1849 
Final R indexes [all data] R1 = 0.0938, wR2 = 0.1289  R1 = 0.0944, wR2 = 0.1854  R1 = 0.1273, wR2 = 0.1990 
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 Complex 3.11  Complex 3.12        Complex 3.14 
Empirical formula  C36H31Cl2N4O2Ru  C41H42Cl2N5O3Ru C38H35Cl2N4O2Ru 
Formula weight  723.62  824.76 751.67 
Temperature/K  150.01(10)  120.2(5) 150.01(10) 
Crystal system  monoclinic  monoclinic monoclinic 
Space group  P21/c  P21/c P21/c 
a/Å  11.7085(4)  14.8410(9) 12.6058(4) 
b/Å  14.8952(4)  16.1225(7) 14.7133(4) 
c/Å  18.3985(6)  16.1394(8) 18.8157(5) 
α/°  90  90 90 
β/°  100.220(3)  104.058(6) 102.993(3) 
γ/°  90  90 90 
Volume/Å3  3157.80(17)  3746.1(3) 3400.46(17) 
Z  4  4 4 
ρcalcg/cm
3  1.522  1.462 1.468 
μ/mm-1  0.706  5.069 0.659 
F(000)  1476.0  1700.0 1540.0 
Crystal size/mm3  0.32 × 0.12 × 0.07  0.64 × 0.04 × 0.02 0.41 × 0.24 × 0.05 
Radiation  MoKα (λ = 0.71073)  CuKα (λ = 1.54184) MoKα (λ = 0.71073) 
2Θ range for data collection/°  4.5 to 62.48  7.872 to 147.592 3.55 to 62.516 
Index ranges  -11 ≤ h ≤ 17, -21 ≤ k ≤ 18, -25 ≤ l ≤ 26  -17 ≤ h ≤ 15, -18 ≤ k ≤ 19, -19 ≤ l ≤ 15 -18 ≤ h ≤ 17, -20 ≤ k ≤ 16, -22 ≤ l ≤ 26 
Reflections collected  23726  15691 28049 
Independent reflections  9095 [Rint = 0.0435, Rsigma = 0.0674]  7210 [Rint = 0.0674, Rsigma = 0.0858] 9790 [Rint = 0.0462, Rsigma = 0.0655] 
Data/restraints/parameters  9095/0/408  7210/0/475 9790/0/428 
Goodness-of-fit on F2  1.039  1.019 1.053 
Final R indexes [I>=2σ (I)]  R1 = 0.0445, wR2 = 0.0759  R1 = 0.0635, wR2 = 0.1625 R1 = 0.0447, wR2 = 0.0765 
Final R indexes [all data]  R1 = 0.0654, wR2 = 0.0849  R1 = 0.0944, wR2 = 0.1854 R1 = 0.0648, wR2 = 0.0871 
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 Complex 3.15    Complex 3.16        Complex 3.17 
Empirical formula   C48H59Cl2N4O4RuS2 C46H53Cl2N6O4Ru C45.25H51.25Cl2N5.75O3.75Ru 
Formula weight   992.08 925.91 907.64 
Temperature/K   150.00(10) 120.00(13) 293(2) 
Crystal system   monoclinic monoclinic monoclinic 
Space group   P21/n P21 P21/n 
a/Å   9.4082(4) 9.0540(17) 9.1057(4) 
b/Å   14.4854(7) 15.442(7) 29.0066(12) 
c/Å   17.6893(9) 16.397(5) 16.7871(13) 
α/°   90 90 90 
β/°   92.648(4) 95.14(3) 97.926(5) 
γ/°   90 90 90 
Volume/Å3   2408.2(2) 2283.4(13) 4391.6(4) 
Z   2 2 4 
ρcalcg/cm
3   1.368 1.347 1.373 
μ/mm-1   0.570 4.240 4.392 
F(000)   1034.0 962.0 1884.0 
Crystal size/mm3   0.54 × 0.04 × 0.02 0.19 × 0.09 × 0.04 0.22 × 0.02 × 0.02 
Radiation   MoKα (λ = 0.71073) CuKα (λ = 1.54184) CuKα (λ = 1.54184) 
2Θ range for data collection/°   4.61 to 62.208 7.88 to 150.486 8.09 to 147.542 
Index ranges   -13 ≤ h ≤ 13, -16 ≤ k ≤ 19, -25 ≤ l ≤ 16 -11 ≤ h ≤ 11, -19 ≤ k ≤ 17, -19 ≤ l ≤ 20 -11 ≤ h ≤ 11, -31 ≤ k ≤ 35, -19 ≤ l ≤ 20 
Reflections collected   17439 7513 18123 
Independent reflections   6786 [Rint = 0.0517, Rsigma = 0.0847] 7513 [Rint = ?, Rsigma = 0.0571] 8643 [Rint = 0.0796, Rsigma = 0.1153] 
Data/restraints/parameters   6786/6/281 7513/506/543 8643/24/546 
Goodness-of-fit on F2   1.037 0.997 1.029 
Final R indexes [I>=2σ (I)]   R1 = 0.0659, wR2 = 0.1281 R1 = 0.0623, wR2 = 0.1644 R1 = 0.0721, wR2 = 0.1642 
Final R indexes [all data]   R1 = 0.1069, wR2 = 0.1471 R1 = 0.0870, wR2 = 0.1804 R1 = 0.1154, wR2 = 0.1874 
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 Complex 3.18 Complex 3.20  Complex 3.23  
Empirical formula   C43H46N5O3Cl2Ru C40H35Cl2F6N6O4Ru C32H21Cl2F2N4O2Ru 
Formula weight   852.82 949.71 703.50 
Temperature/K   150.00(10) 120.00(10) 119.99(15) 
Crystal system   triclinic monoclinic monoclinic 
Space group   P-1 Cc P21/c 
a/Å   10.1238(7) 16.2080(5) 17.533(5) 
b/Å   13.4444(10) 8.0049(3) 8.963(2) 
c/Å   15.4499(11) 30.0705(9) 20.614(6) 
α/°   107.429(7) 90 90 
β/°   96.541(6) 95.556(3) 94.95(3) 
γ/°   93.243(6) 90 90 
Volume/Å3   1984.1(3) 3883.1(2) 3227.3(14) 
Z   2 4 4 
ρcalcg/cm
3   1.427 1.624 1.448 
μ/mm-1   0.576 0.622 5.846 
F(000)   882.0 1924.0 1412.0 
Crystal size/mm3   0.14 × 0.05 × 0.03 0.26 × 0.11 × 0.05 0.05 × 0.04 × 0.01 
Radiation   MoKα (λ = 0.71073) MoKα (λ = 0.71073) CuKα (λ = 1.54184) 
2Θ range for data collection/°   3.53 to 62.18 5.05 to 62.304 8.612 to 179.752 
Index ranges   -14 ≤ h ≤ 11, -18 ≤ k ≤ 17, -20 ≤ l ≤ 21 -23 ≤ h ≤ 19, -10 ≤ k ≤ 11, -33 ≤ l ≤ 43 -21 ≤ h ≤ 20, -11 ≤ k ≤ 9, -23 ≤ l ≤ 20 
Reflections collected   21885 12737 16704 
Independent reflections   11046 [Rint = 0.0883, Rsigma = 0.2077] 7894 [Rint = 0.0371, Rsigma = 0.0725] 6454 [Rint = 0.1557, Rsigma = 0.1831] 
Data/restraints/parameters   11046/18/495 7894/161/591 6454/393/364 
Goodness-of-fit on F2   1.018 1.056 0.970 
Final R indexes [I>=2σ (I)]   R1 = 0.0839, wR2 = 0.1191 R1 = 0.0571, wR2 = 0.1050 R1 = 0.1252, wR2 = 0.3246 
Final R indexes [all data]   R1 = 0.1959, wR2 = 0.1545 R1 = 0.0627, wR2 = 0.1084 R1 = 0.2393, wR2 = 0.4601 
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 Complex 3.24   Complex 3.25        Complex 3.26  
Empirical formula   C35H28Cl2F2N5O3Ru C34H27Cl2F2N4O3RuS C34.2H25.6Cl2F4N4O3.1RuS1.1 
Formula weight   776.59 781.62 825.42 
Temperature/K   119.99(13) 119.99(18) 119.99(10) 
Crystal system   triclinic monoclinic monoclinic 
Space group   P-1 P21/c P21/c 
a/Å   10.6955(13) 15.2765(4) 11.2585(5) 
b/Å   12.6800(11) 8.4816(2) 20.5455(9) 
c/Å   12.9715(11) 24.0986(7) 14.5593(7) 
α/°   74.676(7) 90 90 
β/°   82.485(8) 95.691(3) 101.760(4) 
γ/°   70.882(9) 90 90 
Volume/Å3   1601.2(3) 3107.05(15) 3297.0(3) 
Z   2 4 4 
ρcalcg/cm
3   1.611 1.671 1.663 
μ/mm-1   5.985 6.775 0.773 
F(000)   786.0 1580.0 1661.0 
Crystal size/mm3   0.16 × 0.11 × 0.03 0.22 × 0.02 × 0.02 0.14 × 0.11 × 0.07 
Radiation   CuKα (λ = 1.54184) CuKα (λ = 1.54184) MoKα (λ = 0.71073) 
2Θ range for data collection/°   7.074 to 148.528 7.374 to 146.686 6.454 to 62.602 
Index ranges   -13 ≤ h ≤ 13, -15 ≤ k ≤ 15, -15 ≤ l ≤ 16 -19 ≤ h ≤ 18, -8 ≤ k ≤ 10, -29 ≤ l ≤ 26 -15 ≤ h ≤ 16, -29 ≤ k ≤ 27, -21 ≤ l ≤ 17 
Reflections collected   9863 11777 22418 
Independent reflections   9863 [Rint = ?, Rsigma = 0.0856] 6076 [Rint = 0.0383, Rsigma = 0.0543] 9286 [Rint = 0.0520, Rsigma = 0.0867] 
Data/restraints/parameters   9863/0/436 6076/0/426 9286/38/499 
Goodness-of-fit on F2   0.937 1.034 1.038 
Final R indexes [I>=2σ (I)]   R1 = 0.0542, wR2 = 0.1282 R1 = 0.0403, wR2 = 0.0912 R1 = 0.0647, wR2 = 0.1206 
Final R indexes [all data]   R1 = 0.0798, wR2 = 0.1351 R1 = 0.0553, wR2 = 0.0982 R1 = 0.0987, wR2 = 0.1358 
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     Complex 3.27  Complex 3.28   Complex 3.29 
Empirical formula  C34H25Cl2F4N4O3RuS C35H28Cl4N5O3Ru C35H28Cl4N5O3Ru 
Formula weight  817.61 809.49 809.49 
Temperature/K  120.03(18) 119.97(12) 119.99(12) 
Crystal system  monoclinic monoclinic triclinic 
Space group  P21/c C2/c P-1 
a/Å  17.2650(12) 17.6902(9) 10.5921(13) 
b/Å  8.9406(5) 14.3662(5) 12.522(3) 
c/Å  21.0198(14) 26.9972(10) 14.2189(17) 
α/°  90 90 96.967(14) 
β/°  97.820(6) 98.080(4) 96.459(10) 
γ/°  90 90 114.707(17) 
Volume/Å3  3214.5(4) 6793.0(5) 1672.5(5) 
Z  4 8 2 
ρcalcg/cm
3  1.689 1.583 1.607 
μ/mm-1  6.672 0.821 0.833 
F(000)  1644.0 3272.0 818.0 
Crystal size/mm3  0.09 × 0.04 × 0.02 0.25 × 0.07 × 0.04 0.17 × 0.12 × 0.04 
Radiation  CuKα (λ = 1.54184) MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/°  8.492 to 147.492 3.844 to 62.502 6.622 to 56.56 
Index ranges  -12 ≤ h ≤ 19, -10 ≤ k ≤ 9, -26 ≤ l ≤ 23 -17 ≤ h ≤ 24, -19 ≤ k ≤ 19, -39 ≤ l ≤ 27 -14 ≤ h ≤ 9, -15 ≤ k ≤ 16, -17 ≤ l ≤ 18 
Reflections collected  13021 21722 8713 
Independent reflections  6142 [Rint = 0.0804, Rsigma = 0.1108] 9596 [Rint = 0.0401, Rsigma = 0.0706] 8713 [Rint = ?, Rsigma = 0.1606] 
Data/restraints/parameters  6142/0/444 9596/8/424 8713/404/433 
Goodness-of-fit on F2  1.032 1.049 1.099 
Final R indexes [I>=2σ (I)]  R1 = 0.0643, wR2 = 0.1322 R1 = 0.0560, wR2 = 0.1152 R1 = 0.1142, wR2 = 0.2653 
Final R indexes [all data]  R1 = 0.1143, wR2 = 0.1574 R1 = 0.0772, wR2 = 0.1253 R1 = 0.1711, wR2 = 0.2865 
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 Complex 3.30    Complex 3.32       Complex 3.33 
Empirical formula  C35H28.46Cl4N5O3.23Ru C36H33Cl6N4O5RuS2 C35H28Br2Cl2N5O3Ru 
Formula weight  813.64 979.55 898.41 
Temperature/K  120.6(10) 150.01(10) 120.00(10) 
Crystal system  monoclinic triclinic monoclinic 
Space group  P21/n P-1 C2/c 
a/Å  11.4785(4) 12.1609(6) 17.6359(12) 
b/Å  20.0177(7) 12.5357(6) 14.4253(7) 
c/Å  15.2958(6) 15.0309(7) 27.0013(15) 
α/°  90 74.193(4) 90 
β/°  108.228(4) 78.058(4) 98.201(6) 
γ/°  90 66.041(5) 90 
Volume/Å3  3338.2(2) 2002.67(17) 6798.9(7) 
Z  4 2 8 
ρcalcg/cm
3  1.619 1.624 1.755 
μ/mm-1  0.836 0.943 3.014 
F(000)  1645.0 990.0 3560.0 
Crystal size/mm3  0.12 × 0.06 × 0.04 0.24 × 0.21 × 0.11 0.29 × 0.15 × 0.12 
Radiation  MoKα (λ = 0.71073) MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/°  5.702 to 62.29 3.636 to 62.464 3.838 to 62.608 
Index ranges  -16 ≤ h ≤ 12, -28 ≤ k ≤ 24, -21 ≤ l ≤ 20 -17 ≤ h ≤ 17, -17 ≤ k ≤ 18, -20 ≤ l ≤ 20 -24 ≤ h ≤ 16, -19 ≤ k ≤ 19, -39 ≤ l ≤ 32 
Reflections collected  22990 25048 21096 
Independent reflections  9366 [Rint = 0.0425, Rsigma = 0.0654] 11372 [Rint = 0.0451, Rsigma = 0.0830] 9571 [Rint = 0.0393, Rsigma = 0.0730] 
Data/restraints/parameters  9366/24/442 11372/6/488 9571/9/424 
Goodness-of-fit on F2  1.035 1.045 1.044 
Final R indexes [I>=2σ (I)]  R1 = 0.0448, wR2 = 0.0784 R1 = 0.0523, wR2 = 0.1034 R1 = 0.0527, wR2 = 0.1025 
Final R indexes [all data]  R1 = 0.0686, wR2 = 0.0879 R1 = 0.0795, wR2 = 0.1219 R1 = 0.0783, wR2 = 0.1135 
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 Complex 3.34 Complex 3.35     Complex 3.38  
Empirical formula C34H27Br2Cl2N4O3RuS  C32H21Br2Cl2N4O2Ru C35H28Cl2I2N5O3Ru  
Formula weight 903.44  825.32 992.39  
Temperature/K 119.99(13)  119.99(10) 119.99(12)  
Crystal system triclinic  monoclinic monoclinic  
Space group P-1  P21/c C2/c  
a/Å 8.6512(8)  11.2747(3) 17.7257(6)  
b/Å 13.224(2)  14.8929(4) 14.6461(5)  
c/Å 15.4719(15)  18.4091(5) 26.9124(9)  
α/° 86.475(11)  90 90  
β/° 73.856(9)  98.469(3) 98.602(3)  
γ/° 81.339(11)  90 90  
Volume/Å3 1680.5(4)  3057.42(16) 6908.2(4)  
Z 2  4 8  
ρcalcg/cm
3 1.785  1.793 1.908  
μ/mm-1 8.953  3.339 2.440  
F(000) 894.0  1620.0 3848.0  
Crystal size/mm3 0.38 × 0.04 × 0.01  0.44 × 0.17 × 0.11 0.15 × 0.08 × 0.06  
Radiation CuKα (λ = 1.54184)  MoKα (λ = 0.71073) MoKα (λ = 0.71073)  
2Θ range for data collection/° 6.762 to 125.054  3.532 to 62.09 3.624 to 62.37  
Index ranges -6 ≤ h ≤ 9, -15 ≤ k ≤ 15, -15 ≤ l ≤ 17  -16 ≤ h ≤ 15, -20 ≤ k ≤ 20, -26 ≤ l ≤ 18 -25 ≤ h ≤ 15, -19 ≤ k ≤ 21, -39 ≤ l ≤ 38  
Reflections collected 5231  19208 22534  
Independent reflections 5231 [Rint = ?, Rsigma = 0.0696]  8547 [Rint = 0.0345, Rsigma = 0.0573] 9863 [Rint = 0.0530, Rsigma = 0.0864]  
Data/restraints/parameters 5231/424/448  8547/0/388 9863/83/428  
Goodness-of-fit on F2 0.980  1.028 1.077  
Final R indexes [I>=2σ (I)] R1 = 0.0882, wR2 = 0.2294  R1 = 0.0376, wR2 = 0.0668 R1 = 0.0555, wR2 = 0.0956  
Final R indexes [all data] R1 = 0.1313, wR2 = 0.2524  R1 = 0.0542, wR2 = 0.0720 R1 = 0.0811, wR2 = 0.1071  
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 Complex 3.39    Complex 3.40 
Empirical formula  C35H28Cl2I2N5O3Ru C32H21Cl2I2N4O2Ru 
Formula weight  992.39 919.30 
Temperature/K  120.0(2) 120.00(10) 
Crystal system  monoclinic monoclinic 
Space group  P21/c P21/c 
a/Å  15.5339(2) 11.6666(3) 
b/Å  8.55457(16) 14.8626(3) 
c/Å  26.3905(4) 18.4099(6) 
α/°  90 90 
β/°  100.9518(14) 100.928(3) 
γ/°  90 90 
Volume/Å3  3443.06(10) 3134.33(15) 
Z  4 4 
ρcalcg/cm
3  1.914 1.948 
μ/mm-1  19.555 2.678 
F(000)  1924.0 1764.0 
Crystal size/mm3  0.18 × 0.03 × 0.02 0.34 × 0.12 × 0.09 
Radiation  CuKα (λ = 1.54184) MoKα (λ = 0.71073) 
2Θ range for data collection/°  8.072 to 147.534 6.824 to 62.586 
Index ranges  -19 ≤ h ≤ 14, -10 ≤ k ≤ 10, -22 ≤ l ≤ 31 -16 ≤ h ≤ 16, -21 ≤ k ≤ 21, -21 ≤ l ≤ 26 
Reflections collected  14299 24810 
Independent reflections  6741 [Rint = 0.0456, Rsigma = 0.0591] 8989 [Rint = 0.0433, Rsigma = 0.0593] 
Data/restraints/parameters  6741/0/435 8989/0/388 
Goodness-of-fit on F2  1.022 1.044 
Final R indexes [I>=2σ (I)]  R1 = 0.0393, wR2 = 0.0916 R1 = 0.0383, wR2 = 0.0678 
Final R indexes [all data]  R1 = 0.0517, wR2 = 0.0977 R1 = 0.0555, wR2 = 0.0762 
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